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 Summary 
 
Lymphocytes express highly specific receptors to recognize pathogens and malignant 
cells. At the same time, lymphocytes recognizing self-antigens also develop. These 
need tight regulation in order to prevent autoimmunity. The elimination or control 
of self-reactive cells is ensured by central and peripheral tolerance mechanisms. A 
detailed understanding of tolerance induction and maintenance is indispensable for 
the establishment of novel therapeutic strategies to treat autoimmune diseases and to 
prevent rejection of transplanted tissue. Recently, we identified Dickkopf 3 (Dkk3) as 
a novel immune-mediator in a transgenic model of peripheral T cell tolerance. To 
further clarify the immune-modulatory capacity of Dkk3 we investigated the 
influence of this secreted protein on T and B cell function. 
Experimental autoimmune encephalomyelitis (EAE) is a T cell mediated mouse 
model of the human autoimmune disease multiple sclerosis. Dkk3 deficient mice 
developed more persistent symptoms of EAE with increased numbers of brain 
infiltrating CD4 and CD8 T cells as well as myeloid cells in comparison to wild type 
mice. Lack of environmental Dkk3 was responsible for the observed phenotype as 
shown by adoptive T cell transfers using Dkk3 deficient T cells. Disease persistence 
in Dkk3 deficient mice was associated with an altered local cytokine profile. Absence 
of Dkk3 did not change the differentiation of Th1 and Th17 T cells but led to 
increased levels of Th2 associated cytokines.  
The role of Dkk3 on B cell function was analyzed by investigating antibody and 
cytokine secretion. Both assay systems showed that B1 related functions were 
increased in Dkk3 deficient mice, such as antibody secretion to the antigens LPS and 
phosphorylcholine and IL-10 production. Indeed, Dkk3 deficient mice yielded 
increased numbers of B1 cells. B2 cell development was supported by Dkk3 at the 
step from the pre- to immature B cell stage, whereas Dkk3 negatively regulated B1 
cell generation. The murine MRL/LPR strain, a mouse model of human systemic 
lupus erythematosus (SLE), was used to investigate the role of Dkk3 in a B cell 
mediated autoimmune disease. Treatment of these mice with a Dkk3 neutralizing 
antibody led to increased numbers of B1 cells and higher pathology of SLE, including 
enlarged lymph nodes, higher levels of autoantibodies, increased glomerulonephritis 
and inflammation in pancreas and lung.   
Among the Dkk protein family, only Dkk3 and Soggy share the unique sgy-domain. 
To address the question whether this sgy-domain may be responsible for the 
immune-modulatory capacity we investigated immune functions of Soggy deficient 
mice. Alterations in the T cell compartment were observed, such as decreased 
numbers of regulatory T cells in comparison to wild type mice. Furthermore, Soggy 
deficiency led to an earlier onset and stronger symptoms of EAE in comparison to 
the disease course in C57BL/6 and Dkk3-/- mice.  
In summary, Dkk3 regulates T and B cell mediated autoimmunity. In addition, we 
were able to identify Soggy as a novel immune-mediator suggesting that the shared 
sgy-domain is contributing to the immune-suppressive capacity of Dkk3 and Soggy.  
  
 
 Zusammenfassung 
 
Lymphozyten besitzen hoch spezifische Rezeptoren um Pathogene und maligne Zellen 
zu erkennen. Es entwickeln sich aber auch Lymphozyten, welche Selbst-Antigene 
erkennen. Diese müssen streng kontrolliert werden, damit keine Autoimmunität 
entsteht. Für die Kontrolle oder Elimination solcher autoreaktiven Zellen sorgen 
zentrale und periphere Toleranzmechanismen. Ein detailliertes Verständnis, wie 
Toleranz des Immunsystems induziert und erhalten wird, ist für die Entwicklung von 
neuen therapeutischen Strategien um Autoimmunerkrankungen zu behandeln und 
Transplantatabstoßung zu verhindern, entscheidend. Erst kürzlich identifizierten wir 
Dickkopf 3 (Dkk3) als ein neues immun-modulatorisches Molekül in einem 
transgenen Modell peripherer Toleranz. Um die immun-modulatorische Kapazität 
von Dkk3 weiter aufzuklären, wurde in dieser Arbeit der Einfluß von Dkk3 auf T- 
and B-Lymphozyten-Funktionen untersucht.   
Experimentelle autoimmune Encephalitis (EAE) ist ein durch T-Zellen ausgelöstes 
murines Krankheitsmodell der humanen Multiplen Sklerose. Im Vergleich zu Mäusen 
die Dkk3 exprimieren, entwickelten Mäuse, welche kein Dkk3 besitzen, stärkere EAE 
Krankheitssymptome und wiesen eine erhöhte Anzahl von infiltrierenden CD4 und 
CD8 T-Zellen, sowie myeloide Zellen im Zentralen Nervensystem auf. Durch einen 
adoptiven Transfer von Dkk3-defizienten T -Zellen wurde gezeigt, dass das Dkk3 in 
der Umgebung entscheidend ist. Der verschlimmerte Krankheitsverlauf in Dkk3-
defizienten Tieren war mit einem lokal veränderten Zytokinmileu assoziiert. Die 
Abwesenheit von Dkk3 veränderte die Differenzierung von Th1 und Th17 Zellen 
nicht, sondern führte zu bevorzugter Th2 Differenzierung.  
Die Analyse von Antikörper- und Zytokinsekretion wurden genutzt, um die Rolle von 
Dkk3 auf B Zell Funktionen zu untersuchen. In beiden Assaysystemen zeigte sich, 
dass B1 Zell-Funktionen in den Mäusen, welche kein Dkk3 exprimieren, erhöht sind, 
wie beispielsweise LPS- und Phosphorylcholine-spezifische Antikörperantworten oder 
die Sekretion von IL-10. Tatsächlich fanden wir auch eine erhöhte Anzahl an B1 
Zellen in Dkk3-defizienten Mäusen. Die Entwicklung von B2 Zellen wurde durch 
Dkk3 unterstützt, wohingegen die Generierung von B1 Zellen negativ von Dkk3 
reguliert wurde. Um die Rolle von Dkk3 auf eine B Zell-vermittelte 
Autoimmunerkrankung zu untersuchen, benutzten wir den murinen MRL/LPR 
Stamm, welcher als Mausmodell von humanem systemischen Lupus Erythematosus 
(SLE) gilt. Die Behandlung dieser Mäuse mit einem Dkk3 neutralisierendem 
Antikörper erhöhte B1 Zellzahlen und führte zu einem erhöhten Grad an SLE-
Pathologie. Unter anderem waren vergrößerte Lymphknoten, erhöhte Produktion von 
Autoantikörpern, eine stärkere Glomerulonephritis und vermehrte Entzündungen in 
Pancreas und Lunge zu beobachten.  
Dkk3 und Soggy sind die einzigen Mitglieder innerhalb der Dkk Protein-Familie, 
welche die Sgy-Domäne besitzen. Um herauszufinden, ob die Sgy-Domöne für die 
immun-modulatorische Kapazität von Dkk3 verantwortlich ist, untersuchten wir 
Mäuse, welche kein Soggy exprimieren. In diesen wurde im Vergleich zu Wildtyp-
Mäusen ein verändertes T Zell-Kompartiment, wie beispielsweise eine geringere 
  
Anzahl an regulatorischen T Zellen, gefunden. Desweiteren zeigten Soggy-defiziente 
Mäuse ein früheren Krankheitsausbruch und verstärkte Symptome von EAE.  
Zusammenfassend konnten wir zeigen, dass Dkk3 T and B Zell vermittelte 
Autoimmunität reguliert. Zusätzlich wurde Soggy als ein neuer Immunmediator 
identifiziert. Dieser Befund deutet darauf hin, dass die Sgy-Domäne zur immun-
hemmenden Wirkung von Dkk3 und Soggy beiträgt.  
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INTRODUCTION   
 
1 
1 Introduction 
1.1 The adaptive immune system  
The immune system features an extraordinary set of mechanisms working together to 
maintain on one hand self-tolerance and homeostasis, and on the other hand 
protective immunity to pathogens. It is capable of distinguishing between dangerous 
and non-dangerous signals and reacts subsequently with activation or tolerance [1]. If 
one of these mechanisms fails, exuberant infections, autoimmune or hypersensitivity 
reactions can develop.  
 
The immune system can be divided into two with each other interacting branches, 
the innate and the adaptive immune system. Whereas the innate immune system 
works in a generic, non-specific way, the adaptive immune system bears highly 
specific receptors to recognize antigens.  
 
The adaptive immune system consists of lymphocytes, which are subdivided into T 
and B cells. The development of these, and also of most of the other immune cells, 
takes place in primary lymphoid organs, the bone marrow (BM) and the thymus. 
Initiation of adaptive immune responses, which normally has to be licensed by the 
innate immune system, takes place in secondary lymphoid organs, which include the 
spleen, lymph nodes (LN) or gut associated lymphoid tissue (GALT).  
 
The generation of the antigen-specific receptors, that both B and T cells carry, is a 
random process of recombination, in which different gene subunits are combined [2]. 
The random recombination results in a theoretical repertoire of more than 1011 
different specificities in humans. This enables the adaptive immune system to 
basically recognize every possible antigen with only a small proportion of 
lymphocytes being reactive to one specific structure. The activation by antigen leads 
to an expansion of the antigen-specific lymphocytes in a process called selective 
clonal expansion. It ensures sufficient numbers of lymphocytes specific for a 
particular antigen during an immune response. Some of these clonally expanded 
lymphocytes differentiate into memory cells that are able to react faster and stronger 
to recall infections with the same pathogen. The formation of immunological memory 
and the high specificity to a broad range of antigens are key characteristics of the 
adaptive immune responses.  
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1.2 Mechanisms of tolerance 
The broad diversity of receptors recognizing every possible antigen is required for 
protection against harmful pathogens. However, the random process of receptor 
generation also creates specific receptors recognizing self and harmless antigens. 
Therefore, tight regulatory mechanisms are indispensable to prevent autoimmunity 
and allergy.  
 
The mechanisms ensuring the establishment of tolerance can be divided into central 
and peripheral tolerance. Central tolerance consists of clonal deletion or inactivation 
of self-reactive lymphocytes during development [3]. It takes place in the primary 
lymphoid organs. As B cells develop in the BM their organ of central tolerance is the 
BM [4]. Central tolerance of T cell takes place in the thymus [5]. As tolerance 
induction in these primary lymphoid organs is established during the development of 
B and T cells and as it is different for both lymphocyte types, it will be described 
more in detail in the development section of B and T cells (1.3.1 T cell 
development/1.4.1 B cell development).   
 
Lymphocytes escaping the mechanisms of central tolerance can still be controlled by 
a multitude of mechanisms in the periphery, collectively called peripheral tolerance. 
They include the induction of anergy, the deletion by activation induced cell death 
(AICD), suppression mediated by regulatory cells and the establishment of immune 
privileged sites [3].  
 
Anergy describes a state of unresponsiveness in T and B cells that is characterized 
by an active repression of TCR or BCR signalling resulting in the loss of 
proliferation [6, 7]. Auto-reactive cells which are anergic do not respond to self-
antigens and stay in the anergic state, when encountering antigen (in the case of the 
T cells presented by antigen presenting cells (APC)) despite the presence of co-
stimulatory signals, which are expressed in the presence of danger signals [8].  
 
Another strategy of the immune system to limit overshooting responses and to 
eliminate self-reactive leukocytes is a mechanism called AICD. As the name implies, 
it is influenced by the nature of the initial activation event. The mechanism is 
employed for instance by tolerogenic dendritic cells (DCs) or by regulatory T cells 
(Tregs), which can be present during the process of activation [9, 10]. Subsequently, 
death is induced by death ligand - death receptor interactions leading to apoptosis 
signalling [11]. The most prominent subclass of death receptors is the tumor necrosis 
factor receptor (TNFR) family. Within this family, CD95-mediated  cell death is the 
best studied mechanism of AICD [12]. Mice deficient for CD95, also called Fas-
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receptor, (MRL.Faslpr/lpr) or FasL (C57BL/6.FasLgld/gld) are prone to spontaneous 
autoimmunity with age [13].  
 
A widely-used mechanism in the immune system to prevent unwanted immune 
responses against self is the suppression mediated by regulatory cells. There are 
several different cell types known, including mesenchymal stem cells (MSCs)[14], 
myeloid derived suppressor cells (MDSCs) [15], and the most studied Tregs, which 
can be divided into natural and induced Tregs (nTregs/iTregs) [16]. Suppressive cell 
types employ several mechanisms to inhibit immune response, such as secretion of 
immune-suppressive factors (e.g. IL-10, TGF-β, IL-35, IDO), contact-dependent 
suppression, which can lead to induction of apoptosis (e.g. CTLA-4, PD-L1), 
induction of anergy, cytolysis of effector cells by granzyme secretion (e.g. Granzyme 
A or B), or the metabolic disruption by the consumption of pro-inflammatory 
molecules (e.g. IL-2 or ATP consumption) [14, 15, 17, 18].  
 
Described so far are the mechanisms to establish a systemic immunological tolerance. 
In addition, there are special tissues – so called immune privileged sites -, which need 
an immune-suppressive microenvironment in order to assure local protection. In such 
tissues strong immune-responses and inflammation would lead to irreparable damage. 
Therefore, life essential tissues or/and tissues with a limited capacity of regeneration 
need a special protection by immuno-regulatory mechanisms. The brain, the eye, or 
organs of the reproductive system for example belong to the immune privileged sites. 
The prevention or dampening of immune responses in these sites occurs through 
different mechanisms. Often immune privileged sites are anatomically separated by 
structural barriers [19, 20], which might present the only passive mechanisms of 
immune deviation. Streilein describes a mechanism taking place in the eye, called 
anterior chamber-associated immune deviation (ACAID), which emphasized that 
immune privilege is actively acquired and maintained by the immune system itself 
[21]. By the mechanisms of ACAID, infections of the eye result in harmless immune 
responses [22]. Numerous active mechanisms used commonly by immune privileged 
sites have been described. MHC I molecules are absent from the neurons of the brain 
[23], the corneal epithelium and the retina as well as from the trophoblast [24]. 
Additionally, a number of immunosuppressive molecules are expressed by immune 
privileged  tissues, such as the non-classical MHC Ib molecules leading to inhibition 
of NK and cytotoxic T cells [25], suppressive molecules such as IDO or TGF-β [26, 
27],  and molecules leading to AICD and anergy, such as the CD95 or CTLA-4 [28]. 
Besides these soluble or membrane-bound factors the immune-privilege is also 
sustained by the accumulation of Tregs, which are applying their own regulatory 
mechanisms, as described above.  
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1.3 T cells 
T lymphocytes (T cells) are subdivided into αβ-T cells and γδ-T cells, which refers 
to the T cell receptor (TCR) chains they express. αβ-T cells present the majority of 
T cells within the immune system, whereas γδ-T cells are a minor population 
residing preferentially in epithelial layers of tissues underlying surfaces of the body in 
contact with the external environment, such as the skin, the intestinal epithelium or 
the lung [29]. In this thesis only αβ-T cells have been investigated, therefore γδ-T 
cells are not considered in the introduction.  
 
T cells are characterized by their antigen specific receptor, the TCR (Figure 1.1). It 
is a heterodimer consisting of an α and β chain. The TCR is attached to the T cell 
by two transmembrane regions and is not secreted. It is associated with the invariant 
accessory chains CD3γ, CD3δ and CD3ε, which together form the CD3 complex 
that is required for TCR expression and signalling. Additionally, a homodimer of two 
ζ-chains is bound to the complex and is responsible for intracellular signalling. 
Importantly, T cells can only recognize peptides presented via MHC molecules with 
their TCR (further described in 1.3.2 Activation of T cells) [3]. Whole unprocessed 
proteins or non-protein molecules do not lead to signal transduction in T cells.  
 
 
 
 
Figure 1.1  | The T cell receptor (TCR). The TCR is a heterodimer consisting of the α and β chain 
which assemble with the invariant accessory chains CD3γ, CD3δ and CD3ε, which together form the 
CD3 complex. Additionally, a homodimer of two ζ-chains is bound to the complex and is responsible for 
intracellular signalling by using the immunoreceptor tyrosine-based activation motifs (ITAMs / yellow 
segments). Figure from Immunobiology, Janeway et al., 6th edition, 2005 Garland science Publishing.  
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1.3.1 T cell development 
The development of T cells takes place in a specialized organ called thymus. It is the 
primary lymphoid organ for the T cells. T cell progenitors are derived from 
pluripotent stem cells in the BM and migrate into the thymus through the blood, 
where the T cell maturation process, characterized by the TCR assembly, occurs. 
This process takes place throughout life, but is decelerated in adults, where T cell 
numbers are sustained by division of mature T cells outside of primary lymphoid 
organs [30].  
 
T cell development in the thymus is depicted in Figure 1.2. T cell progenitor cells 
from the BM migrate to the thymus to enter at the cortico-medullary junction. At 
this time point they do not express the typical coreceptors CD4 and CD8 nor the 
TCR, whose genes are not yet rearranged. When the progenitor cells enter the outer 
cortex of the thymus and start to interact with thymic stroma cells, consisting of 
epithelial cells, the differentiation into the T cell lineage is initiated [31]. At the end 
of this phase T cells bear the first T cell specific surface markers, as Thy-1 in mice. 
But they are still not expressing the TCR or the correceptors CD4 and CD8. Hence, 
they are called “double-negative” (DN) thymocytes. The double-negative stage can 
be further subdivided into four developmental stages based on the expression of the 
adhesion molecules CD44 and CD25. First, double negative thymocytes express 
CD44 (DN1), in these thymocytes the genes for both chains of the TCR are still 
unrecombined as in the germline. When maturation of thymocytes goes on CD25 
expression starts (DN2). In the next stage (DN3) CD44 is downregulated, when β-
chain rearrangements start. If the rearrangements of the β-chain are not successful, 
cells stay in this stage and die. The cells, which successfully rearrange the β-chain, 
downregulate CD25 (DN4)[5]. They express the pre-TCR, in which a substitute α-
chain, called pTα, interacts with the β-chain to form the receptor together with the 
CD3 molecules. Signalling through this pre-TCR leads to proliferation, migration 
towards the medulla and expression of both coreceptors CD4 and CD8. Therefore, 
this stage is called “double positive” (DP). Double positive cells rearrange the α-
chain genes to form the mature TCR. The interaction of the TCR with self-MHC 
molecules expressed by cortical thymic epithelial cells (cTEC) leads to a process 
called positive selection [31]. Only T cells with sufficient affinity of the TCR to bind 
to self-MHC molecules receive survival signals. The contact leads to the development 
of three T cell lineages. The two major populations are CD4 and CD8 single positive 
T cells (CD4 T cells and CD8 T cells) and the minor population is the natural Treg, 
which expresses CD25. The strength and the duration of the contact between TCR 
and MHC molecule determine the cell type. Cells selected by MHCI will mature to a 
CD8+ T cells, whereas cells selected by MHCII mature to CD4+ T cells [32].  
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Figure 1.2  | T-cell development in the thymus. Committed lymphoid progenitors arise in the bone 
marrow and migrate to the thymus. Early committed T cells lack expression of T-cell receptor (TCR), 
CD4 and CD8, and are termed double-negative (DN) thymocytes. DN thymocytes can be further 
subdivided into four stages of differentiation (DN1: CD44+CD25-, DN2: CD44+CD25+, DN3: CD44-
CD25+, and DN4: CD44-CD25-). Successful pre-TCR expression leads to substantial cell proliferation 
during the DN4 to double positive (DP) transition and replacement of the pre-TCR with the complete 
rearranged TCR. The DP-thymocytes then interact with cortical epithelial cells that express a high 
density of MHC class I and class II molecules associated with self-peptides. The fate of the DP 
thymocytes depends on signalling that is mediated by interaction of the TCR with these self-peptide–
MHC ligands. Too little signalling results in delayed apoptosis (death by neglect). Too much signalling 
can promote acute apoptosis (negative selection); this is most common in the medulla on encounter with 
strongly activating self-ligands on haematopoietic cells, particularly dendritic cells. The appropriate, 
intermediate level of TCR signalling initiates effective maturation (positive selection). Thymocytes that 
express TCRs that bind self-peptide–MHC-class-I complexes become CD8 T cells, whereas those that 
express TCRs that bind self-peptide–MHC-class-II ligands become CD4 T cells; these cells are then 
ready for export from the medulla to peripheral lymphoid sites [5]. Figure from Germain, R. N., 2002, 
Nat Rev Immunol  
 
The next step is one of the most important mechanisms to prevent autoimmunity. It 
is referred to as central T cell tolerance and leads to negative selection of T cells. In 
this process single positive thymocytes which have travelled to the medulla of the 
thymus encounter self-antigens, which are presented by medullary thymic epithelial 
cells (mTEC), macrophages or dendritic cells (DCs) [33].  
In the thymus a ingenious mechanism called promiscuous gene expression is 
observed. This phenomenon builds the basis for the negative selection mechanism. 
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The expression of the transcription factor AIRE (autoimmune regulator) expressed in 
mTECs leads to the ectopic expression of almost all tissue-restricted antigens 
(TRAs) (Figure 1.3), which are then presented by their MHC molecules [34, 35]. The 
very few TRAs, which are not expressed by mTECS can be transported to the 
thymus via DCs or macrophages, as not all of both cell types have been arisen 
intrathymically [36].  
When T cells carrying an auto-reactive TCR receive a strong signal through their 
TCR interacting with a self-peptide-MHC complex at this stage of development, they 
are driven into apoptosis. This ensures self-tolerance by eliminating all T cells with 
strong auto-immune potential. Only T cells with low affinity for self-MHC complexes 
survive and enter the periphery of the immune system as so called naïve CD8 and 
CD4 T cells [32].  
 
 
 
 
Figure 1.3  | Diverse tissues are represented by promiscuous gene expression in medullary thymic 
epithelial cells (mTECs). Gene chip analysis revealed that about one quarter of all mTEC-
overexpressed genes could be categorized as tissue-restricted. A broad diversity of tissues is represented 
in mTECs and the fraction of tissue-restricted genes is probably still underestimated given their low 
expression levels in mTECs and the limited sensitivity of the gene array method. Figure from Derbinski, 
J. et al., 2001, Nat Immunol.  
 
 
1.3.2 Activation of T cells 
Naïve T cell continuously recirculate from blood to the lymphatic system, which 
carries them to secondary lymphoid organs, and from there back to the blood. The 
secondary lymphatic organs are optimally designed to facilitate the encountering of T 
cells with their specific antigen. Antigens are taken up by DCs in tissues, which 
migrate via afferent lymph streams to the draining lymph nodes (LN), where they 
present the antigens by MHC molecules to T cells. Depending on the maturation 
status of the DC, T cells become activated or anergized (tolerized), that means that 
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at this step an additional control mechanism allows or prevents activation of a 
specific T cell [3, 8]. The DC is the crucial cell in this step, in which the outcome of 
the TCR-peptide-MHC interaction is decided. For this decision costimulatory 
molecules (CD80 or CD86), expressed on the surface of the DC, are determining, as 
they interact with the CD28 molecule, expressed on T cells, leading to the activation 
of a T cell. These costimulatory molecules will only be expressed if the DC has 
sensed so called “danger signals” with its pattern recognition receptors (PRR), e.g. 
Toll-like receptors (TLRs). These danger signals are only present if pathogens have 
entered the body. DCs, carrying self-peptides, taken up from e.g. apoptotic tissue 
cells, will not express costimulatory molecules und therefore anergize those T cells, 
which recognize the selfpeptides presented via the MHC molecules. Therefore, auto-
reactive T cells which could escape the negative selection in the process of central 
tolerance will be anergized in the LN due to this additional control mechanism.  
 
1.3.3 T cell differentiation and T cell effector subsets 
Besides the decision whether a T cell is activated or not, it is of importance to which 
effector subset cell type the T cell will differentiate. Especially for the CD4 T cell 
lineage this decision has to me made. CD8 T cells mainly differentiate into cytotoxic 
T effector cells, which have the ability to kill cells in an antigen-specific way.  
 
To which sub cell type CD4 T cells differentiate depends on the cytokines expressed 
by the DC itself. But also other surrounding cells can influence this decision. Here, 
only the main T cell subtypes will be described.  
 
The process of differentiation is not static, which means that T cells usually 
differentiate to more than only one subtype clone and T cells which have 
differentiated to one subtype can change their phenotype to another subset under 
certain conditions. Therefore, the high flexibility and plasticity of the T cell 
differentiation process may not be forgotten when simplifying it in a model with a 
monolithic view (Figure 1.4). IFN-γ and IL-12 are the classical cytokines driving a 
Th1 response. Th-2 cells are generated in the presence of IL-4. Whether a T cell 
differentiates into a Th17 or induced Treg depends on the presence of IL-6 [37]. Both 
cell types need TGF-β for differentiation, but only if IL-6 is present will the T cell 
differentiate into an effector Th17 cell. Th17 cells are further supported by the 
cytokine IL-23 [38-40]. During the process of differentiation, the activation via 
phosphorylation of STAT molecules is important [39](Figure 1.4).  
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Figure 1.4  | The classical monolithic view of CD4 T cell differentiation. Upon interaction with 
dendritic cells, T cells differentiate to different effector subsets. These can be distinguished by specific 
transcription factors or cytokines they secrete. Characteristic STAT molecules are important in the 
activation process of each subset. Figure from J.J. O´Shea and W.E. Paul, 2010, Science. 
 
 
Every subset can be identified by specific master regulator transcription factors or 
cytokines expressed by T cells (Figure 1.4). Th1 cells express T-bet and EOMES as 
their specific transcription factors and secrete IFN-γ and TNF-α. They are 
responsible for the cellular immune response and can enhance the response of 
cytotoxic CD8 T effector cells. Therefore, they belong to the inflammatory CD4 T 
cells [39]. Th1 cells also express the chemokine receptors CXCR3 and CCR5, which 
bind to CXCL9 , CCL3 and CCL4 which are secreted in inflammatory responses by 
other immune cells and attract Th1 cells to these areas [41, 42].  
 
Th17 cells are the second group of inflammatory CD4 T cells. Their name refers to 
the typical cytokine IL-17 which they secrete. The master regulator transcription 
factor which distinguishes them from other CD4 T cell subsets is RoRγT. They 
express a very similar chemokine receptor pattern as Th1 cells to be attracted by 
inflammatory sites [42, 43]. Besides Th1 cells, Th17 have been reported to be the 
initiating and/or triggering cells in autoimmune diseases in a multitude of studies 
[44-46]. In some studies also the cytokine GM-CSF has been found to be expressed 
by Th17 cells and to be indispensable for their pathogenic function [47].  
 
Th2 cells are important CD4 T cells for the extracellular also called humoral immune 
response (see 1.4.4 Activation of B cells by different classes of antigens). They secrete 
IL-4, IL-5, IL-6, IL-10, IL-13 and IL-25. IL-4 can substitute IL-2 and acts as growth 
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factor for these CD4 T cells, therefore these cells are independent in their 
proliferation and effector function from IL-2. The Th2 cytokines IL-4 and IL-13 are 
crucial in the development of IgE antibody responses of B cells [48]. Therefore, these 
cells are in most cases responsible for the development of allergic reactions. 
Furthermore, they inhibit the development of a Th1/Th17 response with their 
secreted cytokines, which can negatively effect the clearance of intracellular 
pathogens [39]. On the other hand, nowadays, the immune modulation from a 
Th1/Th17 response to a Th2 response is used therapeutically in autoimmune disease, 
as in this case Th2 responses are less harmful [49-52]. Th2 cells are characterized by 
the expression of GATA-3 as their specific transcription factor as well as the 
expression of the chemokine receptors CCR3 and CCR4, which bind the chemokines 
CCL5 (Rantes), CCL7 and CCL17 [42].  
 
Regulatory T cells can not only be generated in the thymus (thymic or natural Tregs 
(nTregs)), but can also be induced in the periphery and are then called adaptive or 
induced Treg (iTregs). As nTregs they express the transcription factor FoxP3 and 
the α-chain of the IL-2 receptor CD25 [53, 54]. Besides TGF-β, also other factors can 
contribute to their induction, including IL-10, retinoic acid, or activation by 
immature DCs [55-57]. Helios has been proposed by Thornton et al. as a marker to 
distinguish natural from iTregs, as it was found predominantly on thymic Tregs [58]. 
But this has been questioned by others studies, which demonstrate that Helios can 
be a marker of T cell activation and proliferation [59, 60]. Furthermore, Helios 
positive Tregs have been described to be more suppressive [61].  
Induced Tregs use the same mechanisms as natural thymic Tregs or other 
suppressive cells to inhibit immune responses. They are described in the section “1.2 
Mechanisms of tolerance”. The characteristic suppressive cytokines of Tregs are IL-
10 and TGF-β, but as described they employ a multitude of mechanisms in order to 
suppress other immune cells. The highest proportion of induced regulatory T cells 
can be found in the GALT, where they ensure oral tolerance to food antigens as well 
as the tolerance to the commensal microflora [62, 63].  
 
Whether follicular helper T cells (Tfh) are truly a CD4 T cell subset parallel to Th1, 
Th2, Th17, and iTregs, or a particular state of some or all of these cells is unresolved 
[37, 64]. Tfh cells express Bcl-6, their master regulator transcription factor, but 
unlike T-bet and GATA-3, Bcl-6 is a transcriptional repressor. Tfh cells have distinct 
properties and phenotypes (e.g. expression of CXCR5 and ICOS), however, 
individual Tfh cells may produce Th1 or Th2 signature cytokines, depending on their 
initial activation [64, 65]. Tfh cells are mostly known for their function in supporting 
the development of germinal centers and promoting immunoglobulin class switch 
recombination (CSR) and affinity maturation [37, 64, 65].  
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1.3.4 T cells in autoimmune diseases   
The mechanisms of central and peripheral tolerance work together to prevent auto-
reactive responses. However, under certain conditions, which are still intensively 
studied, tolerance mechanisms fail and autoimmune diseases develop.  
 
T cells have widely been shown to be involved in the pathogenesis of autoimmune 
diseases [66]. Due to their specific antigen-receptor they are capable to target tissues 
specific proteins and lead to the destruction of the tissue either directly by cytotoxic 
T cells or with the help of inflammatory cytokines and chemokines that attract other 
immune cells, which accumulate in the affected organ and lead to a pathogenic 
inflammation with tissue destruction [67-69].  
The simplest model explaining the activation of self-reactive T cells is that a 
professional APC cell, like a DC, takes up self-antigen from an apoptotic cell, which 
at the same time is infected with a virus or bacterium. Therefore, the APC will be 
activated by danger signals, mature and express costimulatory molecules while 
presenting self-peptides from the apoptotic cell to naïve T cells.  T cells, specific for 
this TRA, which could escape central and peripheral tolerance would then be 
activated when encountering such a DC, migrate to the tissue and initiate an 
autoimmune reaction [3]. Fortunately, this model is not sufficient to explain the 
initiation of an autoimmune disease, because infections usually cause apoptosis and 
attraction of DCs, and every organism is exposed to several infections during lifetime 
without developing an autoimmune disease. Therefore, additional mechanisms have 
to be causal.  Susceptibility studies show that autoimmune diseases are not only 
associated with infectious and immunological factors, but also with environmental, 
geographical, and genetic factors, and appear to be increasing especially in the 
western world [70-72]. However, the exact etiology still remains unknown.  
 
That T cells are key players in autoimmune diseases is doubtlessly the case, as 
various animal models show that the transfer of auto-reactive T cells is sufficient to 
induce the autoimmune disease [73-81]. In these animal models Th1 and Th17 have 
mostly been demonstrated to be the disease initiating cells, whereas Tregs and Th2 
cells are able to dampen or even prevent disease development [82-85]. Many therapies 
aim to increase Treg cell numbers or their activity [86-89], others aim the modulation 
of an inflammatory Th1/Th17 response to a less damaging Th2 response [49-52]. The 
crucial role that CD8 T cells play in the onset of several autoimmune diseases should 
also not be underestimated as shown in diabetes, multiple sclerosis or myasthenia 
gravis [90-92].  
 
In the past decades, animal models of T cell mediated autoimmune disease have been 
generated for a multitude of autoimmune diseases including Type I diabetes [93], 
inflammatory bowel disease [94], autoimmune liver disease [75], autoimmune 
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rheumatoid arthritis [95] and multiple sclerosis [96], to just mention a few. Here, the 
animal model of multiple sclerosis should be described more in detail as an example. 
  
1.3.4.1 Experimental autoimmune encephalitis as a model of human multiple 
sclerosis 
One widely studied model for T cell mediated autoimmunity is the model of multiple 
sclerosis, which can be induced in mice where it is called experimental autoimmune 
encephalitis (EAE). In this disease auto-reactive Th1 and Th17 traffic to the central 
nervous system (CNS), where they recognize CNS-specific peptides of the myelin 
sheath with their corresponding TCR and initiate the auto-reactive immune 
response.  
Several cytokines have been implicated to be crucial for disease initiation. Initially,   
IL-12 and IFN-γ were suggested, but during the past years IL-23 and IL-17 gained 
importance [97, 98]. Later, Becher’s and Waisman’s groups demonstrated that 
neither IL-12 nor IL-17 is necessary for disease initiation [99, 100]. Just recently, 
Codarri et al. (Becher’s group) identified GM-CSF as essential factor for the effector 
phase of EAE [47]. But the debate still goes on by intensive research in this field.  
The secretion of pathogenic cytokines leads to the attraction of further immune cells 
including myeloid cells and cytotoxic CD8 T cells [47, 67, 101, 102]. The immune 
response and the inflammatory molecules are multiplied and lead to the destruction 
of oligodendrocytes [103]. The consequence is demyelination and axonal loss [104]. 
First signs of EAE are paralysis of the tail and the legs, caused by missing signal 
transmission of neurons, later it can lead to death of the mice.   
 
The disease in the model of EAE is initiated by active immunization with CNS 
antigens emulsified in complete Freund’s adjuvant (CFA) and administration of 
pertussis toxin (PT), which is supposed to break the blood brain barrier [105-107] 
and provide access of activated auto-reactive T cells to the CNS. The most 
commonly used CNS-derived antigens for immunization are myelin basic protein 
(MBP), myelin oligodendrocyte glycoprotein (MOG) or proteolipid protein (PLP). 
Alternatively, in vitro activated transgenic T cells with specificities for the above 
mentioned antigens can be transferred for disease induction.  
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1.4 B cells 
B lymphocytes (B cells) are characterized by their antigen specific receptor, the B 
cell receptor (BCR/Figure 1.5). It exists in two forms, either as a membrane bound 
BCR or as soluble immunoglobulin (Ig), also called antibody. The structure of the 
BCR receptor is identical to that of its corresponding antibody except for a small 
portion of the C-terminus of the heavy chain, which anchors the molecule in the 
membrane. The variable region recognizes the antigen and is formed by the N-
terminal parts of the two identical heavy and light chains. The heavy chains, which 
form the major part of the constant region, determine the antibody isotype. The two 
light and the two heavy chains are arranged symmetrically to form the typical Y-
shape of an antibody.  
 
Figure 1.5  | The B cell receptor (BCR). The B cell receptor consists of two identical heavy chains 
and two identical light chains. They are connected by two disulfide bonds in the hinge region. Antigens 
are recognized by the antigen binding variable region of the BCR (red). The class of an antibody is 
defined by the structure of the heavy chain, which forms together with the C-terminal part of the light 
chain the constant region (blue).  It is associated with an Igα and Igβ signalling molecule. These each 
have a single immunoreceptor tyrosine-based activation motif (ITAM / yellow segment), in their 
cytosolic tails that enables BCR signalling. Igα and Igβ form a disulfide-linked heterodimer, which is 
associated with the heavy chain. Figure adapted from Immunobiology, Janeway et al., 6th edition, 2005 
Garland science Publishing.  
 
 
In contrast to the TCR, the BCR is able to recognize a broad variety of antigens and 
does not depend on MHC molecules (further described in 1.4.4 Activation of B cells 
by different classes of antigens). The anchored BCR serves for antigen-specific B cell 
activation as it is able to transfer the event of antigen binding with the help of the 
associated Igα and Igβ signalling molecules to the cytoplasm. In contrast the 
function of soluble antibodies is to directly neutralize important structures of 
pathogens in order to prevent their pathogenic action or to opsonize pathogens, 
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which leads to the recognition and destruction of the pathogens by components of 
the innate immune system. Which effector function is conducted by an antibody 
depends on the specific isotype class (IgM, IgD, IgG, IgA, IgE).  
 
1.4.1 B cell development  
From around birth on, B cell development takes place in the bone marrow - which is 
known as the primary lymphoid organ of B cells - but also in peripheral lymphoid 
tissues such as the spleen. In comparison to T cells, B cells are generated from 
pluripotent hematopoietic stem cells during the whole life-time. As the development 
of T cells, B cell development is characterized by the stepwise assembly of the BCR.  
 
The common lymphoid progenitor (CLP) gives rise to the earliest B-lineage cell, the 
pre-pro-B cell. This cell can be recognized by the expression of B220 (CD45R). 
CD19, a molecule whose expression characterizes all later B lineage stages [108], is 
still lacking on the surface (Figure 1.6) at this early stage. The commitment to the B 
lymphoid lineage occurs before D-J recombinations of the heavy chain start [109]. In 
the pro-B cells CD19 expression and heavy chain rearrangement of D to J gene 
segments begin. To produce a complete immunoglobulin heavy chain, the late pro-B 
cells proceeds with a second rearrangement of the heavy chain V gene segments to a 
DJ sequence. A successful rearrangement leads to the production of an intact IgM 
heavy chain and the cell becomes a pre-B cell. In this step, the IgM heavy chain 
associates with λ5 and VpreB, that together form a surrogate light chain (SLC), to 
form the pre-BCR [110]. This pre-BCR assembles with the Ig accessory proteins Igα 
and Igβ, similar to the BCR on mature B cells [111, 112]. Although it is only 
transiently expressed, the pre-BCR marks an important checkpoint in B cell 
development. Signals from the pre-BCR provide rapid feedback about the 
functionality of the recombined IgH gene, so that only pre-B cells that express a 
signalling-competent receptor can continue the process of maturation. Pre-BCR 
signalling induces a burst of proliferation, which serves to increase the number of 
cells that have successfully recombined IgH genes [113] as well as it activates the 
recombination of the Ig light genes [114].  
 
After the proliferation, induced by pre-BCR signalling, the rearrangement of V to J 
gene segments of the light chain occurs. As soon as pre-B cells have successfully 
rearranged the light chain genes, it pairs with the heavy µ chain and they start to 
express the finished BCR as cell surface IgM. This stage is classified as immature B 
cells. Here, the complete BCR is first tested for tolerance to self antigens. The 
tolerance produced in the B-cell repertoire at this stage of development is known as 
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central tolerance of B cells and presents the second important checkpoint in B cell 
development.  
 
Central tolerance of B cells leads to three possible fates for self-reactive immature B 
cells as shown by a number of studies [115-121]. These fates are: cells are eliminated 
by clonal deletion; cells become anergic; or cells revise their BCR to eliminate self-
reactivity, known as receptor editing. It appears likely that high-affinity interactions 
with membrane bound antigen result in deletion, whereas low-affinity interactions 
and soluble antigens allow receptor editing or result in anergy [115, 116, 119, 120, 
122]. Cells that pass this checkpoint, which means that they have been confirmed as 
non-self-reactive, are ready to emerge into peripheral lymphoid tissues. In the 
periphery immature B cells are called transitional B cells. They can also be divided 
into three different stages: T1, T2 and T3 according to the expression of IgM, IgD, 
CD93 and CD23 [4]. Mature B cells express only low levels of IgM and high levels of 
IgD, whereas immature or transitional cells express high levels of IgM and do not yet 
express IgD.  
 
The different stage of B cell development can be detected by analyzing the 
recombination status of the heavy and light chain gene rearrangements or by surface 
markers, which are expressed characteristically at each B cell stage [4] (Figure 1.6).  
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Figure 1.6  | B cell development stages are associated with the assembly of the BCR and specific 
cell surface markers. B cell development takes place in both the bone marrow (BM) and the peripheral 
lymphoid tissues. In the BM all developmental stages can be found, whereas to the periphery only 
immature B cells migrate to continue their maturation process. During the maturation in the BM, 
rearrangements at the immunoglobulin locus occur and lead first to the expression of the pre-BCR at 
the pre-B cell stage and later to the expression of the mature BCR on immature cells. Both, the pre-
BCR and the mature BCR are able to bind antigen and to transfer this signal, which is used to first 
select cells which successfully rearranged the immunoglobulin genes and later to eliminate auto-reactive 
cells. Only cells which have successfully completed these checkpoints are released to the periphery, 
where the last steps of maturation take place. Different stages can be identified with specific surface 
expression markers (shown in the table below the corresponding cell stage). Figure based on Cambier 
J.C. et al., 2007, Nature Reviews.   
 
1.4.2 B cell subsets  
B cells can be divided into two main subsets, B1 and B2 cells. B2 cells are also often 
called conventional B cell as they present the majority of B cells in the secondary 
lymphoid organs. They can be subdivided into follicular (FO) and marginal zone 
(MZ) B cells (Figure 1.7). B1 cells are only found at a very low level in spleen and 
other peripheral lymphoid organs, they are enriched in the pleural and peritoneal 
cavities of the body [123]. They can be subdivided into B1a and B1b cells (Figure 
1.7).  
 
Most mature B cell are recirculating cells that home mainly to B cell follicles in 
secondary lymphoid organs and are known as follicular B cells.  Follicles are adjacent 
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to T cell zones and this arrangement allows activated follicular B cells and activated 
T helper cells to migrate towards each other and interact at the interface between 
these two areas. FO B cells are therefore particularly well suited to participate in T 
cell dependent immune responses to protein antigens.  
 
Marginal zone B cells are sessile cells and resided in the outer white pulp of the 
spleen between the marginal sinus and the red pulp. Pathogens reaching the 
bloodstream are efficiently trapped in the marginal zone by macrophages, and 
therefore MZ B cells are uniquely adapted to provide the first response to such blood 
borne pathogens [124, 125]. They express high levels of CD1d, which facilitate the 
presentation of lipid antigens to invariant natural killer (iNKT) cells  and it is 
probable that MZ B cells are an important source of lipid-specific antibodies [126, 
127]. MZ B cells are generated as naïve B cells that intrinsically have some 
properties that resemble those of memory cells. These include the pre-activated 
phenotype, the ability of self-renewal, and the survival as long as the life-span of the 
host [125, 128, 129]. MZ B cells may be selected during development similarly to B1 
cells, as they share functional characteristics with these cells [130].  
 
Murine B1 cells were first described in 1983 as a relatively small population of CD5 
(earlier known as Ly-1) expressing B cells that spontaneously secrete high amounts 
of IgM and are highly increased in autoimmune prone NZB/NZW F1 mice, thereby 
linking these cells to autoimmunity [131]. Later, a second  subset that closely 
resembles these CD5 expressing cells in terms of their tissue distribution, phenotype 
and development, but which did not express CD5, was found [132]. It was called 
B1b, whereas the CD5 expressing subset was called B1a. To date the functional 
difference between these two subsets is not clear [130]. 
In the pleural and peritoneal cavity B1 cells present a high proportion of the total B 
cells (20-70% depending on the mouse strain) [133]. The spleen and the BM contain 
B1 cells that spontaneously secrete large amounts of IgM, which serves to sustain the 
systemic level of circulating natural antibodies [134, 135]. At least 80% of serum IgM 
is B1 derived [136]. This steady-state production of natural IgM provides a crucial 
barrier against pathogens before the establishment of an adaptive immune response. 
Furthermore, polyspecific IgA-producing B1 cells function as a first layer of immune 
defense in the GALT and in the respiratory tract [137].  Due to these features, B1 
cells are, besides the MZ B cells, seen as part of the innate immune system. They 
also share some other characteristics with MZ B cells, which make these two subsets 
to innate-like players of the immune system. One of these characteristics is for 
example the quick response to blood-borne pathogens with T cell independent 
antibody production [138].  
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Figure 1.7  | Mature splenic B cell subsets. Four subsets of mature B cells are present in the spleen. 
The majority is formed by follicular (FO) and marginal zone (MZ) B cells, which together form the B2 
population. They can be differentiated by the surface markers CD21, CD23, IgM and IgD. B1 B cells 
represent a minor population, which can be identified by the expression of CD43 and the low expression 
of B220. Furthermore, they do not express CD21 and CD23. B1a and B1b cells can be distinguished by 
the expression of CD5. Figure based on Baumgarth, 2011, Nature Reviews.   
 
 
1.4.3 Hypotheses of B1 cell development  
The term “B1-cell” has been adopted for this subset, as they develop earlier than B2 
cells during ontogeny [139, 140]. They are efficiently generated before birth and 
during the first weeks after birth (the neonate state) in the splanchopleura region 
and the fetal liver [140, 141]. In contrast to the continuous de novo development of 
B2 cells in the BM, the BM does only poorly give raise to B1b cells and B1a 
development does almost not occur [141, 142]. Instead, B1 cells seem to be 
maintained by a process termed “self-renewal”. In this process, they undergo limited 
proliferation to replace dying cells and to sustain a stable population size over time 
[133].  
 
Not only do B1 cells develop at different times and locations in ontogeny compared 
to B2 cells, but also does the selection of B1 cells for self-reactivity seem to be 
contrary to existing models of tolerance induction and discrimination between self 
and non-self. This indicates that a distinct developmental program underlies the 
development of this unusual B cell subset. Studies using a natural auto-reactive BCR 
transgenic model revealed clearly a positive role for self-antigen in generating and 
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maintaining the pool of B1 cells [143], whereas B2 cells are rather negatively selected 
by self-antigen (as described in 1.4.1 B cell development). To explain the difference 
in B1 versus B2 cell origin and development two competing models were conceived.  
 
The “selection model” proposes that the decision of a BCR expressing B cell to 
become B1 or B2 is driven by the response to particular antigens [132, 144]. This 
idea was supported by studies which demonstrated that B1 cells were preferentially 
generated in transgenic mice exhibiting B cells that express Ig heavy and light chains 
frequently used by B1 cells [144, 145]. Additionally, several studies reported that B1 
cell characteristics (as e.g. CD5 expression) could be acquired by B2 cells [132]. 
 
The “lineage model” or “layered immune system model” proposes that B1 and B2 
cell belong to separate lineages deriving from distinct progenitors, which emerge at 
different times during ontogeny [146]. This hypothesis arose when studies comparing 
the potential to give rise to B1 or B2 cells from various tissue donor cells 
demonstrated that neonatal liver efficiently reconstitutes B1 cells upon transfer into 
irradiated recipients, whereas BM cells did so poorly [123]. The recent identification 
of a precursor cell in BM and fetal liver that specifically gives raise to B1 cells is the 
most definite evidence in support of this hypothesis [147].  
 
However, Baumgarth suggests that both models do not necessarily need to be 
mutually exclusive [133]. They can function as two coexisting developmental 
pathways that ensure the generation and maintenance of B1 cells. Baumgarth calls 
this model “the two-pathway model of B1 development” [133]. In this model the B1 
cell pool is established as the lineage model hypothesizes. Nevertheless, the positive 
selection of B1 cells by self-antigens can still occur during this development. The B1 
cell pool is then sustained by self-renewal in the adult. If steady-state conditions 
change (for example after whole body irradiation), the B1 cell output from the BM is 
increased, although the involved mechanisms are unknown. In such a situation, it is 
conceivable that B2 cell precursors undergo a B1 cell like selection process and 
contribute to the B1 cell pool.  
 
1.4.4 Activation of B cells by different classes of antigens 
In comparison to T cells, B cell activation does not rely on antigen procession 
followed by antigen-peptide presentation with the help of MHC molecules. Therefore, 
first of all, B cells have a broader spectrum of antigens to which they can respond, 
and secondly, they do not depend on APCs, which have to present the antigens. 
Instead, they can respond to membrane bound or soluble antigens. But for this 
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reason, control mechanisms preventing the activation of auto-reactive B cells that 
escaped central tolerance are indispensable.  
The main control mechanism is the requirement of T cell help in order to enable 
naïve B cells to get fully activated [148]. The costimulatory signal provided by the T 
cell, which is needed in addition to the signal created by the antigen-BCR interaction 
to activate a B cell, is the CD40L molecule interacting with CD40 on the B cell 
surface [149]. CD40L is not permanently expressed on T cells but only when they are 
activated by DC or other APCs expressing costimulatory signals for T cells 
upregulated by danger signals (as described in 1.3.2 Activation of T cells). 
Additionally, only T cells recognizing the same antigen (or linked antigens) as B cells 
can provide the required help with the CD40L. This is ensured by the mechanisms 
that B cells take up the antigen, being specifically bound to the BCR, by 
internalizing the entire BCR-antigen complex, then process the antigen, and finally 
present peptides of the antigen in MHC molecules on their surface. The B cell is only 
activated if the interaction of the TCR with the presented peptides of the antigens is 
strong enough to also lead to the interaction of CD40L and CD40 on the B cells.  
Once B cells received T cell help, they themselves transform into professional APCs 
expressing the B7 molecules (CD80 and CD86). With that, they provide the 
costimulatory signal for the T cell, which in turn upregulates CD40L, providing the 
T cell help to B cells, and therewith multiplying the whole immune response of T 
and B cells.  
 
T cells can only control immune responses to protein antigens, but B cells can 
recognize a vast variety of chemical structures. Therefore, additional mechanisms are 
necessary which control the process of activation. One of these mechanisms is the 
equipment of B cells themselves with PRR (e.g. TLR) to sense danger signals. This 
can directly provide the costimulatory signal required in addition to the antigen-
BCR interaction signal. Furthermore, other cells can substitute the CD40L signal of 
T cells. These cells are epithelial cells, DCs, macrophages and granulocytes, which 
can be activated by TLR and other PRRs leading to the secretion of BAFF and 
APRIL [150]. These proteins are CD40L related class switch recombination (CSR) 
factors, which are besides CD40L able to provide the costimulatory signal to B cells 
[151, 152].  
 
Antigens, which do not elicit T cell responses are called thymus- or T cell 
independent (TI) antigens [153]. They can be divided into two classes, namely type I 
and type II antigens (Table 1.1). TI type I antigens activate B cells by binding to 
the BCR and giving the costiumlatory signal via a PRR. An example is LPS that 
binds to TLR4. In high concentrations such antigens act as mitogens and activate B 
cells in a polyclonal way leading to proliferation and differentiation regardless of 
their BCR specificity [154].  
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TI type II antigens consist of highly repetitive structures (e.g. long polysaccharides). 
They lead to extensive crosslinking of the BCR which is sufficient to activate the B 
cell, without any further costimulatory signals [155]. Whereas TI type I antigens can 
activate both immature and mature B cells, TI type II antigens can activate only 
mature B cells; immature B cells are negatively selected during the process of central 
tolerance. Table 1.1 shows examples of T cell dependent (TD) and TI antigens.   
 
In comparison to the classification of B cell responses according the nature of the 
antigens, B cell responses can also be classified according to the cell type (Table 1.2). 
This is important when considering antigens which can not directly be classified in 
the first table, as for example phosphorylcholine (PC). This antigen is the most 
typical antigen stimulating B1 cells [132]. Structurally it belongs to the TI type II 
antigens class, but several studies also show that T cells can strongly enhance the 
response to this antigen [156]. However, type II antigens can not generally be related 
to B1 cells, as for example TNP-Ficoll, which is also a type II antigen, activates 
mainly MZ B cells [157].  
 
Table 1.1 | Classification of B cell responses according to the type of antigen  
 
 
 
Table 1.2 | Classification of B cell responses according the cell type 
 
 
 
Activated B cells proliferate and differentiate into plasma cells, which secrete large 
amounts of antibodies. During the differentiation into plasma cells a phenomenon 
called affinity maturation takes place. In this process recombined genes of antibodies 
gain somatic hypermutations. This leads to increased affinity of the BCR to antigens 
as only B cells will receive sufficient survival signals with their BCR possessing a 
high affinity for antigens. Additional, class switching of the antibody is induced by 
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recombination of the heavy chain constant region genes. Both of these processes are 
regulated by an enzyme called activation induced deaminase (AID) [158].  
 
The class of an antibody determines its effector function; therefore it is an important 
decision which subclass of antibody will be produced by activated B cells. In earlier 
times it was thought that only TD antigens can induce class switch as only then 
CD40L-CD40 signalling would be present. Later studies, however, showed that also 
TI antigens can elicit CSR [159], as this is also induced by BAFF and APRIL, which 
are expressed by other cell types than T cells [150-152]. Besides the structure of an 
antigen, which seems to be important for the class switch, cytokines are pivotal 
factors in deciding to which isotype the B cell will switch [159, 160]. Various 
cytokines have been implicated in this step, including IFN-γ and GM-CSF [153, 159, 
160] (leading to IgG2a and IgG3 class switch), IL-5 (leading IgA and IgE ) [161], IL-
4 (leading to IgG1 an IgE)[48, 162] , IL-13 (leading to IgE) [48, 163]  and TGF-β 
(leading to IgA and IgG2b) [164]. The presence of one or more cytokine and their 
action together directs the CSR and therefore the specific function of an antibody.  
 
1.4.5 B cells in autoimmune diseases 
Similar to T cells, B cells also carry an antigen-receptor, which can recognize even a 
broader range of antigens with higher affinity than the TCR. Therefore, B cells are 
the other class of lymphocytes of the adaptive immune system being able to 
recognize self-structures therewith leading to autoimmune diseases.  
 
As B cells can not cause direct cell killing, the damage is mainly caused by auto-
antibodies, which can act directly or form immune-complexes activating the 
complement and FC receptor system (Figure 1.8) [165]. Additionally, secretion of 
inflammatory cytokines, participation in antigen presentation, and the generation of 
ectopic lymphogenesis are involved in B cell mediated autoimmune diseases (Figure 
1.9) [165, 166]. Numerous autoimmune diseases in which B cells play important roles 
in pathogenesis have been described; for instance systemic lupus erythematosus 
(SLE), myasthenia gravis, autoimmune hematolytic anemia, sjorgens’s sydrom or 
rheumatoid arthritis [165, 166].  
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Figure 1.8  | Antibody-driven mechanisms of B cell autoimmunity. Classic antibody-dependent 
mechanisms are responsible either directly (top) or through immune complexes (bottom) for the 
pathogenesis of specific autoimmune diseases. (Abbreviations: SLE, systemic lupus erythematosus; 
ANCA, antineutrophil cytoplasmic antibody–associated vasculitis; AIHA, autoimmune hemolytic 
anemia; ITP, immune-mediated thrombocytopenia.). Figure from Martin, F., 2006, Annu Rev Immunol.  
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Figure 1.9  | Antibody-independent mechanisms of B cell autoimmunity. B cells can present auto-
antigens by MHC molecules on their surface as well as costimulatory signals of the B7 family, thereby 
leading to the activation of auto-reactive T cells (left). Secreted cytokines acting on T cells, DCs and 
other immune cells are another mechanism how B cells can drive autoimmune diseases (left). 
Furthermore, B cells can contribute to autoimmunity by the ability to support de novo lymphoid tissue 
organization (ectopic lymphogenesis) through expression of e.g. LTα or LTβ, which interacts with LT 
receptors on stroma cells or follicular dendritic cells (FDCs) leading to the expression of specific 
chemokines (e.g. ELC, SLC and BLC) thereby attracting other immune cells, such as T cells and 
dendritic cells (DCs)(right). Figure from Martin, F., 2006, Annu Rev Immunol. 
 
 
It has been shown that B1 cells are the key players in B cell mediated autoimmune 
diseases [132, 167]. This might be due to the fact that the selection process of B1 
cells depends on self-antigens [133, 143] (as described in 1.4.3 Hypotheses of B1 cell 
development). Once B1 cells are recruited to germinal centers, they can undergo 
CSR and affinity maturation, which was found in a study of human CD5+ B cells 
[168], leading to highly auto-reactive B cells. Elevated numbers of B1 cells have been 
reported in patients with Sjorgens’s sydrom [169] and rheumatoid arthritis [170]. In 
mice, increased numbers of B1 cells have been observed in a number of naturally 
occurring and genetically manipulated strains that develop autoimmune 
manifestations [131, 171]. Even in T cell mediated autoimmune disease B1 cells 
promote critical steps in the development, such as in type 1 diabetes [172]. Evidence 
that B1 cells are not only related but causative in the development of autoimmune 
disease comes from several studies performed in mouse models of autoimmune 
hematolytic anemia, SLE or gene targeted transgenic mice [132]. Murakami et al. 
strikingly proofed that elimination of B1 cells abrogates autoimmune symptoms in 
autoimmune prone NZB mice [173].  
 
Furthermore, IL-10 seems to play a crucial role in the activation of auto-reactive B1 
cells. It is produced by B1 cells themselves and can activate them [132, 133, 174]. 
This mechanism leads to an enormous enhancement of the B1 response. Continuous 
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administration of anti-IL-10 antibody has been demonstrated to abrogate or delay 
autoimmune symptoms [175-177], while continuous administration of IL-10 
accelerated disease [178].  
A very recent study shows that IL-10 cooperates in the class switch to IgG when B 
cells are activated by the antigen CpG-DNA [179]. Since in systemic lupus 
erythematosus  (SLE) and rheumatoid arthritis (RA), anti-DNA IgG antibodies are 
highly pathogentic [180], these findings suggest that the high levels of IL-10 observed 
in patients of SLE and RA are connected to development of high autoantibody titers 
against DNA.  
 
1.4.5.1 Animal models of systemic lupus erythematosus  
In comparison to an organ-specific immune disease as multiple sclerosis, SLE is a 
systemic autoimmune disease, which can manifest in multiple organs. The etiology of 
SLE is considered to be a combination of multiple genetic and environmental factors 
whose amalgamation breaks the threshold of immune tolerance [165]. The disease 
develops through a type III hypersensitivity reaction, in which auto-antibodies form 
immune complexes leading to further responses (as described above). Most typical 
symptoms are nephritis, arthritis, pleural effusions, or heart problems.  
 
There are numerous animal models that have long been employed in an effort to 
understand the cellular and genetic requirements for SLE induction [181, 182]. The 
most widely used ones are the NZB/NZW F1 and the MRL/lpr animal models. Both 
mouse strains develop the disease spontaneously and disease reflects the pathologies 
of human SLE, including lymph node enlargement, increased IgG levels, antinuclear 
antibody (ANA) production, proteinuria, and kidney failure caused by inflammation 
of the glomeruli [182].   
 
The MRL/lpr model of SLE shows the most severe clinical disease of all spontaneous 
models. This accelerated phenotype is attributed to a recessive autosomal mutation 
termed lymphoproliferation (lpr). The lpr mutation, located on chromosome 19, 
alters transcription of the Fas receptor [183]. Due to the mutation, the Fas receptor 
is not functional and both T and B cells show defects in apoptosis leading to 
lymphoproliferation [184]. SLE symptoms attributed to Fas deficiency in MRL/lpr 
mice have been shown to depend on both CD4+ T cells and B cells as their absence 
decreases autoimmunity [185, 186]. Furthermore, the MRL genetic background is 
important for SLE development as expression of the lpr mutation in either the 
C3H/HeJ and C57BL/6J strains did not result in nephritis [187]. In contrast, Fas-
sufficient mice on the MRL background displayed the pathological effects of 
nephritis, though onset of symptoms was significantly delayed when compared to 
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MRL/lpr mice [187]. Therefore, the MRL background genes play an important role 
in the development of the disease.  
1.5 The Dickkopf family 
The Dickkopf (Dkk) family consists of five members, Dkk1-4 and the divergent 
member DkkL1, which is also called Soggy. All five members share a sequence 
identity of 37-50% [188, 189] and are secreted proteins, therefore containing a N-
terminal signal sequence for secretion. Dkk1-4 proteins share two conserved cysteine 
rich domains (Figure 1.10). Each of these cysteine-rich domains exhibits 10 highly 
conserved residues [188, 190]. The N-terminal cysteine-rich domain (DKK_N) is 
unique to the Dkk protein family whereas the C-terminal cysteine-rich domain is 
related to the colipase fold [191]. The role of colipases in general is to facilitate the 
interaction of pancreatic lipases with lipid micelles. According to structure-function 
analysis, the colipase fold domain has been suggested to be sufficient for the 
biological activity of the Dkk family members 1, 2 and 4 [188]. The biological 
activity of these three members is to modulate the Wnt pathway, presumably with 
the help of the collipase fold domain interacting with lipids of the cell membrane.  
 
 
 
 
Figure 1.10 | The family of Dickkopf proteins. Domain structures of the Dkk1-4 and the distant 
family member DkkL1 (Soggy). Dkk1-4 share two conserved cyteine rich domains (the DKK_N and the 
colipase fold domain). The Soggy domain is unique to Dkk3 and DkkL1. Figure from Niehrs, C. et al, 
2006, Oncogene.  
 
 
Contrary to the conserved cysteine-rich domains, the linker region between the 
DKK_N domain and the colipase fold domain is highly variable between the Dkk 
proteins and is notably smaller in Dkk3 (12 amino acids, compared to 50-55 amino 
acids in Dkk1, 2 and 4). This and the additional Soggy- (sgy) domain make Dkk3 to 
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a structurally divergent member of the family. Soggy is the most distant member of 
the family as it does not contain the two cysteine-rich domains. It is most related to 
Dkk3, as both proteins share the conserved sgy-domain with 44% of homology in 
mice (NCBI database).  
 
Furthermore, Dkk1, 3 and Soggy posses potential glycolsylation sites [188]. While 
Dkk1 has only a single potential glycosylation site, Dkk3 displays four, and Soggy 
two potential glycosylation sites. Additionally, Dkk proteins carry several potential 
proteolytic cleavage sites. In Dkk3, Hermann et al. identified a dibasic amino acid 
motif at position 142/143 directly at the C-terminal site of the sgy domain [192]. 
Notably, the presence of such dibasic residues serves as cleavage sites in prohormones 
like insulin. A recent study demonstrated that Dkk3 is a substrate of the matrix 
metalloproteinase 2 and 9 (MMP2 and MMP9) [193].  
 
The Dkk family is known for involvement in the Wnt signalling as mentioned above. 
It has been shown that Dkk1, 2 and 4 bind to LRP5/6 and the Kremen receptors 
[191]. Whether Dkk3 plays a role in Wnt signalling is still controversial [188, 194-
196]. The involvement of Soggy in this pathway has only been addressed by one 
study, which shows that Soggy does not influence Wnt signalling [197]. Supporting 
the functional difference between Dkk3 and soggy to the rest of the protein family, 
phylogenetical analysis also revealed that both family members diverged from other 
Dkk proteins already early in evolution [198]. Thus, Dkk3 and Soggy appear to be 
divergent members of the family, which manifest by their structural and functional 
differences to the other members of the family.  
 
1.5.1 Dkk3 
For a long time no function for Dkk3 had been discovered. First studies looked at the 
Wnt pathway as other Dkk family members are well known to influence this 
pathway. But no influence of Dkk3 on this pathway had been found [188, 190]. Later 
these findings were questioned, when Yue et al. found that Dkk3 prevents nuclear 
translocation of β-catenin and expression of the TCF-4  targets c-Myc and Cyclin D1 
[195], which was confirmed in osteosarcoma and PC12 rat pheochromocytoma cells 
[194, 199]. Controversially, other studies reported that Dkk3 is able to act as a 
positive regulator of Wnt signalling [196]. So the debate if and how exactly Dkk3 
acts on Wnt signalling is still ongoing.  
 
It has been observed that the expression of Dkk3 is downregulated in several tumors 
including lung carcinoma [200], lymphoblastic leukemia [201], renal cell carcinoma 
[202], melanoma [203] and glioma [204]. Therefore, it is also called REIC, which 
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stands for “Reduced Expression in Immortalized Cells” and is regarded as a tumor 
suppressor gene. The attenuated expression of Dkk3 in tumors and tumor derived 
cell lines has been explained by hypermethylation of the Dkk3 promotor [195, 200]. A 
recent study confirmed that the methylation status of Dkk3 plays a key role in Dkk3 
gene silencing in a broad range of human malignancies [205]. According to these 
results, it was observed that overexpression of Dkk3 leads to tumor cell death in 
prostate cancer [206], glioma [204], breast cancer [207], and renal cell carcinoma 
[208], thus suggesting Dkk3 as a therapeutic target in human cancers.  
Although many studies focused on the function of Dkk3 as a tumor suppressor, there 
are opposing studies indicating that Dkk3 promotes tumor growth. Ketase et al. 
showed that mutation in the Dkk3 locus was associated with a better prognosis of 
lymph node metastasis in neck squamous cell carcinoma [209], Gregorieff et al. 
showed the overexpression of Dkk3 in adenomas [210], and Pei et al. the 
overexpression of Dkk3 in hepatoblastoma and hepatocellular carcinoma [211]. 
Hence, the role of Dkk3 in tumors might depend on the cell type and the particular 
condition which is examined.  
 
Dkk3 is a secreted molecule being expressed in the brain, eye, heart, liver, hair 
follicle, uterus, embryo, placenta and pancreatic beta islet cells [188, 192, 212]. The 
expression pattern indicates that Dkk3 is primarily expressed in immune privileged 
sites. This feature lead our laboratory to the investigation of Dkk3 in the immune 
system, when it appeared to be highly upregulated in a differential gene analysis 
profile in a special tolerogenic CD8 T cell [212]. In this transgenic system a specific 
CD8 T cell is conferring tolerance to other T cells exhibiting the same TCR 
specificity [213] and Dkk3 is not only indispensable but also sufficient for the CD8 T 
cell mediated regulation [214].  
 
In 2006, Dkk3 deficient mice (Dkk3-/-) were generated and characterized [189].   
Dkk3-/- mice are, however, viable, fertile, and do not show tumor formation or 
obvious signs of misled tolerance, which would manifest by symptoms of 
autoimmunity. Within the hematological and immunological parameters they only 
displayed a few alterations, which are elevated heamtokrit and hemoglobin levels, 
higher IgM levels and a slightly increased frequency of natural killer (NK) cells.  
1.5.2 Soggy 
The soggy gene is unique to mammals and its mRNA has been reported to be 
expressed in developing sperms, trophoblast, placenta, fetal eye, neural tissues and 
lymphocytes of the spleen [215, 216]. Furthermore, it has been found in several 
tumor cell lines including the T lymphoma EL-4 and the B cell lymphoma A20, 
MPC-11 and CH1 [216].  
INTRODUCTION   
 
29 
Functional analysis of the Soggy gene was in all published studies carried out in a 
site where Soggy was known to be abundantly expressed, the testis. Kohn et al. 
found that Soggy is first post-translationally N-glycosylated and then deglycosylated 
again  while locating to the acrosome of the mature sperm [216].  In the acrosome, 
Soggy is probably modified by phosphorylation and remains sequestered in this site 
despite the presence of the signal sequence. In contrast, a different study showed that 
Soggy in the acrosome of mature sperm is truncated and only partially 
deglycosylated [217]. Continuing the study of the actual function of Soggy in 
spermatocytes, Kohn reported recently that acrosomal Soggy facilitates sperm 
penetration of the zona pellucida during in vitro fertilization [218].  
 
To further improve the understanding of the function of Soggy, the Soggy gene was 
disrupted by replacing the first 45 amino acid codons with the LacZ gene [197]. Mice 
lacking Soggy are viable and fertile. However, Dakhova et al. demonstrated that 
Soggy regulates postpubertal spermatocyte apoptosis thereby regulating sperm 
counts [197]. Additionally, they found that Soggy locally leads to increased 
testosterone production in older animals. Molecular analysis revealed that FasL 
expression is induced by Soggy, which explains the decreased apoptosis of sperms in 
Soggy deficient mice. Therefore, Soggy is suggested to be a new pro-apoptotic factor.  
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1.6 Aims of this study 
Protection of tissues against the devastating consequences of immune responses is 
essential for the integrity of the organism. Potential auto-reactive lymphocytes are 
either clonally deleted or controlled by mechanisms of peripheral tolerance. The 
search of potential mediators of peripheral tolerance led our laboratory to the protein 
Dkk3. Interestingly, the cells secreting the highest levels of this protein are comprised 
in tissues traditionally defined as immune-privileged sites, such as the brain, spinal 
cord and eye. Many mechanisms used by the immune system for tolerance induction 
and establishment of an immune privileged site are overlapping as reported for 
several factors like FasL, [219, 220] IDO [25, 221], or TGF-β [222, 223]. It is possible 
that Dkk3 is one of these molecules acting as a key player in tolerance induction and 
limiting immune responses in immune privileged sites.  
Recently, we indeed demonstrated that Dkk3 is essential to maintain peripheral CD8 
T cell tolerance in a TCR-transgenic mouse model [214]. This is the first finding 
showing that Dkk3 is influencing the immune system.  
 
The aim of the thesis is to further clarify the immuno-modulatory capacity of Dkk3.  
In the first part of the thesis the question will be addressed whether and how Dkk3 is 
contributing to the immune suppressive milieu of immune privileged sites thereby 
limiting auto-reactive T cell responses.  
 
B cells are essential players of adaptive immune responses which also need to be 
controlled to prevent auto-reactivity. Therefore, in the second part of the thesis, 
main characteristics of B cells like antibody body responses and cytokine secretion 
will be compared between Dkk3 deficient and sufficient mice. To analyze whether 
Dkk3 regulates B cell mediated autoimmunity, a model of systemic lupus 
erythematosus will be used.  
 
In the third part of the thesis, we will address the question which structural part of 
Dkk3 might be responsible for the immuno-modulatory function. Dkk3 shares the 
unique and homologous sgy domain with the protein Soggy. Therefore, Soggy-/- mice 
will be investigated for an immunological phenotype. This will reveal, whether Soggy 
exhibits a similar immuno-modulatory capacity to Dkk3.  
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2 Material and Methods 
2.1 Material 
2.1.1 Chemicals 
Name Company 
2-isopropanol  Fluka  
Acetic Acid (C2H4O2)  Merck  
Aceton  VWR  
Acrylamide, 30%  Roth, Karlsruhe  
Agar  Sigma  
Agarose Ultra Pure®  Roth  
Ammoniumpersulfate  Appli Chem  
Amplicillin  Roth  
Bacto-Agar  Beckton Dickenson, USA  
Bacto-Trypton  Roth  
Bromophenol Blue  Sigma  
BSA  Gerbu  
Calcium Chloride (CaCl2)  Merck  
CFSE  Sigma  
Chloroform  VWR  
DELFIA® Enhancement Solution  PerkinElmer  
DELFIA® Eu (europium) –labeled streptavidin  PerkinElmer  
Desoxyribonucelic acid, activated from calf thymus Sigma 
Dickkopf-3-IgG2 recombinant protein  DKFZ (D050)  
Dimethylsulfoxid (DMSO)  Merck  
Disodium carbonate (Na2CO3)  Roth  
Disodium hydrogen phosphate (Na2HPO4)  Merck  
dNTPs  Fermentas  
Dulbecco’s Modified Eagle Medium (DMEM)  Invitrogen  
Dulbecco’s Phosphate Buffered Saline (dPBS)  Invitrogen  
EDTA disodium salt (Na2EDTA)  Pharmacia Biotech  
EGTA  Pharmacia Biotech  
Ethanol  Sigma  
Ethidium bromide  Appli Chem  
Fetal calf serum (FCS)  Biochrom AG  
Formic acid (HCO2H)  Sigma  
G418 – Geneticin  Gibco  
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Gelantine  Roth  
Glucose  Sigma  
Glutamine  Gibco  
Glycerin (C3H8O3)  Merck  
Glycine  Gerbu  
H2O (30%)  Sigma  
H2SO4  Merck  
Heparin Ratiopharm 
HEPES  Roth  
Hexaaminecobaltchloride  Sigma  
Hydrochloric Acid (HCl)  J.T. Baker  
Ketanest Pfizer 
Lipofectamine 2000 Reagent  Invitrogen  
Lithiumchloride (LiCl)  Sigma  
Magnesium Chloride (MgCl2)  Sigma  
Magnesium Sulfate (MgSO4)  Merck  
Rompun Bayer 
β-Mercaptoethanol  Merck  
 
 
2.1.2 Buffers and Media 
Molecular cloning and DNA analysis  
DNA loading buffer 5 x  30% Glycerol  
0.1% Bromphenol Blue  
0.1% Xylenxyanol  
Fast-MINIPREP pre-lysis buffer  25 mM Tris/HCl  
50 mM Glucose  
10 mM EDTA  
pH 8.0  
Fast-MINIPREP lysis buffer  1 M NaOH  
1% SDS  
Fast-MINIPREP neutralizing buffer  3M Potassium acetate/  
Formic acid  
TAE buffer  40 mM Tris/HCl  
1 mM EDTA  
0.114% Acetic Acid  
pH 8.0  
TE buffer  10 M Tris/HCl  
2 mM EDTA  
pH 8.0  
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Tail buffer  200 mM NaCl  
100 mM Tris/HCl  
5 mM EDTA  
0.2% SDS  
pH 8.5  
Transformation buffer  10 mM Potassium acetate  
45 mM MnCl2  
10 mM CaCl2  
100 mM KCl  
3 mM 
Hexamminecobaltchloride  
10% Glycerin  
pH 7.5  
 
Protein analysis  
ELISA carbonate buffer 50mM Na2CO3 
50mM NaHC03 
pH 9.6 
ELISA blocking buffer  PBS  
0.2% Gelantine  
0.1% NaN3  
ELISA development buffer  0.1 M KH2PO4  
1 µl/ml H2O2  
1 mg/ml OPD  
pH 6.0  
IL-2 ELISA assay buffer  50 mM Tris/HCl  
20 M EDTA  
0.9% NaCl  
0.5% BSA  
0.1% Tween20  
pH 7.8  
Lysis buffer  20 mM Tris/HCl  
150 mM NaCl  
1 mM EDTA  
1 mM EGTA  
0.5% NP-40  
pH 7.6  
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Protein loading buffer 6x  72 mM Tris/HCl  
36% Glycerol  
18% SDS  
9% β-Mercaptoethanol  
0.24% Bromphenole Blue  
pH 6.8  
SDS-PAGE running buffer  25 mM Tris/HCl  
192 mM Glycine  
0.1% SDS  
0.2  
pH 8.3  
SDS-PAGE sample buffer 6x  62.5 mM Tris/HCl  
714 mM β-Mercaptoethanol  
20% Glycerin  
2% SDS  
0.025% Bromophenol blue  
pH 6.8  
Separating gel buffer 4 x  1.5 M Tris/HCl  
pH 8.8  
Sodium carbonate buffer  50 mM Na2CO3  
50 mM NaHCO3  
pH 9.6  
 
Stacking gel buffer 4 x  1 M Tris/HCl  
pH 6.8  
Western blot blocking buffer  PBS  
0.1% Tween20  
5% Skim Milk Powder  
 
Western blot transfer buffer  48 mM Tris  
39 mM Glycine  
1.3 mM SDS  
20% Methanol  
pH 9-9.4  
 
Cell biology and common laboratory buffers  
Dulbecco’s PBS (dPBS)  PBS supplied with MgCl2 
and CaCl2 (Invitrogen)  
FACS buffer  dPBS  
2% FCS  
0.1% NaN3  
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Heparinbuffer  dPBS 
2% FCS 
5u/ml heparin 
MACS buffer  PBS (Gibco)  
2 mM EDTA  
0.5% FCS  
pH 7.2  
Phosphate buffered saline (PBS)  130 mM NaCl  
2.6 mM KCl  
15 mM KH2PO4  
4 mM Na2HPO4  
pH 7.2  
Phosphate buffered saline and Tween20 (PBS-
Tween)  
PBS  
0.05% Tween20  
 
Cell culture media  
Cell-freezing medium  Heat-inactivated FCS  with  
20% DMSO  
DMEM-full medium  DMEM (Invitrogen)  
10 mM HEPES  
2 mM L-Glutamine  
10% Heat-inactivated FCS  
100 units/ml Penicillin  
100 g/ml Streptomycin  
 
RPMI-full medium  RPMI 1640 (Gibco)  
10 mM HEPES  
2 mM L-Glutamine  
0.05 mM β-Mercaptoethanol  
10% Heat-inactivated FCS  
100 units/ml Penicillin  
100 g/ml Streptomycin  
 
MATERIAL AND METHODS 
 
 
36 
2.1.3 Kits 
Name Company 
Absolute™ QPCR SYBR® Green ROX Mix  Thermo Scientific  
CD19 Microbeads Miltenyi Biotec 
CD4+ CD62L+ T cell isolation kit Miltenyi Biotec 
CD45R Microbeads Miltenyi Biotec 
Cytometric bead array – Mouse Inflammation Kit BD Bioscience 
Cytometric bead array – Mouse Th1 Th2 Th17 
Cytokine Kit 
BD Bioscience 
Dynal® Mouse CD4 T cell negative isolation kit  Invitrogen  
Dynal® Mouse T cell negative isolation kit  Invitrogen  
Foxp3 Fixation/Permeabilization Concentrate and 
Diluent  
eBioscience  
Immobilon Western Chemiluminescent HRP 
Substrate  
Millipore  
Mouse IL-10 ELISA Kit eBioscience 
Pierce BCA protein assay  Thermo Scientific  
Precellys Ceramic Kit  Pequlab  
ReverseAid Reverse Transcriptase kit Thermo Scientific 
RNeasy mini kit  Quiagen  
  
2.1.4 Primers 
Primers for β-actin cDNA template amplification  
F-Primer  5’ TGA CAG GAT GCA GAA GGA GAT TA 3’  
R-primer  5’ AGC CAC CGA TCC ACA CAG A 3’  
Primers for HPRT cDNA template amplification  
F-Primer  5’ ACA CCT GCT AAT TTT ACA GGC AAC A 3’  
R-Primer  5’ TGG AAA AGC CAA ATA CAA AGC CTA 3’  
Primers for GAPDH cDNA template amplification  
F-Primer  5’ CAT GGC CTT CCG TGT TCC TA 3’  
R-Primer  5’ TGT CAT CAT ACT TGG CAG CTT TCT 3’  
Primers for Soggy cDNA template amplification  
F-Primer  5’ AGG TCA CCG ACA GCT TGC A 3’  
R-Primer  5’ TGG CAT CTT CAT GAT CCA GAA 3’  
Primers for Dkk3 cDNA template amplification 
F-Primer  5’ TCC CAT TGC CAC CTT TGG  3’  
R-Primer  5’ CCA GTT CTC CAG CTT CAA GTA CAC 3’  
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2.1.5 Antibodies 
2.1.5.1 Western blot and ELISA 
Name Company 
Goat anti-mDKK3-Biotin  RnD Systems  
Goat anti-mouse IgG1-HRP Southern Biotech 
Goat anti-mouse IgG2a-HRP Southern Biotech 
Goat anti-mouse IgG2b-HRP Southern Biotech 
Goat anti-mouse IgG3-HRP Southern Biotech 
Goat anti-mouse IgG-HRP Jackson Immuno Research 
Goat anti-mouse IgM/IgG Jackson Immuno Research 
Goat anti-mouse IgM-HRP Southern Biotech 
Goat anti-mSoggy-1-Biotin  RnD Systems  
Goat anti-rabbit IgG-Peroxidase-
conjugated  
Jackson ImmunoResearch Laboratories 
Inc.  
Monoclonal anti-mDKK3-4.22  DKFZ (Dr. Gerhard Moldenhauer)  
Monoclonal anti-mDKK3-4.22-Biotin  DKFZ (Dr. Gerhard Moldenhauer)  
Monoclonal rat anti-mouse Soggy-1  RnD Systems; Clone: 192425  
Rabbit anti-mDKK3  Sino Biological Inc.  
Rat anti-mouse IL-2  BioLegend; Clone: JES6-1A12  
Rat anti-mouse IL-2-Biotin  BioLegend; Clone: JES6-5H4  
  
2.1.5.2 FACS staining 
 
Name Company 
B220 APC eBioscience; Clone: RA3-6B2 
CD19 biotin Biolegend; Clone: MB19-1 
CD19 biotin BD Biociences; Clone: 1D3 
CD21/CD35 FITC BD Biociences; Clone: 7G6 
CD23 PE-Cy7 Biolegend; Clone: B3B4 
CD25 PE  BD Biosciences; Clone 3C7  
CD25 PerCP-Cy5.5 BioLegend; Clone: PC61  
CD3 PE BD Biociences; Clone: 145-2C11 
CD4 APC-Cy7  BD Biosciences; Clone: GK1.5  
CD4 Pacific blue  BD Biosciences; Clone: RM4-5  
CD43 PE BD Biociences; Clone: S7 
CD44 PE-Cy7  eBiosciences; Clone: IM7  
CD5 Pacific blue eBioscience; Clone: 53-7.3 
CD62L FITC BD Bioscience: Clone MEL-14 
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CD8 biotin  BD Biociences; Clone: 53-6.7 
CD8 eFluor450  eBiosciences; Clone: 53-6.7  
CD8a Alexa Fluour647  BioLegend; Clone: 53-6.7  
CD93 APC Biolegend; Clone: AA4.1 
Fc-Block  DKFZ, D050  
Foxp3 PE  eBiosciences; Clone: FJK-16S  
Helios APC  Biolegend; Clone: 22F6  
IFN-γ PE-Cy7 BD Biociences; Clone: XMG1.2 
IgM PerCP BD Biociences; Clone: R6-60.2 
IL-10 PE BD Biociences; Clone: Jes5-16E3 
Streptavidin APC-Cy7 BD Biociences 
CD11b Pacific blue Biolegend; Clone M1/70 
IL-17 APC Biolegend; Clone: TC11-18H10 
GM-CSF PE Biolegend; Clone: MP1-22E9 
T-bet PE eBioscience; Clone: eBio4B10 
EOMES Alexa Fluour 647 eBioscience; Clone: Dan11mag 
RORγt PE eBioscience; Clone: AFKJS-9 
GATA-3 PE eBioscience; Clone: TWA-J 
CD127 (c-Kit) Pe-Cy7 eBioscience; Clone: 2B8 
 
2.1.6 Reagents used in cell simulation and differentiation assays 
Name Company 
Brefeldin (Golgi-Plug) BD Biosciences 
CpG TIB Molbiol 
F(ab’)2 fragment goat anti-mouse IgM Jackson Immuno Research 
Ionomycin calcium salt Sigma-Aldrich 
LPS  Sigma Aldrich, L4391 
Monesin (Golgi-Stop) BD Biosciences 
Monoclonal hamster anti-mouse CD28  BD Biosciences; Clone: 37.51  
Monoclonal hamster anti-mouse CD3  BD Biosciences; Clone: A19-3  
Monoclonal rat anti-mouse CD40 Biolegend; Clone 3/23 
Monolocal rat anti-mouse IFN- γ  Biolegend; Clone: R4-6A2 
Monolocal rat anti-mouse IL-17 Biolegend; Clone: TC11-18H10.1 
Monolocal rat anti-mouse IL-4 Biolegend; Clone: 11B11 
Phorbol 12-myristate 14-acetate (PMA) Sigma 
Polyinosinic–polycytidylic acid potassium 
salt (Poly I:C) 
Sigma-Aldrich 
Recombinant human TGF-β -1 Preprotech 
Recombinant mouse IL-2  Gibco 
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Recombinant murine IFN-γ Preprotech 
Recombinant murine IL-12 Preprotech 
Recombinant murine IL-12 R&D 
Recombinant murine IL-12 (p70) Preprotech 
Recombinant murine IL-2 Gibco 
Recombinant murine IL-4 Preprotech 
Recombinant murine IL-6 Preprotech 
  
2.1.7 Reagents used for in vivo applications 
Name Company 
LPS  Sigma Aldrich, L2630 
Monoclonal anti-mDKK3-4.22  DKFZ (Dr. Gerhard Moldenhauer) / 
BioXCell (Purification) 
Monoclonal MOPC21 Isotype control 
(IgG1) 
BioXCell 
Myelin oligodendrocyte glycoprotein 
peptide 33-55 (MOG)  
 
Peptide specialty laboratories  
Amino acid sequence: 
MEVGWYRSPFSRVVHLYRNGK 
Phosphorylcholine-keyhole limpet 
hemocyanin (PC-KLH) 
Biosearch Technologies 
TNP-AECM-Ficoll (TNP-Ficoll) Biosearch Technologies 
TNP-BSA Biosearch Technologies 
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2.1.8 Mice 
Strain Source 
C57BL/6N (wt) Charles River Laboratories  
C57BL/6N Dkk3-/-  (Dkk3-/-) Provided by Christof Niehr’s 
laboratory from the DKFZ, Heidelberg 
(Niehrs et al., 2006)  
C57BL/6N Soggy-/-  (Soggy-/-) Charles River Laboratories   
C57BL/6N Rag2-/- (wt.Rag2-/-) Charles River Laboratories  
C57BL/6N Rag2-/- Dkk3-/- (Dkk3-/- Rag2-/-) Established by crossing of C57BL/6N 
Dkk3-/- with C57BL/6N Rag2-/- at the 
DKFZ 
NOD.Rag2-/- 
Name at Jackson laboratories: 
 NOD.129S7(B6)-Rag1tm1Mom/J 
Provided by Dr. Freurer’s laboratory 
from the DKFZ 
Bdc2.5/NOD  
Name at Jackson laboratories  
NOD.Cg-g(TcraBDC2.5,TcrbBDC2.5) 
Provided by Dr. Freurer’s laboratory 
from the DKFZ 
FoxP3.LuciDTR-4 Established in the laboratory 
Name at Jackson laboratories: 
 MRL/MpJ-Faslpr/J 
(MRL/LPR) 
Jackson Laboratories 
2D2.Dkk3-/-  Established by crossing of C57BL/6N 
Dkk3-/-  with 2D2 mice at the DKFZ 
 
All mice were bred and maintained under specific pathogen-free conditions (SPF) at 
the animal facility of the German Cancer Research Center.  
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2.2 Methods 
2.2.1  RNA analysis 
2.2.1.1 Isolation of RNA from tissues 
Organs frozen in liquid nitrogen were disrupted with Precellys Ceramic Kit 1.4mm 
and the FastPrep Homogenizer in buffer RLT (Quiagen) containing RNase 
inhibitors. Total RNA was purified from disrupted tissue using the RNeasy mini kit 
according to manufacturer’s instructions. Additionally, RNA was desoxyribonuclease-
I treated (Quiagen). RNA concentration was measured by Nanotrop and stored at -
20°C.  
 
2.2.1.2 cDNA reverse transcription 
Complementary DNA (cDNA) was synthesized from messenger RNA (mRNA) using 
the ReverseAid Reverse Transcriptase kit. The cDNA synthesis was done according 
to the protocol in Table 2.1. The total volume of the synthesis reaction was 20µl. 
cDNA was diluted 1:50 and stored at -20°C for later use by RT-PCR.  
 
Table 2.1 | Temperature profile and pipetting scheme of the cDNA synthesis 
               Component              Final amount 
Purified RNA in RNase-free water 2 µg 
dNTPs 0.5 mM (each) 
Oligo dTs 5 mM 
5 min, 68°C 
afterwards directly chilled on ice 
5 x RT buffer 1 x 
DTT 10 mM 
RiboLock RNase Inhibitor 2 U/µl 
Reverse Transcriptase 10 U/µl 
1 h, 42°C 
15 min, 70°C 
 
2.2.1.3 Quantitative real-time PCR  
Quantitative real-time PCR was done by using the Absolute Q-PCR SYBR Green 
ROX Mix containing all the components necessary for the PCR with the exception of 
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primer and cDNA template (synthesized as described above) (Table 2.2/Table 2.3). 
The final volume of the reaction was 25µl. For comparative analysis, the cDNA 
subjected to quantitative real-time PCR was internally normalized to β-actin levels 
as a control housekeeping gene. Samples were measured in triplicates by a 7500 Real-
Time PCR System and cycle threshold (Ct) values, representing the number of PCR 
cycles that were required to reach a given level of fluorescence, were analyzed by the 
Applied Biosystems Sequence Detection Software 1.4. Since SYBR green 
unspecifically binds DNA, the dissociation curves were analyzed for each target gene 
in order to control the specificity of the signal. Relative ∆Ct values of the sequence 
of interest were calculated according to:  
 
2 -∆Ct = 2 -(Ct -β-actin – Ct sequence of interest)  
 
Table 2.2 | Pipetting scheme of the quantitative real-time PCR  
               Component              Final amount 
cDNA 80 ng 
Forward and reverse primer each 200 nM 
Absolute Q-PCR SYBR Green 
ROX Mix 2 x 
1 x 
 
 
Table 2.3 | Temperature profile of the quantitative real-time PCR 
Temperature [°C] Time [sec] 
50 120 
95 600 
95 15
60 60
 
 
 
 
 
    40 cycles 
95 15 
60 60 
95 15 
 
 
2.2.2 Protein analysis 
2.2.2.1 Preparation of protein lysates from tissues/cells 
Organs were taken, directly frozen in liquid nitrogen and stored at -80°C. Organs 
frozen in liquid nitrogen were disrupted in lysis buffer containing Protease Inhibitor 
Cocktail (Roche) with Precellys Ceramic Kit 1.4 mm and the FastPrep Homogenizer 
followed by 30min incubation on ice. Then, cell debris was separated by 
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centrifugation (16.000 x g, 10min, 4°C), the supernatant was transferred to a new 
tube and centrifuged again. Supernatant was again transferred to a new tube and 
stored on ice until usage.  
2.2.2.2 Western Blot and immunodetection of proteins  
Proteins that were first separated by SDS-PAGE were transferred to a PVDF 
membrane (Millipore) and were detected by specific antibodies. The gel and the 
membrane were put in direct contact to each other in a Semidry Transfer Cell 
(BioRad) and a righted electric field was applied. Due to their negative charge, the 
proteins migrated from the gel towards the anode and were fixed onto the PVDF 
membrane via hydrophobic interactions. By this means, the electrophoretic patterns 
are conserved onto the membrane. First, the PVDF membrane was activated in 
100% methanol for 1min. Afterwards, the membrane, filter papers (Whatman) and 
gel were incubated shortly in transfer buffer and assembled to a “sandwich” Western 
blot. Finally, proteins were transferred at 2A and 18V for 20 min.  
 
Non-specific binding sites on the membrane were blocked with blocking buffer 
containing 5% milk powder for 1h. Afterwards, the membrane was incubated with 
the primary biotinylated antibody (diluted to 1µg/ml in 2.5% milk in PBS-Tween) 
specific for the protein of interest diluted in blocking buffer containing 2.5% milk 
powder ON at 4°C. The membrane was washed four times with PBS-Tween for 
10min. The peroxidase-conjugated streptavidin was diluted 1:40.000 in blocking 
buffer containing 2.5% milk powder. After 1 h of incubation, the membrane was 
washed four times with PBS-Tween for 10 min. This streptavidin was coupled to 
peroxidase that enabled the visualization of the complex by a chemiluminescence 
reaction. For detection of the peroxidase-conjugated streptavidin, the Immobilon 
Western Chemiluminescent HRP substrate was used according to the manufacturer’s 
instructions. 
 
2.2.2.3 ELISA 
2.2.2.3.1 Immunoglobulin ELISA 
Immunoglobulin ELISA was used to determine the concentration of antigen-specific 
or unspecific immunoglobulin isotypes in serum or in supernatants after B cell 
stimulation in vitro. For antigen-specific immunoglobulin detection, Costar 96-well 
polystyrene microplates (Sigma) were coated with 10µg/ml of antigen (TNP-BSA, 
TNP-Ficoll, TNP-LPS or PC-BSA). For the standard curve, wells on the same plate 
were coated with goat-anti-mouse IgM/IgG. Coating was performed in sodium 
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carbonate buffer at 4°C ON. Plate was then washed twice with PBS-Tween and then 
blocked with blocking buffer at 4°C ON or until usage. After blocking plates were 
washed twice with PBS-Tween and samples were mounted with different dilutions 
depending on the samples on the coated plates. As standard, purified 
immunoglobulin of the isotype of interest was used in a dilution row of 1:2 dilutions 
starting with 500ng/ml until 4ng/ml. Samples and standards were incubated 2 hours 
at RT, then washed 5 times with PBS-Tween. Afterwards, HRP-conjugated 
antibodies against the isotype of interest were added to the wells to detect the 
antigen-specific isotype and incubated 1 hour at RT. Plates were washed 5 times 
with PBS-Tween before development buffer was added. After the color development 
the reaction was stopped with 1M H2SO4. Absorption was measured at 492nm at the 
ELISA reader (Victor 1420 Multilabel counter photometer/ PerkinElmer).  
 
2.2.2.3.2 IL-2 ELISA 
The IL-2 ELISA was used to determine the IL-2 production of T cells in culture 
supernatants after stimulation in vitro. Supernatants were collected 24 hours after 
stimulation of T cells and stored at –20°C or directly used. Nunc F96 Micro Well™ 
PolySorp™ Black (Thermo Scientific) microplate were coated ON at 4°C with 
1µg/ml rat anti-mouse IL-2 capture antibody in sodium carbonate buffer, washed 
twice with PBS-Tween and blocked with blocking buffer. Plates were washed 5 times 
with PBS-Tween and culture supernatants were transferred to the plates and 
incubated ON at 4°C. Then plates were washed five times with PBS-Tween and the 
IL-2 protein was detected by incubation with 0.25µg/ml rat anti-mouse IL-2-biotin 
detector antibody in PBS-Tween for 2h at RT. Afterwards, the plates were washed 
five times with PBS-Tween and 0.1µg/ml DELFIA europium (Eu)-labeled 
streptavidin diluted in IL-2 assay buffer was added. Plates were incubated 45 
minutes at RT. The reaction was enhanced by the addition of DELFIA 
Enhancement solution 30 minutes later, the plate was read by the ELISA reader 
using 340 nm and 615 nm fluorescent filters. 
 
2.2.2.3.3 IL-10 ELISA 
The IL-10 ELISA was used to determine the IL-10 production of B cells in culture 
supernatants after stimulation in vitro. Supernatants were collected 24 hours after 
stimulation of B cells and stored at –20°C or directly used. IL-10 ELISA was 
performed using the IL-10 ELISA kit from eBioscience and Costar 96-well 
polystyrene microplates. The assay was performed according to manufacturer’s 
instructions.  
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2.2.2.3.4 Soggy ELISA 
The ELISA for Soggy was used to analyze the expression pattern of Soggy in 
different mouse organs and serum. Costar 96-well polystyrene microplates were 
coated with 3µg/ml monoclonal rat anti-mouse Soggy-1 antibody in PBS and 
incubated ON at 4°C. The plates were washed twice with PBS-Tween and blocked 
with blocking buffer ON at 4°C. All organ lysates were adjusted to a concentration 
of 10mg/ml and diluted in lysis buffer containing protease inhibitors. As a standard, 
Soggy peptide (R&D) was diluted in lysis buffer in a dilution row of 1:2 dilutions 
starting 100ng/ml until 1.5ng/ml. After plates were washed 5 times with PBS-Tween 
samples and standards were added and incubated ON at 4°C. The plate was washed 
five times with PBS-Tween and incubated 1h at RT with 1µ g/ml biotinylated goat 
anti-mouse Soggy-1 antibody in PBS-Tween. Afterwards, the plates were washed 
again five times with PBS-Tween and Soggy was detected by incubation with 
peroxidase-conjugated streptavidin diluted 1:1000 in PBS-Tween for 1h at RT. 
Plates were washed 5 times with PBS-Tween before development buffer was added. 
The reaction was stopped immediately by adding 25µl of 1M H2SO4 per well and the 
absorption was measured at 492 nm at the ELISA reader.  
 
2.2.2.4 Cytometric Bead Array 
Cytometric Bead Arrays were used to determine cytokines secreted by B cells (CBA 
Inflammation Kit, BD) or to analyze T cell differentiation (CBA Th1, Th2, Th17 
differentiation, BD). The assay was performed according to manufacturer’s 
instructions and samples were measured at FACS Canto II (BD Biosciences). Data 
were analyzed using FCAP array software (BD Biosciences).  
 
2.2.3 Preparation of leukocyte cell suspensions 
2.2.3.1 Preparation of single cell suspensions from lymphatic tissues 
Spleens, LN or BM were isolated from mice and placed into dPBS. Cells were 
extracted by forcing organs trough a 40µm nylon cell strainer (Falcon) using a 
syringe plunger. The cell strainer was then rinsed with ice-cold dPBS, cells were 
washed and placed into FACS buffer or RPMI depending on the experiment.  
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2.2.3.2 Isolation of mononuclear cells from blood 
Mouse blood was taken directly into heparinbuffer and pipetted onto Lymphoprep 
(Axis-Shield, Oslo, Norway), which is a medium with a density of 1,077g/ml. The 
tubes were centrifuges 20min at 1800rpm without breaks. During centrifugation, 
erythrocytes and polynucleated cells pass trough the Lymphoprep due to their higher 
density, while mononuclear cells accumulate on top of the Lymphoprep phase due to 
their low density and become visible as a white band. This band is isolated and 
washed once with ice-cold dPBS. The cells are then resuspended in FACS buffer for 
FACS staining.  
2.2.3.3 Isolation of peritoneal cavity cells 
Skin was opened at the belly of the mice leaving the peritoneum intact and 5ml of 
ice-cold dPBS were injected i.p.. The belly of the mice was then massaged for about 
1min. Then dPBS was sucked out with a syringe. This process was repeated to 
increase absolute cell numbers. Cells were washed and resuspended in RPMI, FACS 
buffer or MACS buffer depending on the following experiment.  
 
2.2.3.4 Isolation of leukocytes from the brain 
Mice were lethally anesthetized with 700µl of 5mg/ml Ketanest and 0,2% Rompun 
solution, which was injected i.p.. The pleural cavity was opened without injuring the 
heart. Then the right atrium was cut open and into the left ventricle 37°C warm 
HBSS was injected slowly. This process leads to perfusion of the liver but also the 
brain and the spinal cord leading to a white color.  
Brain and spinal cord were isolated, placed into ice-cold dPBS and cut into small 
pieces. Then they were digested with 2,5mg/ml Collagenase D (Sigma-Alrich) and 
1mg/ml Desoxyiribonuclease I (Sigma-Aldrich) in dPBS/10%FCS for 30min at 37°C. 
The digested brain and spinal cord were forced several times through a metal sieve 
with the help of syringe plunger, washed and resuspended in 2,5ml RPMI. To enrich 
the leukocyte fraction the suspension was mixed with 1ml isotonic (density of 
1.13g/ml) Percoll (GE Healthcare). This was then underplayed with 1ml of Percoll 
with a density of 1.08g/ml. The gradient was established through centrifugation for 
20min at RT at 2500 rpm without breaks. The interphase containing the leukocyte 
fraction was isolated washed and used for FACS staining or T cell restimulation.  
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2.2.4 Magnetic cell sorting 
Magnetic cell sorting provides a system where specific cell types can be isolated from 
cell suspension with high purity. Different companies provide super-paramagnetic 
colloids conjugated either to monoclonal antibodies that can bind to specific surface 
markers, or to Streptavidin that can bind to biotinylated antibodies. After labeling 
the cells with the magnetic beads directly or indirectly they can be separated from 
unlabelled cells with the help of a magnet. In this study Dynal beads (Invitrogen) 
were used for negative isolation strategies (e.g. T cell negative isolation) and MACS 
microbeads (Milteny Biotec) were used for positive isolation strategies (e.g. CD19+ or 
CD45R+ cell isolation). The purification protocol was performed according to 
manufacturer’s instructions. 
 
2.2.5 Fluorescence-Activated Cell Staining (FACS) 
2.2.5.1 Staining of cell surface makers 
To block unspecific binding cells were incubated with FC-Block. Depending on the 
experiment 0,5-5 x 106 cells were incubated with monoclonal antibodies (listed in  
2.1.5.2 Antibodies for FACS staining) in 50-100µl FACS buffer on ice for 30-60min in 
the dark. Cells were washed, and where relevant, biotinylated antibodies were 
incubated with fluorochrome-conjugated streptavidin on ice for another 30-60 min in 
the dark and washed again. Stained cells were resuspended in FACS buffer. FACS 
buffer could contain propidium iodide for dead cell exclusion (diluted 1:000) and 
SpheroTM Blanc calibration particles 6-6.5µm (BD) in order to determine the total 
number of cells per well/organ. Data were collected with FACS Canto (BD 
Biosciences) and analyzed using FlowJo software (Tree star). Absolute numbers of 
cells were determined by collecting a certain number of beads added to a specific 
volume of FACS buffer during FACS sample acquisition. The absolute number of a 
specific cell population can then be extrapolated to whole organs or culture wells 
with the help of the collected bead number. 
 
2.2.5.2 Staining of intracellular cytokines 
To measure intracellular cytokines cells have to be restimulated and incubated the 
last 4-6 hours with the relevant protein transport inhibitor Monesin or Brefeldin to 
prevent secretion of cytokines. Following the staining of cell surface markers (2.2.5.1 
Staining of cell surface makers), 0,5-5 x 106 cells were washed with FACS buffer and 
fixed with Cytofix (BD) for 30 min at 4°C. Then cells were stained with antibodies 
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detecting intracellular cytokines in permeabilization buffer (BD) for 30 min at 4°C. 
After this step cells were washed and resuspended in FACS buffer for flow 
cytometric data collection.  
 
2.2.5.3 Staining of intracellular transcription factors 
Following the staining of cell surface markers (2.2.5.1 Staining of cell surface 
makers), cells were stained for intracellular transcription factors. 0.5-5 x 106 cells 
were incubated for 30-60 min with freshly prepared fixation solution (eBiocience)t 
4°C in the dark. Cells were then washed with permeabilization buffer (eBiocience) 
and stained with relevant antibodies diluted in permeabilization buffer at 4°C for 30-
60 min in the dark. Cells were then washed again with permeabilization buffer, 
before resuspending in FACS wash for flow cytometric data collection.  
 
2.2.6 In vitro assessment of T and B cell function 
2.2.6.1 In vitro (re-)stimulation of T cells 
Cytokines secreted by T cells were analyzed either by using the intracellular cytokine 
staining protocol (2.2.5.2 Staining of intracellular cytokines) or by quantitatively 
analyzing the secreted cytokines in the supernatant, which was done by ELISA 
(2.2.2.3 ELISA) or by CBA (2.2.2.4 Cytometric Bead Array).  
To (re-)stimulate T cells for cytokine analysis by ELISA or CBA, 96-well microplates 
were coated at 37°C ON with anti-CD3 (5µg/ml - 0.156µg/ml) and anti-CD28 
(2.5µg/ml - 0.078µg/ml) antibodies diluted in dPBS. Before the T cells were added, 
the dPBS was removed cautiously from each well. Then, T cells resuspended in 
RPMI were transferred to the well plates with a density of 5x105 cells/well/200µl. 
Where mentioned, 2µg/ml soluble α.-CD28 was added. 48h later supernatants were 
collected and analyzed by ELISA, CBA or stored for later analysis at -20°C.  
For intracellular cytokine analysis, cells were plated on 24 well plates at a density of 
1x106 cells/well/ml, which were coated before with 5µg/ml anti-CD3, and 
restimulation was peformed for 24 hours. Monesin (Golgi-Stop/BD) or Brefeldin A 
(Golgi-Plug/BD) was added for the final 4-6 hours to prevent cytokine secretion. To 
measure intracellular IL-2, in addition to Brefeldin A, 500ng/ml ionomycin and 
5ng/ml PMA cells were added for the final 4-6 hours.  
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2.2.6.2 In vitro differentiation of T cells 
To analyze the differentiation of T cells in vitro, naïve T cells were positively 
purified using the CD4+ CD62L+ T cell isolation kit. Cells were plated on 24 well 
plates at a density of 7x105 cells/well/ml in the presence of 5µg/ml soluble anti-CD3 
and 5µg/ml soluble anti-CD28. Additionally, cytokines and antibodies for T cell 
differentiation were added as follows: 10µg/ml anti-CD4 and 10ng/ml IL-12 for Th1 
conditions; 10µg/ml anti-IFN-γ and 10ng/ml IL-4 for Th2 conditions; 30ng/ml IL-6, 
5ng/ml TGF-β, 50ng/ml IL-23, 10µg/ml anti-IL-4, and 10µg/ml anti-IFN-γ for Th17 
conditions; 30ng/ml IL-6, 10µg/ml anti-IFN-γ, 10µg/ml anti-IL-4 and 20µg/ml anti-
TGF-β for Tfh conditions. Following 2 days of incubation at 37°C T cells were 
analyzed for intracellular cytokines and transcription factors by FACS.  
 
2.2.6.3 In vitro (re-)stimulation of B cells 
Similar to the T cells, B cell cytokines or immunoglobulins were analyzed upon (re-) 
stimulation by intracellular staining, CBA or ELISA.  
To measure cytokines in the supernatant, B cells were plated to 96 well plates with a 
density of 5x105 cells/well/200µl and stimulated with 10µg/ml anti-CD40 and 
different concentration of LPS or CpG as described in Results. 24 hours later 
supernatants were collected and analyzed by ELISA, CBA or stored for later analysis 
at -20°C.  
On the intracellular level IL-10 secretion by B cells was assessed as follows. B cells 
from spleen or PerC were isolated and restimulated with 10µg/ml LPS, 500µg/ml 
ionomycin and 5ng/ml PMA in RPMI in a 24 well plate with a cells density of 1x106 
cells/well/ml for 6 hours at 37°C. To block secretion of IL-10, Monesin was added 
during the whole time of stimulation.  
 
2.2.6.4 In vitro proliferation analysis 
To analyze proliferation of T or B cells, CFSE dilution profile was used for 
assessment. To this end, splenocytes, purified T cells or purified B cells were labeled 
with 0,5µM CFSE for 10min at 37°C. The reaction was stopped by adding pre-
warmed dPBS containing 10% FCS. Cells were washed and plated in RPMI at a 
density of 2x105 cells/well/200µl in 96 well plates and at 5x105 cells/well/ml in 24 
well plates.  
For T cell stimulation, the 96-well microplates were coated ON at 37°C with anti-
CD3 (5µg/ml - 0.156µg/ml) and anti-CD28 (2.5µg/ml - 0.078µg/ml) antibodies 
diluted in dPBS. Before the T cells were added, the dPBS was removed cautiously 
from each well. Then, T cells resuspended in RPMI were added to each well.  
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For B cell stimulation, cells were stimulated with 5µg/ml anti-CD40, 10µg/ml anti-
IgM or 10µg/ml LPS in RPMI.  
After 2 and 3 days at 37°C, both T and B cell proliferation assays were analyzed for 
their CFSE-fluorescence dilution, which progressively decreases with every cell 
division.  
 
 
2.2.7 In vivo assessment of T and B cell function 
2.2.7.1 Active induction of experimental autoimmune encephalitis (EAE) and EAE 
score definition 
C57BL/6N or C57BL/6N Dkk3-/- mice were immunized with Myelin oligodendrocyte 
glycoprotein 33-55 (MOG33-55) emulsified in Complete Freund´s Adjuvants (CFA). 
Each mouse received a subcutaneous (s.c.) injection in the flank of 100µl CFA 
containing 200µg MOG33-55. At the time point of immunization and 48 hours later 
mice received 200ng of Pertussis toxin (PT) in 0,5ml PBS i.p.. The mice were 
observed for clinical signs and EAE was scored on a scale from 0 to 5 as follows:  
0 = no overt signs of disease,  
1 = limp tail or hind limb weakness (but not both),  
2 = Limp tail and hind limb weakness,  
3 = partial hind limb paralysis,  
4 = complete hind limb paralysis,  
5 = moribund state or death by EAE.  
 
2.2.7.2 Passive induction of EAE by transfer of in vitro restimulated cells 
2D2.Dkk3-/- mice were immunized with MOG33-55 in CFA. Each mouse received 100µl 
CFA containing 200µg MOG33-55 injected s.c. at two different spots of each 50µl 
volume in the flank. 10 days post immunization spleens and draining lymph nodes 
were isolated and single cell suspensions were prepared. Cells were plated in a 24 well 
plate at a density of 1x106 cells/well/ml and restimulated with 20µg/ml MOG33-55 
and 20ng/ml IL-12. After 3 days of restimulation, 1x107 cells were transferred i.p. 
into C57BL/6N Rag2-/-  or C57BL/6N Rag2-/- Dkk3-/- recipient mice, which were 
treated with PT as described above. The mice were observed for clinical signs and 
EAE scores were measured.  
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2.2.7.3 Diabetes induction and analysis 
Naïve CD4 T cells of Bdc2.5/NOD mice were purified by negative isolation with 
Dynal beads. Briefly, splenocytes were labeled with a mix of biotinylated CD8, 
CD44, CD25, Cd11b, CD11c, CD19, B220 and CD49b antibodies. Then streptavidin 
conjugated magnetic beads were added to remove labeled cells (as described in 2.2.4 
Magnetic cell sorting). 10.000 cells were transferred intravenous (i.v.) into 
NOD.RAG recipient mice. NOD.RAG mice were treated with 0,7mg/mouse of either 
anti-mDkk3-4.22 antibody or MOPC21 isotype control every three days, starting 6 
days before cells were transferred i.v. to the mice. Glucose in the blood was measured 
at the beginning of the experiment every 2 days and every day once it started to 
increase.  
 
2.2.7.4 Induction of inflammatory bowel disease (IBD) and analysis 
For induction of colitis CD4 T cells of FoxP3.LuciDTR-4 mice were used as donors. 
Splenocytes were in a first step purified by CD4 negative isolation Dynal beads and 
in a second step, eGFP+ cells, which are the FoxP3 expressing regulatory cells, were 
depleted by FACS sorting. 5x105 cells of the regulatory T cell depleted cells were 
injected i.v. per mouse into either C57BL/6N Rag2-/-  or C57BL/6N Rag2-/- Dkk3-/- 
recipient mice. Mouse weight was measured every 2-3 days for 5 weeks.  
 
2.2.7.5 Immunization of mice for analysis of T cell differentiation  
To analyze T cell differentiation in vivo, C57BL/6N and C57BL/6N Dkk3-/- mice 
were immunized with MOG33-55 in CFA for Th1/Th17 differentiation or with MOG33-
55 in incomplete Freund’s adjuvant (IFA) for Th2 differentiation. Each mouse 
received 200µg MOG33-55 in a volume of 100µl CFA or IFA, which was injected s.c. at 
the belly at two different spots of each 50µl volume. 8 days post immunization spleen 
and LN were taken, single cell suspensions were prepared and cells were restimulated 
with 5µg/ml plate-bound anti-CD3 for 48 hours. Then supernatants were collected 
and analyzed by CBA.  
 
2.2.7.6 Immunization of mice for analysis of B cell responses 
In this study four different antigens were used to immunize mice to assess antibody 
responses in C57BL/6N and C57BL/6N Dkk3-/- mice. TNP-BSA is applied s.c. in a 
100µl emulsion of CFA containing 50µg TNP-BSA per mouse. PC-KLH is applied 
s.c. in a 100µl emulsion of CFA containing 100µg PC-KLH per mouse. S.c. 
MATERIAL AND METHODS 
 
 
52 
immunization were injected at the belly at two different spots of each 50µl volume. 
TNP-Ficoll (50µg/mouse) and LPS (4mg/g weight) were used in a solution with PBS 
and injected i.p.. Blood was taken before immunization, at day 7, day 14 and day 21. 
Serum was prepared from the blood and analyzed by ELISA for concentration of 
antigen-specific or total antibody titers of relevant isotypes.   
 
2.2.7.7 Treatment and analysis of MRL/LPR mice 
In this study it was investigated whether anti-mDKK3-4.22 or MOPC21 isotype 
control treatment of MRL/LPR mice leads to a different level of disease. Mice were 
treated with 0,7mg/mouse anti-mDkk3-4.22 antibody or MOPC21 isotype control i.p. 
twice a week. Treatment was started at an age of 5 weeks and lasted for 6 weeks. At 
an age of 12 weeks mice were sacrificed and analyzed for symptoms of systemic lupus 
erythematosus (SLE). Before, after 4 weeks of treatment and at the time point of 
scarification blood was taken to prepare serum. Analysis included organ weight 
measurement, T and B cell phenotype analysis by FACS, serum analysis for e.g. 
protein levels and kreatinines, ELISA to determine levels of autoantibodies in the 
serum as well as a histological examination of organs.  
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3 Results 
3.1 The role of Dkk3 in T cell function 
Previous studies of our group focused on the function of Dkk3 as a mediator of CD8 
T cell tolerance [214]. These studies were carried out in a transgenic system. 
However, it is also of interest whether Dkk3 is able to control polyclonal T cell 
responses. It has been shown by our laboratory that Dkk3 is expressed in immune 
privileges sites [212]. The brain is one of these organs expressing high levels of Dkk3, 
but it also has been shown to be expressed in the crypts of the gut and in the β-islet 
cells of the pancreas [192, 210, 224]. Therefore, we decided to investigate T cell 
reactivity in the absence of Dkk3 in three different animal models: Experimental 
autoimmune encephalitis (EAE), inflammatory bowel disease (IBD) and diabetes 
type I.  
3.1.1 Dkk3 regulates effector T cell subsets in experimental 
autoimmune encephalitis  
In our laboratory the model of MOG35-55 induced EAE is employed. Papatriantafyllou 
revealed that Dkk3 deficient mice develop an exacerbated course of EAE with 
prolonged EAE symptoms [212], which was confirmed during the course of my PhD 
thesis (Figure 3.1).  
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Figure 3.1  | Absence of Dkk3 results in more severe and persist EAE symptoms. C57BL/6 (wt) 
and Dkk3-/- mice were immunized with MOG33-55 in CFA and treated with pertussis toxin. EAE scores 
were determined for a period of 3 months (A) and 18 days (B) until mice were sacrificed for analysis. 
Mean EAE score and SEM are shown for each group (n=9). Curves were compared using 2-way 
ANOVA, p-values of column factors are shown, single time points were compared using student t-test 
(ns=not significant; *=p<0,05, ***=P<0,0005).  
 
It could be argued that a different thymic selection of auto-reactive T cells (including 
MOG-specific T cells) occurs in the absence of Dkk3, which might be the reason for 
the higher susceptibility of Dkk3-/- animals to EAE. To address this point, and to 
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clarify whether a Dkk3 sufficient environment (without possible T cell intrinsic 
Dkk3) is able to regulate the pathogenic T cell response in EAE, Dkk3 deficient T 
cells were transferred to Rag2-/- mice being either sufficient or deficient for Dkk3. 
Rag2-/- mice were used as recipients to ensure that only T cells which were 
transferred from the same donor source and therefore feature exactly the same T cell 
repertoire can provoke the disease. We used T cells of transgenic 2D2.Dkk3-/- mice , 
which bear a TCR specific for the MOG peptide. In detail, cells from draining lymph 
nodes (LN) and spleens of MOG33-55 immunized 2D2.Dkk3-/- mice were restimulated 
in vitro with MOG33-55 and IL-12 and transferred to wt.Rag2-/- or Dkk3-/-Rag2-/- 
recipients. Recipient mice were treated with pertussis toxin (PT) to facilitate the 
migration through the blood-brain barrier of MOG-specific T cells.  
The onset of disease in this transfer experiment was delayed in comparison to the 
actively induced EAE by immunization. Interestingly, an earlier onset and more 
severe symptoms of EAE were observed in Dkk3-/-Rag2-/- recipients compared to their 
Dkk3 sufficient controls. Hence, T cell responses appear to be dampened by 
environmental Dkk3 and a different T cell repertoire does not seem to be the reason 
for the increased affection of Dkk3-/- mice by EAE.  
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Figure 3.2  | Environmental Dkk3 is able to regulate EAE symptoms in a transfer model.    
2D2.Dkk3-/- mice were immunized with MOG33-55 in CFA. 10 days post immunization cells of spleens and 
draining lymph nodes were prepared and restimulated in vitro with MOG33-55 and IL-12. After 3 days of 
restimulation, 1x107 cells were transferred i.p. into wt.Rag2-/- or Dkk3-/-Rag2-/- recipient mice, which 
were treated with pertussis toxin. EAE scores were determined over a period of 7 weeks. One 
representative out of 2 independent experiments is presented. Mean EAE score and SEM are shown for 
each group (n=10). Curves were compared using 2-way ANOVA, p-value of column factor is shown 
(**=P<0,005).  
 
 
To examine the cellular and molecular basis of the more severe EAE phenotype in 
Dkk3-/- mice, leukocyte infiltrates of the CNS of diseased Dkk3-/- and wt mice, in 
which EAE was directly induced (as described in Figure 3.1), were compared for 
parameters demonstrated to be involved in disease initiation and progression [47, 
225, 226]. To this end, leukocytes from the brain and the spinal cord were isolated 
and either stained directly for surface marker and transcription factors or 
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restimulated over night, followed by a protein secretion blockage, for staining of 
intracellular cytokines.  
 
The analysis of leukocyte infiltrates was carried out at two different time points. The 
first analyzed time point was the peak of disease or rising phase, depending on the 
experiment (day 11-13), characterized by no difference in disease score between wt 
and Dkk3-/- animals. The second analyzed time point was the so called recovery 
phase (starting around day 17), in which wt mice recover. As Dkk3-/- mice show a 
more persisent EAE, the differences in disease score at this time point were 
significant.  
 
At the peak of disease/rising phase (Figure 3.3) the CNS was infiltrated by the same 
numbers of CD4+ and CD8+ and myeloid CD11b+ cells in wt and Dkk3-/- mice. 
Surprisingly, higher numbers of Tregs (CD25+ FoxP3+ CD4 T cells) were found in 
the CNS of Dkk3-/- mice. Furthermore, no difference was observed in GM-CSF or 
IFN-γ secreting CD4 or IFN-γ secreting CD8 T cells. However, the CNS of Dkk3-/- 
mice yielded higher numbers of IL-17 producing CD4 T cells. In the periphery 
(spleen and LN) T cell population were not altered. Interestingly, the number of 
CD11b+ myeloid cells was decreased in the spleen.  
 
In the recovery phase (Figure 3.4) the Dkk3-/- CNS was infiltrated by higher numbers 
of CD4+, CD8+ and myeloid CD11b+ cells in comparison to the wt CNS. Numbers of 
CD4 and CD8 T cells were also increased in the spleen of Dkk3-/- mice, whereas 
numbers of CD11b+ cells were decreased in the spleen, as also already observed at 
the peak of disease/recovery phase. Furthermore, numbers of Foxp3+ cells were 
decreased in the spleen of Dkk3-/- mice, presumably due to the selective expansion of 
other CD4 T cells (as described above). Cytokine analysis revealed no difference in 
the production of IL-17 and GM-SCF within the CD4 T cell subset, but a higher 
production of IFN-γ by CD4 and CD8 T cells in Dkk3-/- CNS. However, as the 
number of CD4 and CD8 T ell among the whole CNS infiltrating cells was increased 
in the CNS of Dkk3-/- mice, the number of T cells secreting any analyzed cytokine 
will also be higher in the Dkk3 deficient environment.   
 
In summary, in the absence of Dkk3 more severe EAE symptoms were observed. 
These were associated with changes in the CNS infiltrating leukocyte populations 
and the local cytokine production.  
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Figure 3.3  | Analysis of CNS infiltrates at the peak of disease / rising phase. At day 11 upon EAE 
induction, spleen, lymph node (LN) and central nervous system (CNS) infiltrating leukocytes of 
C57BL/6 (black symbols) and Dkk3-/- (red symbols) mice were isolated and stained for surface markers 
and transcription factors (A-D). Intracellular cytokines were stained after cells were restimulated with 
5µg/ml plate-bound anti-CD3 in vitro for 24 hours, including the addition of protein-transport 
inhibitor for the final 6 hours (E-H). Summary data from 3 independent experiments are presented. One 
dot represents cells of 1 mouse for the spleen and the LN group and cells of 2-3 pooled mice for the CNS 
group. Horizontal bars represent the mean for each group. Groups were compared using student t-test 
(ns=not significant; *=p<0,05, **=P<0,005). 
RESULTS  
 
57 
Myeloid cells CD11b +
0
10
20
30
40
50
**
*
spleen LN CNS
%
 
CD
45
.
2h
ig
h  
CD
11
b+
o
f C
D4
5.
2+
ce
lls CD8+
0
5
10
15
20
25
*
*
spleen LN CNS
%
 
CD
8+
 
ce
lls
 
o
f l
eu
ko
cy
te
s
CD4+
0
10
20
30
40
**
*
spleen LN CNS
%
 
CD
4+
 
ce
lls
 
o
f l
eu
ko
cy
te
s
FoxP3+ CD4+
0
10
20
30
40
*
ns
spleen LN CNS
%
 
Fo
x
P3
/C
D2
5+
o
f C
D4
+
 
ce
lls
IL-17+ CD4+
0
10
20
30
spleen LN CNS
ns
%
 
IL
-
17
+
 
o
f C
D4
+
 
ce
lls
GM-CSF+ CD4+
0
5
10
15
20
spleen LN CNS
ns
%
 
G
M
-
CS
F+
 
o
f C
D4
+
 
ce
lls
IFN-γ+ CD4+
0
20
40
60 *
spleen LN CNS
%
 
IF
N
γ+
 
o
f C
D4
+
ce
lls
IFN-γ+ CD8+
0
20
40
60
80
*
ns
spleen LN CNS
%
 
IF
N γ
+
 
o
f C
D8
+
 
ce
lls
A B
C D
E F
G H
 
Figure 3.4  | Analysis of CNS infiltrates in the recovery phase. At day 18 upon EAE induction, 
spleen, lymph node (LN) and central nervous system (CNS) infiltrating leukocytes of C57BL/6 (black 
symbols) and Dkk3-/- (red symbols) mice were isolated and stained for surface markers and transcription 
factors (A-D). Intracellular cytokines were stained after cells were restimulated with 5µg/ml plate-
bound anti-CD3 in vitro for 24 hours, including the addition of protein-transport inhibitor for the final 
6 hours (E-H). Summary data from 3 independent experiments are presented. One dot represents cells 
of 1 mouse for the spleen and the LN group and cells of 2-3 pooled mice for the CNS group. Horizontal 
bars represent the mean for each group. Groups were compared using student t-test (ns=not significant; 
*=p<0,05, **=P<0,005). 
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3.1.2 Dkk3 does not regulate CD4 T cells in a model of inflammatory 
bowel disease 
Dkk3 has been shown to be expressed the villus mesenchyme and myenteric plexuses 
of the intestine [210]. These areas of the intestine are important for tolerance 
induction and maintenance to oral antigens as well as to the commensal microflora of 
the gastrointestinal tract [227, 228]. Hence, we wanted to investigate whether Dkk3 
contributes to tolerance induction in a model of IBD.  
 
IBD is induced by CD4 T cells in the absence of Tregs [229]. Hence, we used 
FoxP3.LuciDTR-4 mice [230] as donors of CD4 T cells. These mice express eGFP 
under the FoxP3 promotor and eGFP+ cells can be easily depleted by FACS sorting 
(Figure 3.5 A). CD4+ purified T cells depleted for Tregs were transferred to either 
wt.Rag2-/- or Dkk3-/-Rag2-/- recipient mice and weight was measured every other day 
for 5 weeks (Figure 3.5 B). No difference in weight change was found between Dkk3 
sufficient and deficient mice. Therefore, Dkk3 produced in the gut does not seem to 
regulate the pathogenic CD4 T cell response in this animal model of IBD.  
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Figure 3.5  | Dkk3 does not regulate the pathogenic CD4 T cell response in a model of 
inflammatory bowel disease (IBD). CD4+ T cells of FoxP3.LuciDTR-4 mice were first purified by 
magnetic cell sorting for CD4 T cell enrichment and then depleted of eGFP+ (FoxP3+) cells by FACS 
sorting (B) (Pre=before purification). Gated on leukocytes (left) and on CD4+ cells (right). 5x105 cells 
were transferred i.v. to wt.Rag2-/- or Dkk3-/- Rag2-/- recipient mice and weight was measured every 2-3 
days for 5 weeks (B). Percentage of the mean weight of the weight on day 0 (day of cell transfer) for 
each group (wt, Dkk3-/-: n=7) and SEM is shown. Control group consists of 2 wt.Rag2-/- and 2 Dkk3-/-
Rag2-/- mice. One out of 2 representative experiments is shown.  
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3.1.3 Dkk3 does not regulate CD4 T cells in a transgenic model of 
diabetes type 1 
Hermann et al. demonstrated that Dkk3 is expressed in subset of human pancreatic 
β- cells [192]. Therefore, it was intriguing to study whether Dkk3 produced in this 
area is able to dampen diabetes induction. We used a diabetes model with a 
relatively short disease induction phase. In this model CD4 T cells from 
Bdc2.5/NOD mice, carrying a transgenic TCR specific for a β-islet antigen [231], are 
transferred into NOD.Rag2-/- mice. These transgenic CD4 T cells were purified and 
depleted for memory and activated T cells as well as CD25+ Tregs (Figure 3.6 A) 
before being injected into the recipient NOD.Rag2-/- mice, which were either treated 
with isotype control or anti-Dkk3 antibody. Glucose measurement in the blood was 
used as the read-out system for diabetes incidence. No significant difference of 
disease onset or disease severity was observed (Figure 3.6 B). Therefore, Dkk3 
produced in the pancreas is not able to regulate the pathogenic CD4 T cell response 
in the diabetes type 1 model of Bdc2.5/NOD transferred CD4 T cells into 
NOD.Rag2-/- mice. 
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Figure 3.6  | Dkk3 does not regulate the pathogenic T cell response in a model of diabetes type 1. 
Naïve CD4 T cells of Bdc2.5/NOD mice were purified and activated/memory T cells and Tregs were 
depleted by magnetic cell sorting (A) (Pre=before purification/depletion; Post=after 
purification/depletion). Gated on leukocytes (left) and on CD4+ cells (middle and right). 10.000 cells 
were transferred i.v. into NOD.RAG recipient mice. NOD.RAG mice were treated with 0,7mg/mouse of 
either anti-Dkk3 antibody or isotype control every three days, starting 6 days before cells were 
transferred to the mice. Sugar in the blood was measured at the beginning of the experiment every 2 
days and every day once it started to increase (B). Mean and SEM are shown for each group (n=5).  
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3.1.4 Comparison of Dkk3 expression in the brain, the gut and the 
pancreas 
Dkk3 has been demonstrated histologically to be expressed in the gut and the 
pancreas [192, 210, 224]. In the brain our laboratory has investigated Dkk3 
expression histologically and quantitatively [212]. However, a quantitative analysis of 
the Dkk3 expression in the pancreas and the gut has not been conducted so far and 
as the brain, the gut and the pancreas are the locations were the above described T 
cell responses were taking place, we wanted to obtain a quantitative comparison of 
the expression level of Dkk3 between these tissues. Therefore, tissues were analyzed 
for relative mRNA expression of Dkk3 in comparison to β-actin. Strikingly, the 
expression of Dkk3 was 300-500 times higher in the brain and the eye (which was 
used as an additional positive control) compared to the organs of the gut or the 
pancreas. This might explain the failure of Dkk3 to regulate pathogenic T cell 
responses in the model of IBD and diabetes type 1.  
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Figure 3.7  | mRNA expression profile of Dkk3 in different mouse tissues. Total RNA was purified 
from C57BL/6 mouse tissues, reverse transcribed to cDNA and analyzed by quantitative real-time PCR. 
For comparative analysis, the relative Dkk3 mRNA expression level was calculated by using β-actin 
mRNA levels as a control housekeeping gene. Background values of Dkk3-/- mice were subtracted. 
MLN=Mesenteric lymph nodes; PP=Peyer’s patches. Mean and SEM are shown for each analyzed 
tissue (n=4).  
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3.1.5 CD4 T cells of Dkk3-/- mice do not show clear differences in their 
differentiation behavior 
To investigate whether Dkk3 acts on the differentiation of CD4+ T cells, purified 
naïve CD4+ T cells of wt and Dkk3-/- mice were stimulated in vitro under the 
presence of Th1, Th2 or Th17 differentiating conditions. After 72 hours, T cells of 
Dkk3-/- showed less secretion of IFN-γ and were slightly less positive for their master 
regulator transcription factors T-bet and EOMES under Th1 differentiating 
conditions (Figure 3.8 A). In contrast, under Th2 differentiating conditions Dkk3-/- 
CD4 T cells possessed twice the number of IL-10 secreting cells and an elevated 
expression of their specific transcription factor GATA-3 (Figure 3.8 C). However, 
Th2 differentiation in vitro generated only very few IL-10+ cells, therefore it is 
difficult to draw a final conclusion on the Th2 differentiation behavior from these in 
vitro experiments. Nevertheless, both observations (for Th1 and Th2 conditions) 
were consistent throughout the four conducted experiments. Th17 conditions did not 
result in a consistent difference between CD4 T cells of wt and Dkk3-/- mice analyzed 
be the expression of IL-17 and the master transcription factor RoRγt (Figure 1.9 B). 
Therefore, it seems that CD4 T cell of Dkk3-/- mice exhibit a slightly increased 
capacity to differentiate into the Th2 phenotype in vitro.  
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Figure 3.8  | CD4 T cells of Dkk3-/- mice show slightly increased Th2 differentiation in vitro. T 
cells of C57BL/6 (wt) and Dkk3-/- mice were cultured under Th0 (no addition of cytokines or 
antibodies; top of A, B and C), Th1 (A), Th17 (B) or Th2 (C) conditions for 72 hours in the presence of 
anti-CD3 and anti-CD28. Cells were stained for specific cytokines and transcription factors. All FACS 
blots are gated on CD4+ cells. The expression of transcription factors (right panels) are depicted as 
histograms and the fluorescence mean intensity (FMI) is indicated in the graph (grey=wt CD4 T cells; 
red=Dkk3-/- CD4 T cells). One representative out of 4 experiments is shown.  
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3.1.6 The secretion of Th2 associated cytokines is increased in Dkk3-/- 
mice in vivo 
Dkk3 has been shown to be absent in T cells themselves [212, 214]. Therefore, the 
analysis of differentiation in vitro shows the imprint of a Dkk3 sufficient or deficient 
environment where cells were coming from. However, as the assay takes three days, 
the difference might fade as both groups were simulated in a Dkk3 deficient culture 
medium. Therefore, we also analyzed T cell differentiation in vivo, with an ex vivo 
readout system. For this purpose, wt and Dkk3-/- mice were immunized with the 
antigen MOG33-55 either emulsified in CFA or incomplete Freund’s adjuvant (IFA). 
Antigens immunized in CFA have been described to lead to a strong immune 
response of the Th1/Th17 direction and a weak Th2 response, whereas antigens in 
IFA lead to increased immune response of the Th2 direction and reduced Th1/Th17 
responses [232-234]. 8 days post immunization, cells of spleens and draining LN were 
restimulated in vitro with plate-bound anti-CD3 and 48 hours later supernatants 
were analyzed quantitatively for the concentration of Th1, Th17 and Th2 cytokines. 
In detail, IFN-γ, IL-17, TNF-α, and IL-2 served to detect Th1/Th17 differentiation 
as these cytokines are typically secreted by Th1 and Th17 cells [38, 235], whereas IL-
6 (discussed in 4.3 Dkk3 limits Th2 associated cytokine secretion ), IL-4 and IL-10, 
mostly related to Th2 cells, served to detect Th2 differentiation [38, 235, 236].  
 
Immunization with MOG33-55  in CFA resulted in the secretion of substantial levels of 
Th1/Th17 cytokines and modest amounts of Th2 cytokines (Figure 3.9). Upon   
MOG33-55 /CFA immunization no difference between the wt and the Dkk3-/- group 
was found for IFN-γ, IL-17, TNF-α, and IL-2 secretion (Figure 3.9). Although 
immunization with CFA leads preferentially to Th1/Th17 responses, Th2 cytokines 
are still secreted and levels of IL-4 and IL-10 were found to be higher in cell 
supernatants of Dkk3-/- mice compared to wt mice.  
 
Immunization with MOG33-55 in IFA resulted in decreased levels of Th1/Th17 
cytokines and slightly increased levels of IL-10 compared to the immunization with 
MOG33-55  in CFA (Figure 3.10). Thus, in our experiments immunization with IFA as 
adjuvant decreased the Th1/Th17 response, while leaving the Th2 response 
unaffected.  
Upon immunization with MOG33-55 /IFA Dkk3 deficient mice secreted decreased levels 
of IL-17 and increased levels of Th2 associated cytokines IL-6 and IL-10 (Figure 3.10) 
in comparison to wt animals (Figure 3.10). IL-4 secretion, however, was only very 
low upon MOG33-55 in IFA immunization and no difference between the two groups 
was revealed.  
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In conclusion, we found increased levels of Th2 associated cytokines independently of 
the kind of adjuvant, CFA or IFA, and decreased levels of IL-17 upon immunization 
with IFA in Dkk3-/- cell cultures upon ex vivo restimulation. Therefore, Th2 
differentiation seems to be increased in Dkk3-/- mice, which confirms the data 
obtained by in vitro differentiation experiments.  
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Figure 3.9  | Immunization with MOG in CFA does not lead to altered Th1/TH17 differentiation 
in vivo in Dkk3-/- mice. C57BL/6 (wt) and Dkk3-/- mice were immunized with MOG33-55 in CFA. 8 days 
post immunization, single cell suspensions of spleens were prepared and cells were restimulated with 
5µg/ml plate bound anti-CD3 in vitro. 48 hours later supernatants were analyzed by CBA for the 
concentration of IFN-γ (A),    IL-17 (B), TNF-α (C), IL-2 (D), IL-6 (E), IL-4 (D) and IL-10 (G). 
Summary data of 3 independent experiments are shown. Mean and SEM are indicated for each group. 
Groups were compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005).  
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Figure 3.10 | Immunization with MOG in IFA leads to increased secretion of Th2 associated 
cytokines in vivo in Dkk3-/- mice. C57BL/6 (wt) and Dkk3-/- mice were immunized with MOG33-55 in 
IFA. 8 days post immunization, single cell suspensions of spleens were prepared and cells were 
restimulated with 5µg/ml plate bound anti-CD3 in vitro. 48 hours later supernatants were analyzed by 
CBA for the concentration of IFN-γ (A), IL-17 (B), TNF-α (C), IL-2 (D), IL-6 (E), IL-4 (D) and IL-10 
(G). Summary data of 3 independent experiments are shown. Groups were compared using student t-
test (ns= not significant; *p<0,05; **p<0,005). Mean and SEM are indicated for each group. 
 
 
 
 
 
 
In summary, the experiments investigating the role of Dkk3 in T cell function 
showed that environmental Dkk3 is able to regulate the pathogenic T cell 
response in the CNS of Dkk3 deficient mice during the course of EAE. In 
contrast, the pathogenic T cell response in a model of IBD and diabetes type 1 
was not altered in the absence of Dkk3. Thus, there is no general suppression of 
T cell responses in the presence of Dkk3. In vitro and in vivo analysis of T cell 
differentiation indicated that Dkk3 deficiency leads to an increase in Th2 
associated cytokine secretion, while leaving the Th1/Th17 response mostly 
unaffected.  
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3.2 The role of Dkk3 in B cell function 
B cells are besides T cells the major players of the adaptive immune system and have 
been described to exhibit a pathogenic role in numerous autoimmune diseases (as 
described in 1.4.5 B cells in autoimmune diseases). Therefore, we aimed to 
investigate the role of Dkk3 on B cell function, starting with the main characteristics 
of B cells, which are antibody production and cytokine secretion.  
3.2.1 Dkk3-/- mice display increased antibody responses 
Firstly, we investigated the antibody response to different antigens. B cell responses 
were analyzed by ELISA of serum samples taken before immunization and at 
different time points after immunization.  
 
The first antigen we used for immunization was 2,4,6 trinitrophenol (TNP)-BSA. It 
is one of the most typical T cell dependent (TD) antigens used to asses the response 
of follicular (FO) B cells and is used in combination with complete Freund’s 
adjuvant (CFA). It is described to elicit an IgM response between day 7 and 14, 
followed by class switch recombination (CSR) and IgG responses around day 14 to 
21 [237]. TNP-BSA specific IgM levels were elevated under steady-state conditions 
and 7 days post immunization in Dkk3-/- mice (Figure 3.11 A, Day 0) in comparison 
to their wt littermate controls. On day 14 after immunization the difference was less 
visible. In contrary, the TNP-BSA  specific antibody IgG1 response was elevated in 
Dkk3-/- animals after immunization on day 14 and day 21 (Figure 3.11 B). However, 
Dkk3 absence did not change the IgG2a and IgG2b response to TNP-BSA (Figure 
3.11 C/D). IgG3, an isotype often related to TI responses and B1 cells similar to IgM 
[132], was highly elevated in Dkk3-/- upon immunization (Figure 3.11 E).  
 
The second antigens we used for immunization was the T cell independent (TI) 
antigens TNP-Ficoll. TNP-Ficoll, an inert co-polymer of sucrose and epichlorohydrin 
conjugated to TNP, has been used for decades as a prototypic T independent type 2 
(TI-2) antigen [238]. It has been shown to specifically activate marginal zone (MZ) B 
cells [157] and lead to an increase of IgM and IgG3 antibodies around day 7 to day 
14 [239]. As T cell help is not required, it is injected without any adjuvant and only 
the described produced TI generated isotypes IgM and IgG3 (IgG3 which can be 
produced by CSR with the help of the costimulatory molecules APRIL and BAFF 
[151]) were analyzed. No difference was observed in the antibody levels specific for 
TNP-Ficoll upon immunization (Figure 3.12).  
 
RESULTS  
 
69 
IgM
wt Dkk3-/- wt Dkk3-/- wt Dkk3-/-
0
50
100
150
*
*
ns
Day 0 Day 14Day 7
TN
P-
BS
A 
sp
ec
ific
 
Ig
M
 
co
nc
.
 
 
[µg
/m
l]
IgG1
wt Dkk3-/- wt Dkk3-/- wt Dkk3-/- 
0
50
100
150
200
*
*
Day 0 Day 21Day 14
TN
P-
BS
A 
sp
ec
ifi
c-
Ig
G1
 
co
nc
.
 
[µg
/m
l]
IgG2a
wt Dkk3-/- wt Dkk3-/- wt Dkk3-/-  
0
2
4
6
ns
ns
Day 0 Day 21Day 14
 
TN
P-
BS
A 
sp
ec
ifi
c 
Ig
G
2a
 
co
nc
.
 
[µg
/m
l]
IgG2b
wt Dkk3-/- wt Dkk3-/- wt Dkk3-/-
0
20
40
60
80
ns
ns
Day 0 Day 21Day 14
TN
P-
BS
A 
sp
ec
ifi
c 
Ig
G
2b
 
co
nc
.
 
[µg
/m
l]
IgG3
wt Dkk3-/- wt Dkk3-/- wt Dkk3-/-
0
1
2
3
ns
**
Day 0 Day 14Day 7
TN
P-
BS
A 
sp
ec
ifi
c 
Ig
G
3 
co
nc
.
 
[µg
/m
l]
A
D
E
C
B
 
Figure 3.11 | Dkk3-/- mice exhibit an increased antibody response to TNP-BSA. C57BL/6 (wt) and 
Dkk3-/- mice were immunized s.c. with TNP-BSA in CFA on day 0. Serum was taken on day 0, 7, 14 
and 21 and analyzed by ELISA for TNP-BSA specific antibody levels of IgM (A), IgG1 (B), IgG21 (C), 
IgG2b (D), and IgG3 (E). Data are pooled from two-three independent experiments and one dot 
represents the antibody levels of one mouse. Horizontal bars represent the mean for each group. Groups 
were compared using student t-test (ns= not significant; *=p<0,05).  
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Figure 3.12 | Dkk3-/- mice do not show an altered antibody response to TNP-Ficoll . C57BL/6 (wt) 
and Dkk3-/- mice were immunized i.p. with TNP-BSA in PBS on day 0. Serum was taken on day 0, 7 
and 14 and analyzed by ELISA for antibody levels of IgM (A) and IgG3 (B). Data are pooled from two 
independent experiments and one dot represents the antibody levels of one mouse. Horizontal bars 
represent the mean for each group. Groups were compared using student t-test (ns= not significant).  
 
 
LPS has been shown to polyclonally activate all subclasses of B cells by TLRs 
leading to an IgM response of various specificities [154, 240]. However, B1 cells bear 
LPS-specific BCRs and can therefore respond to LPS with the secretion of LPS-
specific IgM antibodies [241, 242]. Both total IgM and LPS-specific antibody levels 
were analyzed after treatment of wt and Dkk3-/- mice with LPS. Total IgM level in 
the steady state (Day0) was increased in Dkk3-/- mice confirming the observation of 
Barrantes et al. [189] (Figure 3.13 B). Upon immunization, strikingly, only the LPS-
specific response was increased in Dkk3-/- mice, whereas total IgM levels were similar 
in wt and Dkk3-/- mice 7 and 14 days post immunization (Figure 3.13).  
 
To analyze the B1 cell response with another antigen typically used to asses B1 cell 
responses [132], wt and Dkk3-/- were immunized with phosphorylcholine (PC). 
Although this antigen is structurally a TI type II antigen, IgG responses have been 
described [156]. Therefore, immunization of mice with PC is carried out in the 
presence of adjuvant or directly by using heat-killed PC+ bacteria to facilitate CSR 
to IgG antibodies [138, 156]. In our experiment CFA was used as adjuvant. Dkk3-/- 
mice exhibited a stronger antibody response to PC compared to wt animals. Both 
PC-specific IgM and IgG levels were highly significantly increased in serum levels 
upon immunization (Figure 3.14).  
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Figure 3.13 | LPS treatment leads to increased levels of LPS-specific IgM antibodies. C57BL/6 
(wt) and Dkk3-/- mice were treated i.p. with LPS on day 0. Serum was taken on day 0, 7 and 14 and 
analyzed by ELISA for total (A) and LPS-specific (B) antibody levels of IgM. Data are pooled from two 
independent experiments and one dot represents the antibody levels of one mouse. Horizontal bars 
represent the mean for each group. Groups were compared using student t-test (ns=not significant; 
**=p<0,005).  
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Figure 3.14 | Dkk3-/- mice exhibit an increased antibody response to phosphorylcholine (PC). 
C57BL/6 (wt) and Dkk3-/- mice were immunized s.c. with phosphorylcholine-KLH (PC-KLH) in CFA 
on day 0. Serum was taken on day 0, 7, 14 and 21 and analyzed by ELISA for PC-specific antibody 
levels of IgM (A) and IgG (B). Data are pooled from two independent experiments and one dot 
represents the antibody levels of one mouse. Horizontal bars represent the mean for each group. Groups 
were compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005; ***=p<0,0005).  
 
 
In conclusion, Dkk3 deficient mice display increased antibodies responses. This effect 
was observed for the FO B cell antigen TNP-BSA, where it was most prominent for 
the IgG3 response, an antibody subclass often related to B1 cells. The MZ B cell 
response to the antigen TNP-Ficoll was the only response where no alteration in 
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Dkk3-/- mice was observed. Both the LPS-specific and the PC antibody response 
where most significantly increased in Dkk3 deficient mice among all the analyzed 
antibody responses to specific antigens.  
 
3.2.2 B cells of Dkk3-/- mice display increased IL-10 secretion 
Secondly, we investigated whether Dkk3 deficiency leads to altered cytokine secretion 
by B cells. To screen for cytokines, which could be altered in the absence of Dkk3, 
initially, splenocytes were stimulated in vitro with five different stimulation 
conditions; anti-CD40, LPS, CpG, anti-CD40 together with LPS, and anti-CD40 
together with CpG. Supernatants were quantitatively analyzed after 24 hours for 5 
different cytokines involved in inflammatory responses and which have been shown 
to be produced by B cells [243-245]: TNF-α, IL-6, MCP-1, IL-10 and IFN-γ. IL-6 
secreted by splenocytes cultures was recently reported to be mainly B cell derived 
[246]. No difference was found for TNF-α, IL-6 and IFN-γ (Figure 3.15 A, B, E). 
MCP-1, also called CCL2, was increased already in the steady state in Dkk3-/- mice 
and its secretion did not change significantly upon in vitro stimulation (Figure 3.15 
C). IL-10 was significantly increased in supernatants of Dkk3-/- splenocytes upon 
stimulation with anti-CD40 together with LPS and CpG (Figure 3.15 D). The 
analysis was repeated twice with CD19+ purified splenocytes and results confirmed 
that indeed B cells of Dkk3-/- mice secreted higher amounts of IL-10, whereas for the 
other cytokines no difference was found (data not shown as detailed analysis below). 
The only difference which appeared using purified B cells was that MCP-1 was not 
detected, demonstrating that this cytokine is not expressed by B cells, and the 
differences observed in the assay when using splenocytes must be due to another 
splenic cell population besides B cells.  
 
To analyze whether the difference between wt and Dkk3-/- B cells in IL-10 secretion 
is dose-dependent, CD19+ B cells were purified and stimulated with different 
concentrations of LPS together with anti-CD40 and CpG. Additionally, peritoneal 
cavity (PerC) B cells were included in the assay, as it was described in the literature, 
that this compartment possesses the highest numbers of IL-10 secreting B cells 
within the body [174]. Analysis of IL-10 concentration in supernatants of splenic B 
cells showed that B cells from Dkk3-/- mice secrete increased levels of IL-10, when 
stimulated with sufficient amounts of LPS or CpG (Figure 3.16 A/B). B cells 
purified from the PerC, however, showed that IL-10 secretion is already increased in 
Dkk3-/- B cells in the steady state without any stimulation (Figure 3.16 C). Upon 
stimulation, PerC B cells secreted 10-fold higher levels of IL-10 compared to splenic 
B cells and the difference between wt and Dkk3-/- group was more pronounced in the 
PerC compartment.   
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Figure 3.15 | Splenocytes of Dkk3-/- mice secrete increased amounts of MCP-1 and IL-10. 
Splenocytes of C57BL/6 (wt) and Dkk3-/- mice were cultures with 10µg/ml anti-CD40, 5µg/ml LPS, 
2µg/ml CpG or a combination of anti-CD40 with LPS or CpG for 24 hours. Supernatants were analyzed 
by cytometric bead array (CBA) for TNF-α (A), IL-6 (B), MCP-1 (C), IL-10 (D), IFN-γ (E), and IL-12 
(not detected). Results show pooled data from 2 independent experiments out of three experiments 
(n=8). Mean and SEM are indicated for each group. Groups were compared using student t-test (ns= 
not significant; *=p<0,05; **=p<0,005; ***=p<0,0005).  
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Figure 3.16 | B cells of spleen and peritoneal cavity secrete increased levels of IL-10. CD19+ 
purified B cells from spleens (A+B) or peritoneal cavity (PerC/C) of C57BL/6 (wt) and  Dkk3-/- mice 
were cultured with different concentrations of LPS together with 10µg/ml anti-CD40 (A+C) or CpG 
(B) for 24 hours. IL-10 concentration in supernatants was determined by ELISA. Results show one out 
of 2 independent experiments (n=4). Mean and SEM are indicated for each group. Groups were 
compared using student t-test (ns= not significant; *p<0,05).  
 
3.2.3 A higher proportion of B1 cells secretes IL-10 in Dkk3-/- mice 
As higher levels of IL-10 were observed in supernatants of cultured PerC B cells, and 
as the PerC is the compartment where B1 cell numbers are very high in comparison 
to other areas of the body, we addressed the question whether the increased levels of     
IL-10, observed in Dkk3-/- B cell cultures, are due to higher numbers of IL-10 
secreting B1 cells, or due to a general IL-10 overproduction by B cells of Dkk3-/- 
mice. For this purpose, IL-10 secretion was analyzed 6 hours upon stimulation with 
LPS in vitro by intracellular FACS analysis enabling us to tract IL-10 secretion on a 
single cell level.  
Upon stimulation, B220low CD19+ B1 cells showed a drastic upregulation of IL-10, 
whereas only 1-2 % of B220high CD19+ B2 cells upregulated IL-10 (Figure 3.17). In 
the PerC this effect was even clearer visible as this compartment yields high numbers 
of B1 cells. Splenic and PerC B1 cells coming from Dkk3-/- mice exhibited higher 
numbers of IL-10 secreting cells compared to wt mice (Figure 3.17 C+D). These 
results demonstrate that the difference observed in IL-10 secretion between B cells 
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from wt and Dkk3-/- mice is not due to a general IL-10 overproduction of the B cell 
compartment, but rather a specific property of Dkk3-/- B1 cells. However, the higher 
proportion of IL-10 secreting cells within the B1 cell subset does not seem the only 
reason for increased IL-10 levels. Additionally, it appeared that total B1 cell numbers 
are increased in Dkk3-/- animals, which would contribute to the observed effect. This 
lead us to a detailed analysis of B cell subsets, described in the next chapter.  
 
 
 
 
Figure 3.17 | A higher proportion of B1 cells secretes IL-10 in Dkk3-/- mice. Splenocytes and 
peritoneal cavity (PerC) cells were isolated and stimulated with LPS, ionomycin and PMA in the 
presence of monesin for 6 hours. Cells were stained for cell surface markers and intracellular IL-10. Dot 
blots show gated CD19+ lymphocytes from the spleen (A) and the peritoneal cavity (B) comparing 
unstimulated with stimulated and C57BL/6 (wt) with Dkk3-/- cells. B1 cells express lower levels of B220 
and can be distinguished from B2 cells via this molecule. Lower panels show summary data of the 
frequency of unstimulated (unstim.) and stimulated (stim.) IL-10 secreting B cells within the pregated 
B1 or B2 population of spleen (C) and PerC (D) cells. Results show one out of 2 independent 
experiments (n=3). Mean and SEM are indicated for each group. Groups were compared using student 
t-test (ns= not significant; *p<0,05; **p<0,005).  
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3.2.4 Dkk3-/- exhibit higher numbers of B1 cells and lower numbers of 
B2 cells  
As described in the introduction, two major B cell populations can be distinguished, 
B1 and B2 cells. To investigate whether the numbers of these populations are altered 
in the absence of Dkk3, different peripheral lymphoid tissues as well as cells of the 
PerC were analyzed for their B cell subpopulations in wt and Dkk3-/- mice by FACS.  
The first noticeable observation was that the frequency of total B cell within the 
leukocyte population was reduced in Dkk3-/- mice in the spleen, the MLN and the 
PerC (Figure 3.18, left FACS dot blots, and numbers on the top). This was due to 
reduced numbers of B2 cells (Figure 3.18). In contrast the frequency of B1 cells 
within the leukocyte population (and B cell population) was increased in the spleen, 
the LN and the PerC of Dkk3-/- mice (Figure 3.18). In all analyzed locations the ratio 
of B1:B1 was shifted towards B1 cells in Dkk3-/- mice.  
 
B1 cells present only a minor population in the lymphatic organs. Therefore, the 
absolute number of B1 cells was determined. This would clarify whether the 
increased frequency of B1 cells in Dkk3-/- deficient mice is due to decreased levels of 
B2 cells, or whether this population is indeed present at higher numbers.  
The absolute number of B1 cells was increased in the same locations in which higher 
numbers of B1 cells were found by frequency analysis: the spleen, LN and PerC 
(Figure 3.19). In the MLN, no difference in B1 cell numbers was found.  
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Figure 3.18 | The ratio of B2:B1 cells is shifted towards B1 cells in Dkk3-/- mice. Cells were isolated 
from spleen (A), mesenteric lymph nodes (MLN/B), lymph nodes (LN/C) and peritoneal cavity 
(PerC/D) of C57BL/6 (wt) and Dkk3-/- mice and analyzed by FACS for their B1/B2 phenotype via 
B220 and CD19 surface markers. Dot plots on the left show frequencies of total B cells (number on 
top), B1 cells (B220low) and B2 cells (B220high) within the leukocyte populations which was gated. Dot 
plots on the right are gated on all B cells and show percentage of B1 and B2 cells within the B cell 
population. The panels in the middle are summary data of the FACS dot blots on the left and show 
numbers of B1 and B2 cells within the leukocyte populations. One dot represents cell numbers of one 
mouse. Horizontal bars represent the mean for each group. The panels on the right are summary data of 
the FACS dot blots on the right and show the ration of B2:B1 within the B cell population (n=9). 
Mean and SEM are indicated for each group. Groups were compared using student t-test (ns= not 
significant; *=p<0,05; **=p<0,005; ***=p<0,0005).  
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Figure 3.19 | Dkk3 deficiency leads to increased absolute numbers of B1 cells. Cells were isolated 
from spleen, mesenteric lymph nodes (MLN), lymph nodes (LN) and peritoneal cavity (PerC) of 
C57BL/6 (wt) and Dkk3-/- mice and analyzed by FACS for their B1 phenotype via B220 and CD19 
surface markers. Absolute numbers of B1 cells per organ/site were determined using Sphero Blank 
Calibration beads during sample acquisition. Mean and SEM are indicated for each group. Groups were 
compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005; ***=p<0,0005). 
 
 
3.2.5 The reduction of B2 cells in Dkk3-/- mice is due to decreased 
numbers of follicular B cells 
B2 cells can be further subdivided into FO and MZ B cells. As the name tells, MZ B 
cells are primarily found in the marginal zone of the spleen. Therefore, to analyze 
whether the reduction in B2 cell numbers in Dkk3-/- mice is due to decreased levels of 
FO or MZ B cells, or both, the proportion of these populations was determined 
within the leukocyte population of splenic cells. FO and MZ B cells were 
distinguished by the surface markers CD21/CD35 and CD23. Clearly, the reduction 
in B2 levels was due to decreased numbers of FO B cells (Figure 3.20). MZ B cells 
were present at similar numbers in wt and Dkk3-/- mice.  
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Figure 3.20 |  Dkk3-/- mice exhibit reduced levels of follicular B cells. Cells were isolated from spleen 
of C57BL/6 (wt) and Dkk3-/- mice and analyzed by FACS for their FO and MZ phenotype. The 
identification of FO, MZ and B1 cells by the surface markers CD21 and CD21/CD35 is shown in A for 
cells of wt and Dkk3-/- mice. FACS dot plots were gated on CD19+ lymphocytes. Summary data of two 
independent experiments are presented in B showing resulting percentages of FO and MZ B cells which 
were back calculated to frequencies of leukocytes. One dot represents cell numbers of one mouse. 
Horizontal bars represent the mean for each group. Groups were compared using student t-test (ns= not 
significant; ***=p<0,0005).  
 
 
 
3.2.6 Both B1a and B1b cell are increased in Dkk3-/- mice 
B1 cells are further subdivided into B1a and B1b cells. To analyze whether the 
increased B1 cell numbers are due to an augmentation in one of these two subsets, 
levels of B1a and B1b cells from different locations in wt and Dkk3-/- mice were 
compared. In this analysis B1 cells were identified by using several markers (CD19+ 
B220low, CD21/CD35-, CD23-, IgM+, CD43+), this way combining different gating 
strategies described in the literature [132, 133], followed by the discrimination of B1a 
and B1b cells via the expression of CD5 (Figure 3.21 A). Numbers of B1a and B1b 
cells were calculated as percentages of total B cells. Results demonstrated that both 
B1a and B1b cells were increased in the spleen, MLN, LN and PerC of Dkk3-/- mice 
(Figure 3.21).  
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Figure 3.21 | B1a and B1b cells are increased in Dkk3-/- mice. Cells were isolated from spleen, 
mesenteric lymph nodes (MLN), lymph nodes (LN) and peritoneal cavity (PerC) of C57BL/6 (wt) and 
Dkk3-/- mice and analyzed by FACS for their B1a/B1b phenotype. The gating strategy is shown in A as 
an example for wt (top) and Dkk3-/- mice (below) PerC cells. First FACS dot blot (left) is gated on 
leukocytes. Summary data of two independent experiments are presented in B. One dot represents cell 
numbers of one mouse. Horizontal bars represent the mean for each group. Groups were compared using 
student t-test (ns= not significant; *=p<0,05; **=p<0,005; ***=p<0,0005).  
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3.2.7 B cell development in neonatal Dkk3-/- mice is impaired  
B1 cell development takes mainly place in the fetus and in the neonate. There, the 
splanchopleura and the liver have been described to posses B1 precursor cells [140, 
141]. However, final steps of B1 cell development occur in the neonatal spleen [139]. 
In the spleen immature (in peripheral organs also called transitional and mature B 
cells can be distinguished in general by the expression of CD93 (AA4.1) and the 
substages of transitional cells can be identified by different CD23 expression levels 
(Figure 3.22 A) [4]. Unfortunately, no marker has been found so far to distinguish B1 
and B2 transitional cells. Therefore, we can only talk about transitional cells in 
general without knowing to which cells they would differentiate in the process of 
maturation. To solve this problem, Montecino-Rodriguez et al. suggested that PerC 
cells could indicate which transitional cells (B1 or B2) are present in the spleen, as 
this compartment exhibits the matured B cells immigrated from the spleen [247]. 
Therefore, we decided to look at the distribution of transitional and mature B cells in 
neonatal spleen and PerC of wt and Dkk3-/- mice.  
 
Surprisingly, similar numbers of CD93+ transitional B cells were found in the PerC 
and the spleen of 5 days old neonatal mice (Figure 3.22 B), thus the analysis of the 
PerC was not able to tell us which cell fate will transitional B cells from the spleen 
take. However, already at this early time of B cell development total B cell numbers 
were drastically decreased in Dkk3-/- animals, which was due to decreased numbers of 
transitional B cells (Figure 3.22). In contrast to adult mice, at this stage of B cell 
development no difference in FO B cell numbers was found. B1 cells were increased 
in the spleen similar to adults. Interestingly, besides B1 cells, MZ B cells were also 
increased in neonatal mice, which could be due to the similar selection process of MZ 
B cells to B1 B cells.  
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Figure 3.22 | B cell development in neonatal Dkk3-/- mice is impaired. Cells were isolated from 
spleen and peritoneal cavity (PerC) of C57BL/6 (wt) and Dkk3-/- 5 days old neonatal mice and analyzed 
by FACS for their B cell phenotype. The gating strategy is shown in A as an example for wt (top) and 
Dkk3-/- mice (below) splenic cells. First FACS dot blot is gated on leukocytes. Summary data from two 
out of three independent experiments are shown in B. One dot represents cell numbers of one mouse. 
Horizontal bars represent the mean for each group. Groups were compared using student t-test (ns= not 
significant; *=p<0,05; **p<0,005; ***=p<0,0005). Abbreviations: T=transitional B cells; FO= 
follicular B cells, MZ= marginal zone B cells. 
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3.2.8 B cell development in adult bone marrow is impaired in Dkk3-/- 
mice 
Analysis of neonatal spleen only allows the investigation of the late steps of B cell 
maturation. Although adult BM has been shown to poorly generate B1 cells [141, 
142], it is still generating the pool of B2 cells and also in this population a 
developmental alteration was observed. In order to investigate full B cells 
development with all B cell developmental stages, BM of wt and Dkk3-/- mice was 
analyzed.  
 
In contrast to peripheral organs in adult and neonatal Dkk3-/- mice, total B cell 
numbers were not impaired in adult bone marrow of Dkk3-/- mice (Figure 3.23). The 
first B cell stages, which are the prepro- and the pro- B cells (B220+ CD93+ CD25-     
c-kit+ CD43+ cells), were increased in Dkk3-/- BM. Pre- B cell numbers (B220+ 
CD93+ CD25+ cells) were unchanged. Similar to the analysis in neonatal mice, 
numbers of immature B cells (B220+ CD93+ CD25- c-kit- CD43- IgM+ cells) were 
decreased, whereas numbers of mature FO B cells (B220+ CD93- CD21/CD35+ 
CD23+ cells) were unaltered in the BM of Dkk3 deficient mice in contrast to the 
periphery (which will be discussed in chapter 4.5 Dkk3 regulates B cell development 
and maintenance). These results demonstrate that B cell development at the step 
from the pre-B cells to the immature B cells seems to be impaired in Dkk3-/- mice. B 
cells which do not continue the maturation from the pre-B cell stage might 
accumulate to a low level already in the prepro/pro stage (perhaps by a feedback 
mechanism) or disappear by apoptosis. B1 cells (B220+ CD93- CD21/CD35- CD23- 
cells) were also in the adult BM observed to be increased in Dkk3-/- mice, which 
could be due to an increased generation of B1 cells in the BM but also due to 
migration from peripheral tissues to the BM, in which a part of mature B cells rests. 
Why total B cell numbers did not show an alteration in Dkk3-/- and wt mice similar 
to the neonatal mice can be explained by the low representation (~5-10%) of 
immature B cells in adult BM and the additional compensation by B1 and 
prepro/pro B cells.  
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Figure 3.23 | B cell development in adult bone marrow of Dkk3-/- mice is impaired. Cells from bone 
marrow of adult C57BL/6 (wt) and Dkk3-/- mice were isolated and analyzed by FACS for their 
developmental B cell stage. The gating strategy is shown in A. First FACS dot blot is gated on 
leukocytes. Dashed line indicated where gates were dragged to subgates in order to determine gate 
borders. In B summary data from two out of three independent experiments are presented and one dot 
represents cell numbers of one mouse. Horizontal bars represent the mean for each group. Groups were 
compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005).  
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3.2.9 The self-renewal capacity of B1 cells is increased in Dkk3-/- mice 
B1 cell numbers in adults are mainly maintained by self-renewal. Therefore, there are 
two possibilities why increased B1 cell number appear in Dkk3-/- mice. Either B1 cells 
possess a selection advantage during the development in Dkk3-/- mice or they receive 
increased survival signals and therefore have an increased self-renewal capacity.  
 
As the first hypothesis is presently not testable because immature (transitional) B1 
cells can not be distinguished from immature B2 cells, but this is the cell stage which 
would indicate an altered developmental process, we decided to test whether the self-
renewal capacity of B1 cells is increased. CD19+ B cells of spleens from adult mice 
were purified (Figure 3.24 A) and transferred to either Dkk3-/-Rag2-/- or wt.Rag2-/- 
mice. To additionally answer the question whether environmental or intrinsic Dkk3 
leads to the observed effect the experiment was performed with donor cells from wt 
and Dkk3-/- mice.  
 
The adult spleen contains mainly mature B cells, therefore de novo generation of B 
cells can not take place and the cell numbers after a longer time of incubation reflect 
the self-renewal/survival capacity of B cells. We decided to give the transferred cells 
4 weeks to expand and maintain themselves by self-renewal before being analyzed.  
 
After 4 weeks higher numbers of B cells were detected in recipient spleen and PerC 
in the groups of either B cells transferred to a Dkk3 deficient environment or cells 
coming from Dkk3-/- deficient mice (Figure 3.24 B). This was due to increased B1 cell 
numbers in spleen and PerC (Figure 3.24 C). B1 cell numbers exceeded 5 times the 
numbers of B2 cells, even in spleens, where normally B1 cells are only a minor 
population within the B cell subsets, confirming that B1 cells have a higher capacity 
of self-renewal/survival than B2 cells. 
 
FO cell numbers were also determined in this experiment, to analyze whether 
decreased numbers observed in the periphery of adult Dkk3-/- mice are due to a lower 
self-renal/survival rate or due to impaired B cell development (as indicated by the 
experiment described in the last chapter). No difference between the four groups was 
found in FO cells numbers (Figure 3.24 D). This demonstrates that the reduction of 
FO B cells in the absence of Dkk3 is due to a developmental impairment and not due 
to differences in self-renewal/survival.  
 
Furthermore, serum IgM levels were analyzed 4 weeks after cell transfer. As B1 cells 
are the major producer of natural IgM in serum and this has also been demonstrated 
for immunodeficient mice in which B cells were transferred [156], this function can be 
used as readout system for B1 cell numbers and their IgM secreting activity. Indeed, 
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total IgM levels in serum of the four groups mirrored B1 cell numbers detected by 
FACS (Figure 3.24 C). Cells transferred to a Dkk3 deficient environment generated 
higher IgM levels, than the cells transferred to a Dkk3 sufficient environment. 
However, cells of a Dkk3-/- origin generated even higher IgM levels in serum in 
comparison to wt control cells, similar to the increased B1 cell numbers detected by 
FACS.  
 
These observations were additionally confirmed by ex vivo IL-10 secretion analysis of 
splenocytes (Figure 3.24 D), as IL-10 was shown to be selectively expressed by B1 
cells (3.2.3 A higher proportion of B1 cells secretes IL-10 in Dkk3-/- mice).  
 
Thus, the results of all three readout-systems suggest that the increased numbers of 
B1 cells found in Dkk3-/- mice are due to increased self-renewal capacity of B1 cells. 
How environmental and intrinsic Dkk3 contributes to this effect is unclear.  
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Figure 3.24 | B1 cells from Dkk3-/- mice  and B1 cells transferred to a Dkk3 deficient environment 
display increased self-renewal capacity. CD19+ B cells were purified from spleens of C57BL/6 (wt) or 
Dkk3-/- mice (A; Pre= Before purification; Post= After purification) and 7x106 cells were transferred to 
either wt.Rag2-/- (wt) or Dkk3-/-Rag2-/- (Dkk3-/-) mice. 4 weeks after transfer spleens and peritoneal 
cavity cells (PerC) of recipient mice were analyzed for numbers of total B cells, B1 cells and follicular B 
cells (FO) within the leukocyte population by FACS analysis (B). 4 weeks after transfer total IgM in 
serum was determined by ELISA (C). One dot represents cell numbers/ IgM serum concentration of one 
mouse and horizontal bars represent the mean for each group (B/C). Furthermore, 4 weeks after 
transfer, splenocytes were cultured with different concentrations of LPS together with 10µg/ml anti-
CD40 for 24 hours. IL-10 concentration in supernatants was determined by ELISA (D). Mean and SEM 
are indicated for each group (D). Results show summary data from two independent experiments. 
Groups were compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005).  
 
 
3.2.10 Dkk3 is not expressed by splenic or peritoneal cavity B cells 
It has been shown by our group, that Dkk3 is not detected in the spleen on the 
protein level [212]. However, it is possible that low amounts of Dkk3 are expressed 
by B cells, and that this can not be detected when using the complete tissue of the 
spleen. To additionally have a comparison between B1 and B2 cells, CD19+ cells of 
spleen (yielding mainly B2 cells) and PerC (yielding high numbers of B1 cells) were 
purified and RNA was extracted to analyze the Dkk3 expression level specifically in 
B cells. The tissue of the eye was used as a positive control, whereas Dkk3-/- samples 
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served as background controls. RNA expression analysis revealed that Dkk3 is not 
expressed by mature splenic or PerC B cells (Figure 3.25). The detected expression 
levels were in the range of the background levels of Dkk3-/- mice.   
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Figure 3.25 | Dkk3 is not expressed by splenic and peritoneal B cells. Total RNA was purified from 
C57BL/6 (wt) and Dkk3-/- CD19+ purified B cells of spleen, peritoneal cavity (PerC) and from the 
tissue of the eye as comparison, reverse transcribed to cDNA and analyzed by quantitative real-time 
PCR. For comparative analysis, the relative Dkk3 mRNA expression level was calculated by using β-
actin mRNA levels as a control housekeeping gene. Mean and SEM are shown (n=4).  
 
 
3.2.11 Dkk3 neutralization leads to increased symptoms of lupus 
erythematosus in MRL/LPR mice 
B1 cells have been described to play important roles in autoimmune diseases, 
especially in systemic lupus erythematosus (SLE) [132, 167]. In the previous chapters 
it was demonstrated that, Dkk3-/- mice yield increased numbers of B1 cells, show 
increased B1 cell antibody responses and display increased IL-10 secretion, a B1 
derived cytokine which was shown to play a crucial role in lupus erythematosus [175-
178]. Thus, we aimed to analyze whether Dkk3 neutralization would result in 
deteriorated autoimmune symptoms in a model of SLE. For our studies we used the 
MRL/LPR mouse model of SLE, as disease onset (at 5-8 weeks of age) and 
progression in this strain occurs in a suitable time frame [248] for Dkk3 antibody 
treatment. Anti-Dkk3 antibody or isotype control treatment was started when mice 
had an age of 5 weeks, just shortly before first SLE symptoms appear. Treatment 
was carried out twice a week for a time period of 6 weeks. Serum was taken at 
several time points to allow the determination of autoantibodies. Mice were sacrificed 
at an age of 12 weeks and analyzed for multiple parameters, including weight of 
organs, phenotype of lymphocytes, levels of autoantibodies, as well as the 
inflammatory status of organs by histological analysis.  
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Figure 3.26 | Experimental setup for anti-Dkk3 antibody treatment of MRL/LPR mice. Anti-Dkk3 
antibody or isotype control treatment of MRL/LPR mice was started at an age of 5 weeks. Mice were 
treated twice a week with 0,7mg anti-Dkk3 antibody or isotype control for 6 weeks. At an age of 12 
weeks mice were analyzed for symptoms of SLE. Blood was collected several times for serum extraction.  
 
 
3.2.11.1 Anti-Dkk3 antibody treatment results in enlarged lymph nodes and 
kidneys in MRL/LPR mice 
MRL/LPR mice suffer from enlarged organs, caused by the failure of lymphocytes to 
go into apoptosis leading to organ infiltration and inflammation [181]. Therefore, 
when mice were sacrificed weight of different organs was measured. The spleen was 
huge in both, the isotype control and the anti-Dkk3 antibody treated, groups. The 
heart and liver also had a similar weight in both groups and can therefore serve as 
control organs. Interestingly, all measured LN, axillary, inguinal and mesenteric LN, 
were increased to a higher level in anti-Dkk3 antibody treated MRL/LPR mice. 
Furthermore, kidneys, the typical inflamed organ in SLE patients, of anti-Dkk3 
antibody treated mice possessed a significantly higher weight than the control 
treated mice.  
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Figure 3.27 | Anti-Dkk3 antibody treatment results in enlarged lymph nodes and kidneys in 
MRL/LPR mice. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 weeks 
as described in Figure 3.26. One week after treatment was finished, weight of spleen (A), inguinal LN 
(B), axillary LN (C), mestenteric lymph nodes (MLN/D), heart (E), liver (F), and kidney (G) was 
determined. Summary data of 3 independent experiments are shown. One dot represents weight of one 
organ. Horizontal bars represent the mean for each group. Groups were compared using student t-test 
(ns= not significant; *=p<0,05; **=p<0,005; ***=p<0,0005).  
 
 
3.2.11.2 Anti-Dkk3 antibody treatment results in higher numbers of B1 cells in 
PerC and spleen of MRL/LPR mice 
The disease of MRL/LPR mice is caused by increased numbers of lymphocytes, 
which do not undergo apoptosis, proliferate, infiltrate organs, and produce numerous 
inflammatory stimuli as well as auto-reactive antibodies. B1 cells are especially 
known for the capacity to secrete auto-reactive antibodies as well as disease 
exacerbating     IL-10 [132]. Therefore, we were interested whether the phenotype of 
lymphocytes was differing between isotype control and anti-Dkk3 antibody treated 
MRL/LPR mice. Spleen, LN and PerC cells were isolated and analyzed for different 
B and T cell markers by FACS.  
 
The distribution of B and T cell populations was abnormal in both treatment groups 
(Figure 3.28) compared to C57BL/6 mice (e.g. Figure 3.18). B cells consisted of 
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enormous high numbers of B1 cells, as defined here as B220+, CD19+ CD43+, CD5+/-, 
CD21/CD35- and CD23-. In the spleen the frequency of B1 cells was 2-3 fold 
increased, but in lymph nodes the frequency exceeded 10-20 times the normal 
number of B1 cells found in C57BL/6 wt mice. T cells did not only exhibit an 
abnormal high frequency in lymph nodes but also did they show an abnormal 
phenotype. They highly expressed B220 and were mainly negative for the coreceptors 
CD4 and CD8.  
 
The number of T cells and B cells was similar between isotype control and anti-Dkk3 
antibody treated mice in the spleen and the LN (Figure 3.28 C). However, the PerC 
of anti-Dkk3 antibody treated mice exhibited higher number of B cells than the 
control group, which was due to increased numbers of B1 cells. In the spleen, the 
frequency of B cells was the same in both groups. However, within the B cells of the 
spleen the ratio of B2:B1 changed towards increased numbers of B1 cells in the anti-
Dkk3 antibody treated group. In the lymph nodes, the ratio of B2:B1 was the same 
in the isotype control and anti-Dkk3 antibody treated group. But nevertheless, the 
weight of LN was significantly higher in anti-Dkk3 antibody treated mice; therefore 
increased numbers of all cells were present in the LN, including B1 cells.  
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Figure 3.28 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit increased numbers of B1 
cells. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 weeks as described 
in Figure 3.26. One week after treatment was finished, cells of spleen, axillary lymph nodes (LN), 
inguinal LN and peritoneal cavity (PerC) were stained for different T and B cell markers by FACS. The 
gating strategy of T cells, B1 and B2 cells for spleen, axillary LN and inguinal LN cells is shown in A as 
an example of spleen cells. The gating stategy for PerC cells is shown in B. In C summary data of 3 
independent experiments are presented. Left panels show B220+ T (CD19-CD3+) and B (CD19+ CD3-) 
cells as gated in A and B. Right panels shows analysis of B1 cells in the different lymphatic sites. One 
dot represents cell numbers of one mouse. Horizontal bars represent the mean for each group. Groups 
were compared using student t-test (ns= not significant; **=p<0,005; ***=p<0,0005).  
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3.2.11.3 Anti-Dkk3 antibody treatment leads to increased levels of autoantibodies 
in the serum 
One of the hallmarks of SLE is the high level of autoantibodies in serum which 
contributes to organ destruction [186]. It is assumed that these autoantibodies are 
secreted especially by B1 cells, which are recruited to germinal centers, undergo CSR 
and produce high affinity antibodies. However, this process makes them hard to be 
distinguished from B2 cells, which is the reason why it is still controversial whether 
in deed B1 cells are solely responsible for autoantibody production [132, 249, 250]. As 
B1 cell numbers were increased in Dkk3 deficient and MRL/LPR mice treated with a 
Dkk3 neutralizing antibody, we were interested in the level of autoantibodies in 
serum of isotype control treated and anti-Dkk3 antibody treated MRL/LPR mice.  
 
Four different autoantibody specificities were tested for IgM and IgG concentration 
in serum of MRL/LPR mice. Myelin oligodendrocyte glycoprotein (MOG) and  
myelin basic protein (MPB) specific immunoglobulins are directed to CNS antigens 
and are observed to be increased is patients of SLE and multiple sclerosis [251-253]. 
Antibodies against single and double strand (ss and ds) DNA are most typically 
observed to be increased in patients of SLE and are used as diagnostic parameter for 
SLE [254, 255]. The immunoglobulins of all four analyzed specificities were highly 
increased in MRL/LPR mice at the age of 12 weeks in comparison to 5 weeks old 
MRL/LPR mice or C57BL/6 control mice (Figure 3.29 to Figure 3.32). No difference 
was found in anti-MBP IgM and IgG antibody levels between the isotype control and 
anti-Dkk3 antibody treated group (Figure 3.29). Anti-MOG IgM and IgG antibodies 
were significantly increased in MRL/LPR mice treated with anti-Dkk3 antibody 
(Figure 3.30). Also ss-DNA and ds-DNA IgG antibodies were significantly increased 
in anti-Dkk3 antibody treated mice (Figure 3.31 and Figure 3.32). Therefore, we 
conclude, that Dkk3 neutralization leads to increased numbers of auto-reactive 
antibodies to different target structures which may contribute to the tissue 
destruction in the pathogenesis of SLE in the model of MRL/LPR mice.  
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Figure 3.29 | MRL/LPR mice treated with anti-Dkk3 antibody do not exhibit higher levels of 
anti-MBP antibodies. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 
weeks as described in Figure 3.26. Concentration of anti-MBP specific IgM (A) and IgG (B) antibodies 
was determined in sera taken at the start of treatment (Day0) and one week after treatment was 
finished (7 weeks) by ELISA. Serum of 4-5 months old MRL/LPR mice (old LPR) and 2 months old 
C57BL/6 mice served as positive and negative controls. One dot represents antibody concentration in 
serum of one mouse. Horizontal bars represent the mean for each group. Groups were compared using 
student t-test (ns= not significant).   
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Figure 3.30 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit higher levels of anti-MOG 
antibodies. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 weeks as 
described in Figure 3.26. Concentration of anti-MOG33-55 specific IgM (A) and IgG (B) antibodies was 
determined in sera taken at the start of treatment (Day0) and one week after treatment was finished (7 
weeks) by ELISA. Serum of 4-5 months old MRL/LPR mice (old LPR) and 2 months old C57BL/6 
mice served as positive and negative controls. One dot represents antibody concentration in serum of 
one mouse. Horizontal bars represent the mean for each group. Groups were compared using student t-
test (ns= not significant; *=p<0,05; **=p<0,005).  
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Figure 3.31 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit higher levels of anti-ss-
DNA IgG antibodies. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 
weeks as described in Figure 3.26. Concentration of anti-single strand (ss) - DNA specific IgM (A) and 
IgG (B) antibodies was determined in sera taken at the start of treatment (Day0) and one week after 
treatment was finished (7 weeks) by ELISA. Serum of 4-5 months old MRL/LPR mice (old LPR) and 2 
months old C57BL/6 mice served as positive and negative controls. One dot represents antibody 
concentration in serum of one mouse. Horizontal bars represent the mean for each group. Groups were 
compared using student t-test (ns= not significant; *=p<0,05).  
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Figure 3.32 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit higher levels of anti-ds-
DNA IgG antibodies. MRL/LPR mice were treated with anti-Dkk3 antibody or isotype control for 6 
weeks as described in Figure 3.26. Concentration of anti-double strand (ds) - DNA specific IgM (A) and 
IgG (B) antibodies was determined in sera taken at the start of treatment (Day0) and one week after 
treatment was finished (7 weeks) by ELISA. Serum of 4-5 months old MRL/LPR mice (old LPR) and 2 
months old C57BL/6 mice served as positive and negative controls. One dot represents antibody 
concentration in serum of one mouse. Horizontal bars represent the mean for each group. Groups were 
compared using student t-test (ns= not significant; *=p<0,05).  
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3.2.11.4 Anti-Dkk3 antibody treatment results in kidney, lung and pancreas 
inflammation  
The accumulation of immune complexes and infiltration of lymphocytes in organs of 
SLE patients leads to a strong inflammatory response of the immune system which 
can lead to organ failure [165, 166]. Especially kidneys and lungs are mostly observed 
to be damaged in SLE patients. Also in MRL/LPR mice, glomerulonephritis and 
progress to end-stage renal failure is a typical consequence of disease progression 
[181, 182]. To investigate, whether anti-Dkk3 antibody treatment leads to aggravated 
inflammation of organs, lungs, pancreas and kidneys of isotype control and anti-Dkk3 
treated MRL/LPR mice were histologically examined.  
 
Pancreata, lungs and kidneys of anti-Dkk3 antibody treated mice exhibited increased 
inflammatory foci and higher numbers of infiltrating leukocytes compared to mice 
treated with isotype control (Figure 3.33). The tissues of anti-Dkk3 antibody treated 
mice exhibited severe tissue damage. In future experiments further 
immunohistochemistry will be added to distinguish different leukocytes such as 
macrophages, B and T cells and to examine tissue damage more specifically by e.g. 
collagen staining.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.33 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit higher levels of infiltrating 
leukocytes. MRL/LPR mice were treated with anti-Dkk3 antibody (n=12) or isotype control antibody 
(n=13) for 6 weeks as described in Figure 3.26. Mice were sacrificed and tissues collected in formalin. 
Paraffin tissue sections of pancreas (A), lung (B) and kidney (C) were prepared and stained with 
hematoxylin and eosin. Upper pictures of each tissue are at 20x magnification, lower pictures at 40x 
magnification. Representative pictures for each tissue and treatment group are depicted. Violet dots are 
infiltrated lymphocytes. Stronger leukocyte infiltration in anti-Dkk3 antibody treated mice as shown in 
this figure was observed in 8/12 mice in pancreas tissue. 6/12 mice in lung tissue and 9/12 mice in 
kidney tissue.  
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Figure legend 
on the left 
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The increased inflammation observed in the pancreata of anti-Dkk3 antibody treated 
mice was confirmed by increased levels of blood sugar in these mice in comparison to 
isotype treated mice.  
 
 
Figure 3.34 | MRL/LPR mice treated with anti-Dkk3 antibody exhibit 
higher levels of blood sugar. MRL/LPR mice were treated with anti-Dkk3 
antibody or isotype control for 6 weeks as described in Figure 3.26. 
Concentration of Glucose was determined after treatment was finished (7 
weeks) in blood plasma. One dot represents Glucose concentration in plasma of 
one mouse. Horizontal bars represent the mean for each group. Groups were 
compared using student t-test (**=p<0,005).  
 
 
 
Concluding, we found an increased pathology in MRL/LPR mice treated with anti-
Dkk3 antibody, which was asserted on different levels of disease assessment. Firstly, 
lymph nodes and kidneys were enlarged; secondly levels of autoantibodies were 
increased in the serum, and thirdly increased infiltration of organs by leukocytes and 
severe tissue damage in these organs was observed in anti-Dkk3 antibody treated 
mice. These observations were associated with increased numbers of B1 cells in these 
mice compared to isotype treated mice.  
 
 
 
 
 
 
In summary the experiments investigating the role of Dkk3 in B cell function 
revealed that Dkk3 deficient mice exhibit increased B1 cell numbers whereas 
numbers of B2 cells are decreased. Therefore, antigen responses to B1 antigens 
as well as B cell derived IL-10, the typical cytokine secreted by B1 cells, were 
increased in Dkk3-/- mice. B2 cell function was not found to be reduced by Dkk3 
deficiency. B cell development and maintenance analysis showed that B2 
development is impaired in the bone marrow of Dkk3-/- mice. In contrast the 
self-renewal capacity of B1 cells was increased in Dkk3-/- mice as demonstrated 
by transfer experiments. Analyzing the role of Dkk3 in a model of SLE, we 
found that neutralization of Dkk3 leads to higher numbers of B1 cells, increased 
autoantibody production and more severe tissue damage in MRL/LPR mice.  
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3.3 Search for an immunological phenotype in Soggy-/- mice 
Soggy is the most distant member of the Dkk protein family. The sgy domain is 
solely present in the proteins Soggy and Dkk3 [191]. As this domain distinguishes 
Dkk3 from the other members it is tempting to speculate that this domain confers 
the immune-modulatory property to Dkk3. To address this question, the 
immunological phenotype of Soggy-/- mice was explored. This will tell us, whether 
Soggy also exhibits immune-modulatory properties and it will give hints whether the 
sgy domain is important in conferring this feature to Dkk3 and Soggy. (Experiments 
in chapter were performed together with A. Steinbach and also contributed to her 
master thesis.) 
 
3.3.1 Expression of Soggy on the mRNA and protein level 
Dkk3 was described to be expressed primarily in immune privileged sites [212]. We 
were interested whether soggy displays a similar expression pattern, which would 
provide a first indication whether Soggy may be relevant as an immune regulatory 
candidate similar to Dkk3. Furthermore, the expression pattern of Soggy was 
analyzed in wt and Dkk3-/- mice revealing whether genetic deletion of Dkk3 has an 
effect on the Soggy expression level, because based on their homology, (sgy domain 
has 41% homology in Dkk3 and Soggy (Figure 3.35)) they may complement their 
functions. To address these questions, the expression of Soggy was assessed on the 
mRNA and on the protein level.  
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Figure 3.35 | The sgy domain of Dkk3 and Soggy exhibit 41% homology. Multiple sequence 
alignment was carried out with ClustalW algorithm of murine Dkk3 and Soggy protein sequences found 
in the NCBI database. The location of the sgy domain (as described by Niehrs [191]) is indicated by the 
yellow shaded box. Stars (*) indicate homologue amino acids. The sgy domain exhibits 24 homologue 
amino acids out of 58 total amino acids in Dkk3 and Soggy, counting up to 41% domain identity. The 
overall sequence identity of the Soggy and Dkk3 protein is 22%.  
 
 
 
The analysis of mRNA and protein expression of Soggy revealed that Soggy is highly 
expressed in the testis and to a lower level in the brain and the skin. Interestingly, 
brain, testis and the proximal hair follicle epithelium in the skin have been described 
to belong to immune privileged sites [25, 28, 256]. Additionally, Soggy was also 
detected to a very low level in the stomach. In all other analyzed tissues, eye, 
pancreas, atrium, ventricle, liver, kidney, spleen, lymph nodes, thymus, lung, small 
intestine, caecum, large intestine and bone marrow, it was absent. In Dkk3-/- mice 
the expression of Soggy was not significantly altered, demonstrating that Dkk3 
deficiency does not lead to a compensatory upregulation of Soggy expression.  
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Figure 3.36 | Soggy is expressed in testis, brain and skin. To determine the expression of Soggy on 
the mRNA level (A), total RNA was purified from mouse tissues of C57BL/6 (wt), Dkk3-/- and Soggy-/- 
mice, reverse transcribed to cDNA and analyzed by quantitative real-time PCR. For comparative 
analysis, the relative Soggy mRNA expression level was calculated by using β-actin mRNA levels as a 
control housekeeping gene. Mean and SEM are shown (n=5). To determine the expression of Soggy on 
the protein level (B), total protein was extracted from mouse tissues of C57BL/6 (wt) and Dkk3-/- mice, 
adjusted to a protein concentration of 10 mg/ml and analyzed by ELISA. Organ lysates from Soggy-/- 
mice were negative for Soggy protein, confirming that Soggy antibodies do not crossreact with Dkk3 
protein. Mean and SEM are shown (n=6). 
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3.3.2 Soggy deficiency does not alter the numbers of mature T cells in 
the thymus 
In order to examine, whether T cell development is altered in Soggy-/- mice, 
thymocytes were analyzed for their phenotypical maturation status.  
 
Soggy deficient mice exhibited changes in the first developmental stages. Slightly but 
significantly increased CD8/CD4 double negative (DN) cells and slightly reduced 
numbers of CD8/CD4 double positive (DP) cells were detected (Figure 3.37). 
Analyzing the DN stage for substages, revealed that the number of CD44+CD25- 
(DN1) cells was reduced in Soggy deficient mice. The other DN stages (DN12-4) were 
not affected by Soggy deficiency. Although differences in the first developmental 
stages were detected, mature single positive CD4 and CD8 T cells were present at 
similar numbers in the thymus of wt and Soggy-/- mice.  
 
Tregs detected by the expression of CD4 and FoxP3 were Helios positive (Figure 
3.38 A), confirming the observation by Thornton et al., which claimed Helios to be a 
marker for thymic Tregs [58]. No difference in Treg numbers in the thymus was 
found in Soggy-/- mice compared to wt controls (Figure 3.38 B).  
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Figure 3.37 | T cell development in the thymus in Soggy deficient mice. Cells were isolated from the 
thymus of C57BL/6 (wt) and Soggy-/- mice. Population frequencies of the different stages of CD4 and 
CD8 T cell development were analyzed by FACS. The gating strategy is shown in A for wt and Soggy-/- 
mice. Upper FACS dot blot are gated on thymocytes. Summary data of three independent experiments 
are presented in B. One dot represents cell numbers of one mouse. Horizontal bars represent the mean 
for each group. Groups were compared using student t-test (ns= not significant; *=p<0,05; 
**=p<0,005). 
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Figure 3.38 | Numbers of regulatory T cells are not altered in the thymus of Soggy-/- mice. Cells 
were isolated from the thymus of C57BL/6 (wt) and Soggy-/- mice. The number of FoxP3+ regulatory T 
cells was determined by FACS analysis. The FACS dot blots in A are gated on single positive CD4 T 
cells and shows the gating of Helios+ FoxP3+ cells-. Summary data of two independent experiments are 
presented in B. One dot represents cell numbers of one mouse. Horizontal bars represent the mean for 
each group. Groups were compared using student t-test (ns= not significant). 
 
 
3.3.3 T cell subpopulations in peripheral tissues are altered in Soggy-/- 
mice 
To investigate, whether peripheral T cell populations are altered in Soggy-/- mice, 
CD4 and CD8 T cells were analyzed in wt, Dkk3-/- and Soggy-/- mice. Cells were 
stained for the surface molecules CD44 and CD62L commonly used to determine the 
activation status of a T cell and allowing the determination of effector and memory 
status. CD44 is upregulated upon T cell stimulation and expression is sustained on 
memory T cells [257], whereas CD62L is expressed on naïve T cells promoting 
homing to secondary lymphoid organs and its expression is downregulated upon 
stimulation allowing the migration to sites of infection outside of lymphoid organs 
[258-260]. Central memory T cells home to secondary lymphoid organs and therefore 
express CD62L, whereas effector memory cells reside mainly in specific tissues and 
therefore do not express CD62L. Additionally, cells were stained for FoxP3 and 
CD25 to identify Tregs. Helios has been described to distinguish natural from iTregs, 
as it was found predominantly on thymic Tregs [58]. Therefore, we used this marker 
to get an impression, whether we find differences in Treg origin in Soggy-/- mice 
compared to wt and Dkk3-/- mice.  
 
T cell analysis of splenic cells (Figure 3.39) revealed, that the spleen in Soggy-/- 
exhibits slightly but significantly less CD8 T cells.  Furthermore, memory cells 
(CD44high cells) were reduced among CD4 and CD8 T cell subsets, in Soggy-/- spleens. 
In the CD4 T cell subset this was due to a reduction of both central and effector 
memory T cells, whereas in the CD8 T cell subset this was due to a reduction of only 
central memory T cells. Strikingly, Treg cell numbers were decreased in Soggy-/- 
spleens as both FoxP3 and CD25 positive cells were decreased. Interestingly, in the 
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spleen higher numbers of Helioslow cells within the Treg cell population were found, 
pointing to an increased number of induced Tregs in Soggy-/- spleens.  
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Figure 3.39 | Soggy-/- mice display decreased levels of memory and regulatory T cells in the 
spleen. Cells were isolated from spleen of C57BL/6 (wt), Dkk3-/- and Soggy-/- mice and CD4, CD8 and 
regulatory T cells were analyzed by FACS for their numbers and expression of different 
activation/memory markers. Summary data of four independent experiments are presented. One dot 
represents cell numbers of one mouse. Horizontal bars represent the mean for each group. Groups were 
compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005; ***=p<0,0005). 
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In the MLN a similar T cell distribution compared to the spleen was observed for   
Soggy-/- mice (Figure 3.40). Numbers of CD8 T cells were equal in wt, Dkk3-/- and 
Soggy-/- mice. But still the ratio of CD8/CD4 T cells was shifted towards CD4 in 
Soggy-/- MLN, as higher numbers of CD4 T cells were present in Soggy-/- MLN. The 
expression of CD44 was reduced in both CD4 and CD8 T cells also in the MLN of 
Soggy-/- mice and, exactly as in the spleen, in the CD4 T cell subset this was due to 
the reduction of both central and effector memory T cells, whereas for the CD8 T 
cells this was due to only the reduction of central memory T cells. The number of 
regulatory T cells was also in the MLN found to be reduced. However, in contrast to 
the spleen, the proportion of induced Tregs (Helioslow Tregs) was lower in Soggy-/- 
MLN compared to wt and Dkk3-/- MLN.  
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Figure 3.40 | Soggy-/- mice display decreased levels of memory and regulatory T cells in the 
mesenteric lymph nodes. Cells were isolated from mesenteric lymph nodes of C57BL/6 (wt), Dkk3-/- 
and Soggy-/- mice and CD4, CD8 and regulatory T cells were analyzed by FACS for their numbers and 
expression of different activation/memory markers. Summary data of two independent experiments are 
presented. One dot represents cell numbers of one mouse. Horizontal bars represent the mean for each 
group. Groups were compared using student t-test (ns= not significant; *=p<0,05; **=p<0,005; 
***=p<0,0005).  
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3.3.4 Soggy deficiency leads to increased proliferation of CD4 T cells, 
while proliferation of CD8 T cells is not affected 
The expressions of Soggy in immune privileged sites as well as the altered numbers of 
T cell populations in peripheral lymphoid organs indicate that Soggy is a candidate 
that may regulate the immune system. Therefore, it is of great interest whether T 
cell reactivity is affected in Soggy deficient mice. T cells from Dkk3-/- mice have been 
shown by our laboratory to possess an increased proliferation capacity under 
suboptimal stimulation conditions compared to T cells from wt mice [214]. In order 
to investigate, whether the proliferation of T cells of Soggy-/- mice is similarly altered, 
splenic T cells of wt, Dkk3-/- and Soggy-/- mice were purified, CFSE labeled and 
stimulated with different concentrations of plate bound anti-CD3 and anti-CD28. 48 
hours after stimulation, proliferation was assed by analyzing the progressive halving 
of CFSE fluorescence upon cell divisions by FACS.  
 
CD4 T cells of Soggy-/- mice exhibited a strongly increased proliferation rate than T 
cells of wt and Dkk3-/- mice (Figure 3.41). Also in this assay, even after T cell 
stimulation the lower CD44 expression level in CD4 T cells of Soggy-/- mice was 
noticeable (Figure 3.41 A) as investigated in the previous chapter.  
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Figure 3.41 | CD4 T cells of Soggy-/- mice display increased proliferation in vitro. T cell were 
purified from spleens of C57BL/6 (wt), Dkk3-/-, and Soggy-/- mice, labeled with CFSE and stimulated 
with titrated concentrations of anti-CD3 and anti-CD28. 48 hours later proliferation was measured by 
FACS analysis. Representative FACS blots are gated on CD4+ T cells and display CD44 expression 
against CFSE dilution (A). Numbers in the upper and lower left-hand quadrants indicate percentages of 
proliferated cells. Summary data show proliferated CD4+ T cell numbers per well (cells with a lower 
CFSE fluorescence that unstimulated cells), which were measured by FACS using Sphero Blank 
Calibration beads (B). In order to pool individual experiments, the highest cell number of proliferated 
wt CD4 T cells was set to 100 and all other cell numbers were calculated in relation. Summary data 
from 2 out of 4 independent experiments (n=6 per group) are presented. Mean and SEM are indicated 
for each group. Groups were compared using student t-test (*=p<0,05; **=p<0,005).  
 
 
CD8 T cells of Soggy-/- mice did not show an altered proliferation rate compared to T 
cells of wt and Dkk3-/- mice (Figure 3.42). Similar to the CD4 T cells the lower CD44 
expression level in Soggy-/- CD8 T cells was noticeable (Figure 3.42 A) as 
investigated in the previous chapter.  
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Figure 3.42 | Soggy deficiency does not affect CD8 T cell proliferation. T cell were purified from 
spleens of C57BL/6 (wt), Dkk3-/-, and Soggy-/- mice, labeled with CFSE and stimulated with titrated 
concentrations of anti-CD3 and anti-CD28. 48 hours later proliferation was measured by FACS analysis. 
Representative FACS blots are gated on CD8+ T cells and display CD44 expression against CFSE 
dilution (A). Numbers in the upper and lower left-hand quadrants indicate percentages of proliferated 
cells. Summary data are depicted in B. Proliferated CD8+ T cells numbers per well (cells with a lower 
CFSE fluorescence that unstimulated cells) were measured by FACS using Sphero Blank Calibration 
beads. In order to pool individual experiments, the highest cell number of proliferated wt CD8 T cells 
was set to 100 and all other cell numbers were calculated in relation. Summary data from 2 out of 4 
independent experiments are presented (n=6 per group). Mean and SEM are indicated for each group.  
 
 
3.3.5 Soggy deficiency leads to increased IL-2 secretion of CD4 T cells 
IL-2 is a cytokine commonly secreted upon T cell stimulation and acts as growth 
factor. Besides the increased proliferation capacity Dkk3-/- T cells have been 
described to secrete higher levels of levels of IL-2 compared to wt T cells [212]. In 
order to analyze whether this is also true for T cells from Soggy deficient mice, 
splenic T cells of wt, Dkk3-/- and Soggy-/- mice were purified and stimulated with 
different concentrations of plate bound anti-CD3 and anti-CD28. 24 hours later 
supernatants were analyzed for IL-2 levels by ELISA. T cells of Dkk3-/- mice 
produced approximately 1,5 fold higher levels of IL-2 compared to T cells of wt mice 
(Figure 3.43). Remarkably, the IL-2 production of T cells from Soggy-/- mice even 
exceeded the production of IL-2 by   Dkk3-/- T cells. Soggy-/- T cells secreted 
approximately 2,4 fold higher levels of IL-2 than wt T cells (Figure 3.43). 
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Figure 3.43 | T cells of Soggy-/- mice secrete higher levels of IL-2. T cell were purified from spleens 
of C57BL/6 (wt), Dkk3-/-, and Soggy-/- mice and stimulated with titrated concentrations of anti-CD3 
and anti-CD28. 24 hours later IL-2 was measured in supernatants by ELISA. In order to pool individual 
experiments, the highest IL-2 value of wt T cells was set to 100 and all other values were calculated in 
relation. Summary data from 3 independent experiments (n=6 per group) are presented. Mean and 
SEM are indicated for each group. Groups were compared using student t-test (*=p<0,05; **=p<0,005; 
***=p<0,0005).  
 
 
Soggy deficiency resulted in a significant reduction of CD8 T cell numbers in the 
spleen. In this assay purified T cells of spleens were used. CD4 T cells - not CD8 T 
cells - are mainly responsible for IL-2 secretion [261]. Hence, it may be argued that 
after T cell isolation, purified T cell cultures of Soggy-/- mice contained higher 
numbers of CD4 T cells compared to purified T cells from wt and Dkk3-/- spleens 
which might have lead to the observed effect. To exclude, that the higher secretion 
of IL-2 by  Soggy-/- T cells is due to higher numbers of CD4 T cells being present in 
the stimulation assay, the assay was performed with purified CD4 T cells from wt 
and Soggy-/- mice.  
 
Higher IL-2 secretion by CD4 T cells from Soggy-/- mice was still observable, when 
exactly same numbers of purified wt and Soggy-/- CD4 T cells were plated (Figure 
3.44). Also here, CD4 T cells of Soggy-/- mice secreted more than twice the amounts 
of IL-2. Therefore, the increased production of IL-2 in T cell cultures of Soggy-/- mice 
was not due to higher numbers of CD4 T cells. 
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Figure 3.44 | Increased secretion of IL-2 in T cell cultures of Soggy-/- mice is not due to higher 
numbers of CD4 T cells. CD4 T cell were purified from spleens of C57BL/6 (wt) and Soggy-/- mice and 
stimulated with titrated concentrations of anti-CD3 and anti-CD28. 24 hours later IL-2 was measured in 
supernatants by ELISA. In order to pool individual experiments, the highest IL-2 value of wt T cells 
was set to 100 and all other values were calculated in relation. Summary data from 2 out of 3 
independent experiments (n=9 per group) are presented. Mean and SEM are indicated for each group. 
Groups were compared using student t-test (*=p<0,05; **=p<0,005; ***=p<0,0005).  
 
 
3.3.6 Increased IL-2 secretion of CD4 T cells might be due to 
decreased levels of regulatory T cells in Soggy-/- mice 
Genetic deletion of Soggy resulted in significantly decreased numbers of Tregs in 
peripheral immune organs including the spleen. Tregs have been shown on one hand 
to inhibit IL-2 secretion of CD4 T cells and on the other hand to consume large 
amounts of IL-2 [262, 263]. Therefore, it is reasonable to investigate whether the 
observed effect of increased IL-2 secretion in T cell cultures of Soggy-/- mice is due to 
decreased numbers of Tregs being present in the stimulation assay. In order to 
analyze this, CD4 T cells were first purified of wt and Soggy-/- spleen suspensions and 
then depleted of CD25+ cells by MACS. Through this procedure, besides the small 
population of CD25+ effector T cells, mainly Tregs were depleted. 
 
After depletion of CD25+ cells, CD4 T cells were stimulated and the resulting 
effector T cells of Soggy-/- mice produced the same amount of IL-2 as effector CD4 T 
cells of wt mice (Figure 3.45). Therefore, the effect of increased IL-2 secretion in T 
cell cultures of Soggy-/- mice seems to be due to decreased numbers of Tregs in the T 
cell cultures.  
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Figure 3.45 | Increased secretion of IL-2 in T cell cultures of Soggy-/- mice is due to lower numbers 
of regulatory T cells. CD4 T cell were purified from spleens of C57BL/6 (wt) and Soggy-/- mice 
depleted for CD25+ cells and stimulated with titrated concentrations of anti-CD3 and anti-CD28. 24 
hours later IL-2 was measured in supernatants by ELISA. In order to pool individual experiments, the 
highest IL-2 value of wt T cells was set to 100 and all other values were calculated in relation. Summary 
data from 2 out of 3 independent experiments (n=6 per group) are presented. Mean and SEM are 
indicated for each group. Groups were compared using student t-test (*=p<0,05; **=p<0,005; 
***=p<0,0005).  
 
 
3.3.7 Soggy-/- mice display increased EAE symptoms 
Above we showed that Soggy is expressed in the brain (3.3.1 Expression of Soggy on 
the mRNA and protein level). Dkk3 the structurally similar member of the Dkk 
protein family, also expressed in the brain, was shown to regulate EAE (3.1.1 Dkk3 
regulates effector T cell subsets in experimental autoimmune encephalitis). 
Additionally, Tregs widely been shown to regulate autoimmune disease, are reduced 
in Soggy-/- mice. Therefore, these mice might be more prone to the development of 
autoimmune diseases including EAE as wt mice. For these reasons it was of great 
interest, whether Soggy is able to regulate the course of EAE similarly to Dkk3.  
 
Wt, Dkk3-/- and Soggy-/- mice were immunized with MOG33-55, treated with pertussis 
toxin and EAE was measured for 3 weeks. Strikingly, Soggy-/- displayed an earlier 
onset and increased symptoms of EAE (Figure 3.46) compared to wt. EAE 
symptoms were even stronger in Soggy-/- mice than in Dkk3-/- mice.  
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Figure 3.46 | Soggy-/- mice display increased symptoms of EAE. C57BL/6 (wt), Dkk3-/- and Soggy-/- 
mice were immunized with MOG33-55 in CFA and treated with pertussis toxin. EAE symptoms were 
measured in for 21 days. Summarized data of two out of three independent experiments with similar 
results are shown. Mean EAE score and SEM are shown for each group (n=16). Curves were compared 
using 2-way ANOVA, p-value of column factor is shown (*=p<0,05, ***=P<0,0005).  
 
 
 
 
 
 
 
In summary the experiments investigating the role of Soggy in the immune 
system, revealed that Soggy-/- mice have an immunological phenotype. The 
expression of Soggy is restricted to only few tissues, the testis, the brain and the 
skin, which belong to the immune privileged sites. Furthermore, T cells in the 
periphery of Soggy deficient mice were altered. Most strikingly expression of 
CD44 was downregulated and numbers of Tregs were reduced. Analyzing T cell 
function, we found increased proliferation of CD4 T cells as well as increased 
secretion of IL-2 in T cell cultures of Soggy-/- mice, which appears to be due to 
decreased numbers of CD25+ cells. Furthermore, Soggy-/- mice displayed 
increased symptoms of EAE compared to wt and Dkk3-/- mice.  
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4 Discussion 
Dkk3 has previously been shown by our laboratory to be necessary for peripheral T 
cell tolerance mediated by regulatory CD8 T cells in a transgenic model [214]. In the 
first two parts of this thesis, the function of Dkk3 on the two lymphocyte 
populations - T and B cells - of the adaptive immune system was studied. As the 
failure of tolerance induction and/or maintenance might lead to autoimmunity, we 
investigated models of T and B cell mediated autoimmune disorders in the absence of 
Dkk3 in a polyclonal T and B cell repertoire. In the last part of the thesis, we 
addressed the question whether the sgy domain might confer the immune-modulatory 
function to Dkk3. Our interpretations and the significance of the findings made in 
the three parts of the thesis will be discussed below.  
 
 
4.1 Dkk3 regulates T cell mediated autoimmunity in 
experimental autoimmune encephalitis 
Experimental autoimmune encephalitis (EAE) is a T cell mediated autoimmune 
disease resembling human multiple sclerosis. It is initiated in mice upon priming of T 
cells with central nervous system (CNS)-derived antigens in the presence of an 
adjuvant [264]. In our studies, a peptide containing the amino acids 33-55 of myelin 
oligodendrocyte protein (MOG33-55) emulsified in complete Freund’s adjuvant (CFA) 
was used for active disease induction. Alternatively to this actively-induced EAE, the 
disease can be passively induced by transferring T cells which were activated in vitro 
with CNS-derived antigens [264]. We used in vitro restimulated transgenic T cells 
with specificity for MOG (2D2 T cells) for passive EAE induction. In both strategies 
of EAE induction mice were treated with pertussis toxin (PT), which facilitates the 
entry of activated MOG-specific T cells into the brain through the neurovasculature 
juncture, also called blood-brain barrier [265]. There, the T cells release cytokines, 
which lead to the activation of microglia secreting high amounts of cytokines and 
chemokines [266]. As a result of the inflammatory process the blood-brain barrier will 
be disrupted and a second wave of leukocytes including blood-borne macrophages, 
dendritic cells (DCs) and granulocytes are recruited to the brain. These cells 
contribute to the pathogenic T cell response by presenting myelin antigens to T cells 
and secreting further proinflammatory cytokines triggering the cascade. Eventually, 
neurotoxic molecules, such as reactive oxygen species (ROS), are secreted by 
microglia and infiltrated leukocytes, and lead to acute focal inflammatory 
demyelination and axonal loss [72, 267].  
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Studies of the EAE model have helped to subdivide the sequence of these 
immunopathological events into two major phases; the initial T-cell 
priming/activation phase and the subsequent recruitment and effector phase [267]. 
However, it is difficult to define the time frame of these phases by only outwardly 
looking at the EAE scores, as both, the activation phase and the recruitment/effector 
phase take place before disease is peaking. Additionally, in contrast to human 
multiple sclerosis, EAE in mice is mostly self-limiting. Therefore, a third phase of 
disease can be defined, the recovery phase. It is characterized by the control of 
inflammation, remyelination and recovery from EAE. The terms of the different 
phases as used in this thesis can be found in Figure 4.1.  
 
The comparison between actively immunized Dkk3 sufficient and deficient mice 
revealed that lack of Dkk3 leads to more severe and persistent EAE symptoms in the 
later stages (Figure 3.1). The initiation phase of EAE did not seem to be affected by 
Dkk3 as the onset of EAE was occurring at the same time point in Dkk3 deficient 
and sufficient animals. Therefore, we assumed that the recruitment/effector phase 
and/or the recovery phase are regulated by Dkk3. It is not clear why the onset of 
disease was taking place at an earlier time point when EAE was passively induced in 
Dkk3-/- Rag2-/- mice compared to wt.Rag2-/- mice. Importantly, the passive induction 
of EAE in Dkk3 sufficient and deficient Rag2-/- mice demonstrated that 
environmental Dkk3 alone is able to dampen disease symptoms. This supports the 
idea that the difference between wt and Dkk3-/- mice observed when EAE was 
actively induced is not due to a different T cell pool initiating the disease but due to 
the regulation of the immune response by environmental Dkk3 present in the CNS.  
 
To investigate in detail how Dkk3 contributes to the control of EAE, leukocytes in 
the CNS and in the periphery (spleen and lymph nodes (LN)) of actively EAE 
induced mice were analyzed at the peak of disease/rising phase and in the recovery 
phase. At the peak of disease/rising phase, mice of both groups were equally affected 
by the disease, whereas in the recovery phase Dkk3 deficient mice were clearly 
suffering from more severe EAE symptoms. In our analysis we were interested in 
different factors which have been demonstrated to play a role in the 
immunopathology of EAE.  
 
Myelin-reactive CD4 T cells are widely accepted to be the key players in the 
development of EAE [267]. The role of CD8 T cells still remains controversial [268, 
269]. While several groups clearly demonstrate the contribution of CD8 T cells to the 
pathology of the disease [91, 270, 271], other groups report that CD8 T cells regulate 
the disease [272-274].  
At the peak of disease/rising phase no difference in numbers of CD4 and CD8 T cells 
was found in the CNS and in the periphery (Figure 3.3), which was not surprising as 
DISCUSSION 
 
119 
EAE scores were similar in wt and Dkk3-/- mice. In the recovery phase, in which both 
groups clearly differed in EAE symptoms, higher numbers of CD4 and CD8 T cells 
were detected in the CNS, but also in the spleen (Figure 3.4). This finding suggests 
that Dkk3 either controls survival by actively inducing apoptosis or that it inhibits 
the proliferation of T cells. Both ways of action would lead to increased numbers of 
CD4 and CD8 T cells when Dkk3 is absent, and increased numbers of T cells most 
likely contribute to the persistent symptoms of EAE in Dkk3 deficient animals.  
 
The activity of Tregs is now recognized as a strong regulatory mechanism in the 
control of autoimmune diseases [89, 275]. Analyzing the numbers of Tregs in our 
experimental system surprisingly revealed higher numbers of Tregs at the peak of 
disease/rising phase in the CNS of Dkk3-/- mice, which was not observed for the 
recovery phase (Figure 3.3/Figure 3.4).  
It is difficult to imagine, why higher numbers of Tregs were observed at the peak of 
disease/rising phase in Dkk3-/- mice, although these are the mice, which will 
eventually not recover from EAE symptoms as fast as the control mice.  
One possible explanation could be that Tregs are expanded in the CNS of Dkk3-/- 
mice as a compensatory mechanism to prevent the stronger disease progression 
observed in these animals. However, this mechanism might be effective only in the 
rising phase, as no difference in EAE scores were observed between the two groups of 
mice in this phase. In the recovery phase then, Dkk3-/- mice suffered from more 
severe symptoms of EAE compared to wt mice. In that phase no compensation of 
EAE pathology by Tregs might take place in Dkk3-/- mice as numbers of Tregs were 
similar in Dkk3-/- and wt animals.  
Alternatively, Tregs might be increased in Dkk3-/- mice due to a lack of regulation by 
Dkk3. This hypothesis is raised by the finding that also IL-17 expressing CD4 T cells 
were present at higher numbers only at the peak of disease/rising phase in the CNS 
and not in the recovery phase of Dkk3 deficient mice. It has been shown that TGF-β 
is necessary for the differentiation of both cell types, Tregs and Th17 T cells [276]. It 
is possible that Dkk3 acts on TGF-β availability or activity. Indeed, Pinho et al. and 
Hsu et al. showed a connection between the TGF-β pathway and Dkk3 in xenopus 
and zebrafish development [277, 278]. Supporting the importance of TGF-β for 
disease induction, Veldhoen clearly demonstrated that TGF-β signalling is required 
for initiation of EAE, as mice with defective TGF-β signalling neither develop the 
Th17 subset nor succumbed to EAE [279]. Furthermore, Tregs have been shown in 
vitro to be a sufficient source of TGF-β for the induction of Th17 cells [279, 280] and 
just recently it was shown that also in vivo Tregs promote Th17 cell development 
[262]. Therefore, it would be interesting to explore in future studies whether the 
increased level of Tregs in Dkk3-/- mice is connected to the increased level of Th17 
cells and whether and how exactly Dkk3 acts on TGF-β signalling in T cells. 
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Th17 cells have clearly been demonstrated to be important for the development of 
autoimmune diseases, such as multiple sclerosis and EAE [281-284]. Whether the 
increased numbers of Th17 cells in the CNS of Dkk3-/- mice are causative for the 
severe and prolonged EAE symptoms in our model is unclear. It is possible that they 
contribute to the severity of the symptoms in the recruitment/effector phase, as 
there (at the peak/rising phase) the number of Th17 cells was specifically increased 
within the CD4 T cell population in Dkk3-/- mice (Figure 3.3). In the recovery phase, 
no difference in population frequency within the CD4 T cell subset was observed 
(Figure 3.4). However, as the number of CD4 T cells was increased in Dkk3-/- brains 
in the recovery phase, also IL17+ and other cytokine secreting cells will be present in 
higher numbers and may contribute to the damage.  
 
IFN-γ is regarded traditionally as the signature cytokine of Th1 immune responses 
and as these cells were found to be implicated in the pathogenesis of autoimmune 
diseases [285-288], it was believed to be inflammatory and therewith destructive 
[289]. Early evidence however indicated an opposing, protective role for IFN-γ. In 
these studies IFN-γ deficient mice were found to be more susceptible to EAE than 
IFN-γ sufficient mice [290, 291]. Therefore, the function of IFN-γ in autoimmune 
disease is still controversial.  
In this thesis, IFN-γ expressing T cells were found at equal numbers in wt and  
Dkk3-/- mice in the periphery and the CNS at the peak of disease/rising phase 
(Figure 3.3). In the recovery phase higher numbers of both CD8 and CD4 T cells 
secreting IFN-γ were found in the CNS of Dkk3-/- mice (Figure 3.4). Two scenarios 
can be imagined to explain the increased number of IFN-γ secreting T cells in the 
CNS of Dkk3-/- mice in this phase. In the first scenario Dkk3 directly controls IFN-γ 
production, leading to increased levels of destructive IFN-γ in Dkk3 deficient mice, 
which leads to increases symptoms of EAE. In the second scenario IFN-γ acts as a 
regulating factor and is upregulated in the late phase of EAE as a compensatory 
mechanism to dampen the stronger EAE progression in Dkk3-/- mice. Feuerer et al. 
showed that IFN-γ acts as a proinflammatory cytokine in the early phase of disease, 
whereas in the late phase IFN-γ controls antigen-specific immune responses [292]. As 
in our model the increased expression of IFN-γ in the absence of Dkk3 was observed 
during the late phase of EAE, the second hypothesis is favored in our laboratory.  
 
GM-CSF has recently been reported by Bechers group to be necessary for disease 
induction [47]. Autoreactive helper T cells lacking GM-CSF failed to initiate 
neuroinflammation despite expression of IL-17A or IFN-γ, whereas GM-CSF 
secretion by IFN-γ/IL-17 negative CD4 T cells was sufficient to induce EAE. The 
expression of GM-CSF was driven by the Th17 cell supporting cytokine IL-23 and 
the Th17 master transcription factor RoRγt. Therefore, it can be assumed that these 
GM-CSF secreting cells in the initiation phase of EAE are a special form of Th17 
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cells. In our model of EAE, no difference was found in CD4 T cells expressing the 
cytokine GM-CSF at both analyzed time points between wt and Dkk3-/- mice. Hence, 
a mechanism employed by Dkk3 involving the regulation of GM-CSF expression by 
T cells can be ruled out in the control of EAE.  
 
It is unlikely that T cells are directly responsible for the demyelination and axonal 
loss. Instead, myeloid cells are supposed to be the damaging cell type in EAE due to 
their arsenal of toxic molecules, which they are able to secrete [266]. Indeed, Codarri 
et al. demonstrated that neuroinflammation was sustained via CD11b+ myeloid cells 
by GM-CSF secreting T cells [47]. Therefore, numbers of myeloid cells in diseased 
CNS and in the periphery were compared between Dkk3 sufficient and deficient 
mice. Dkk3-/- animals, suffering from more severe EAE symptoms in the recovery 
phase, displayed increased numbers of CD11b+ cells in the CNS (Figure 3.4). In the 
spleen significantly reduced numbers of CD11b+ cells at both analyzed time points 
were present in Dkk3-/- mice (Figure 3.3/Figure 3.4), indicating the migration of 
myeloid cells from the periphery to the brain. Most probably, these cells are 
contributing to increased and prolonged symptoms of EAE in Dkk3-/- mice. However, 
we can not distinguish, whether these myeloid cells are directly affected by Dkk3 or 
whether their increased migration into the brain is a consequence of the T cell 
triggered cascade, which was also found to be aggravated in Dkk3-/- mice.  
 
Concluding, the following scenario can be imagined: MOG specific T cells are 
activated in the periphery by immunization. They migrate through the blood-brain 
barrier and enter the brain, thereby inducing the disease. In Dkk3 sufficient animals 
environmental Dkk3 affects survival or proliferation of T cells in the CNS. This 
eventually leads to lower EAE scores and a faster recovery from EAE of wt animals.  
As Dkk3 deficiency leads to increased numbers of CD4 and CD8 T cells in the CNS 
in general in the recovery phase, higher numbers of IL-17, IFN-γ and GM-CSF 
producing T cells will be present. These may contribute to aggravated disease in the 
late phase. In this late phase only the proportion of IFN-γ secreting T cells was 
selectively increased within the CD4 T cells, indicating the existence of a connection 
between Dkk3 and this cytokine.  
The increased T cell response in Dkk3 deficient mice will attract myeloid cells from 
the periphery to the CNS contributing to increased EAE symptoms in Dkk3 deficient 
mice. Alternatively, Dkk3 could also directly influence the migration of these cells. 
Whether Dkk3 acts directly or indirectly on the discussed T cells in vivo remains to 
be determined by future studies. The main findings made in this chapter are 
summarized in a model of Dkk3 action on the immune response in the different 
phases of EAE (Figure 4.1).  
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Figure 4.1  | Model of Dkk3 action on the immune response in the different phases of EAE. The 
curve demonstrates the typical course of EAE observed in Dkk3 sufficient mice. The terms used in this 
thesis for the different phases are indicated. Dkk3 limits the number of FoxP3+ and IL-17+ cells in the 
recruitment/effector phase of EAE. Furthermore, it inhibits the migration of CD11b+ myeloid cells from 
the periphery into the brain, which starts in the recruitment phase/effector phase and continuous until 
the recovery phase. The T cell response is dampened by Dkk3 in the recovery phase by decreasing the 
proliferation and IFN-γ secretion of T cells.  
 
 
4.2 Dkk3 does not regulate the pathogenic T cell response 
in a model of inflammatory bowel disease and diabetes 
type 1 
 
The analysis of EAE in Dkk3 deficient mice showed that Dkk3 is able to regulate 
pathogenic T cells. Hence, it was interesting to explore, whether this is also true for 
other autoimmune diseases. As Dkk3 was shown to be expressed in the intestine [210] 
and in the β-islet cells of the pancreas [192], we decided to analyze the function of 
Dkk3 on T cells in a model of inflammatory bowel disease (IBD) and a model of 
diabetes type 1.  
 
The term IBD covers a group of disorders in which the intestine is attacked by 
autoimmune T cells. However, it is not yet clear whether these T cells are 
responsible for the initiation of tissue destruction or whether their contribution is a 
consequence of tissue inflammation caused by other factors [293]. To address 
immune-regulatory mechanisms in the gut, an adoptive transfer model, which 
employs immune deficient hosts, has been developed and is widely used [294]. In this 
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model the disease is T cell initiated. Flavell’s group furthermore showed that colitis 
induced by CD4+CD45RBhigh cells exhibits a higher Th1 response compared with 
Treg depleted CD4+CD45RBlow cells, which showed an increased Th17 response [295]. 
We decided to not discriminate between CD45RB and to use CD4 T cells depleted of 
Tregs in order to allow both types of T cell responses to take place.  
 
Diabetes type 1, also called nonobese diabetes, is an autoimmune disease, in which 
cellular infiltration and immune-mediated destruction of the insulin-producing islets 
of Langerhans precedes the onset the disease [296]. Different animal models have 
evolved in the past years. The best studied models of human autoimmune diabetes 
involve mice of the non-obese-diabetic (NOD) background [296]. We decided to use 
an adoptive transfer model, in which naïve CD4 T cells with TCR specificity to      
ß-islets (T cells from Bdc2.5 mice) were Treg depleted and transferred to 
immunodeficient mice in the NOD background.  
 
Neither in the mouse model of IBD nor in the model of diabetes type 1, absence of 
Dkk3 led to increased disease progression (Figure 3.5/Figure 3.6). Therefore, we 
concluded that Dkk3 is not able to regulate the pathogenic T cell response in these 
models. One explanation could be the relatively low expression level of Dkk3 found 
in the intestine and the pancreas (Figure 3.7) in comparison to the brain, where 
Dkk3 was found to be expressed 300-500 times higher. Lack of increased disease 
symptoms in Dkk3-/- mice could also be explained by the very robust T cell response 
already taking place in Dkk3 sufficient animals in these models. This robust T cell 
response might not be controllable by Dkk3 and therefore the absence of Dkk3 would 
not lead to increased disease symptoms. We tried to decrease the disease threshold in 
the diabetes type 1 model by transferring fewer cells (data not shown). However, 
only a delay of disease onset was achieved. We can not rule out, that in other models 
of diabetes or IBD, where disease development takes longer or/and disease symptoms 
are rather moderate, disease would be increased in a Dkk3 deficient environment.  
 
4.3 Dkk3 limits Th2 associated cytokine secretion  
Increased numbers of IFN-γ and IL-17 positive cells were found in the CNS of Dkk3 
deficient mice. IFN-γ is the signature cytokine of Th1 immune responses and IL-17 
the signature cytokine of the Th17 immune response [38]. To address the question, 
whether Dkk3 influences the differentiation of T cells, two different approaches were 
started.  
 
In the first approach, we investigated whether T cells coming from a Dkk3 deficient 
environment would differentiate into higher or lower numbers of specific T subsets in 
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vitro under specific differentiating conditions (Figure 3.8). Surprisingly, under Th1 
differentiating conditions, we found lower numbers of IFN-γ positive Th1 cells when 
T cells were coming from Dkk3 deficient mice. Conversely, under Th2 differentiating 
conditions, T cells from Dkk3 deficient mice exhibited slightly increased numbers of 
IL-10 secreting Th2 cells, although the number of IL-10 positive T cells was very low 
in our assay. The differentiation of Th17 cells was not found to be altered by Dkk3.  
 
As Dkk3 has been shown not to be expressed by T cells themselves [212], we found it 
important to also analyze T cell differentiation in vivo in a second approach. For this 
purpose we made use of the properties of complete and incomplete Freund’s adjuvant 
(CFA and IFA). Antigens immunized in CFA have been described to preferentially 
lead to an immune response of the Th1/Th17 direction, whereas antigens in IFA lead 
to a reduced Th1 response and an increased immune response of the Th2 direction 
[232-234]. Confirming the in vitro data, analysis of in vivo differentiation in Dkk3-/- 
deficient mice also revealed that Th2 responses might be increased in the absence of 
Dkk3. This was indicated by increased levels of IL-10 and IL-4 independent of 
immunization, and decreased levels of IL-17, when immunized with MOG33-55 in IFA 
(Figure 3.9/Figure 3.10). However, no difference was found in Th1/Th17 
differentiation between Dkk3-/- and wt mice when mice were immunized with antigen 
in CFA, as levels of IFN-γ and IL-17 were similar (Figure 3.9).  
 
Interestingly, the cytokine IL-6 was increased in Dkk3-/- mice when mice were 
immunized with antigen in CFA (Figure 3.10). IL-6 is a cytokine produced by a 
number of cell types including fibroblasts, macrophages, dendritic cells, T and B 
lymphocytes, endothelial cells, and keratinocytes in response to a variety of external 
stimuli (e.g. IL-1, TNF, and PDGF) [236]. It has been shown to shift the Th1/Th2 
balance towards the Th2 direction by promoting IL-4 production and Th2 
differentiation, and by inhibiting IFN-γ production and Th1 differentiation [236]. 
However, other studies demonstrated that IL-6 is a cytokine important for the 
differentiation of Th17 cells [297, 298]. In our system the Th2 response was increased 
and the Th17 response decreased in Dkk3 deficient mice immunized with antigen in 
IFA. Therefore, IL-6 seems to rather contribute to the Th2 response in Dkk3-/- mice.  
 
In summary, our data suggest that Dkk3 might influence T cell differentiation by 
limiting Th2 responses. As in EAE the Th1 and Th17 response was increased in the 
absence of Dkk3, we can conclude that this seems not to be due to an increased 
differentiation of Th1/Th17 cells in a Dkk3 deficient environment.  
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4.4 Dkk3 regulates B1 cell numbers and function 
B cells are subdivided into different subsets, which exhibit different functions in the 
immune system. Interestingly, Dkk3 deficiency led to approximately twice the 
number of B1 cells found in wt mice, and a reduction of B2 cells of approximately 
30% (Figure 3.18). The B1 subsets consist of B1a and B1b cells, which both were 
found to be increased in Dkk3-/- mice (Figure 3.21). The reduction of B2 cells was 
due to decreased numbers of follicular (FO) B cells, whereas numbers of marginal 
zone (MZ) B cells were similar in Dkk3 deficient and sufficient mice (Figure 3.20).  
 
These findings explain why we observed increased B cell antibody responses to B1 
antigens in Dkk3-/- compared to wt mice. One of the most typical B1 antigens is 
phosphorycholine (PC), an autoantigen being part of many phospholipids within cell 
membranes [132, 299]. Immunization with this antigen led to highly significantly 
increased IgM and IgG levels in Dkk3-/- mice (Figure 3.14) demonstrating clearly the 
increased response to the B1 cell antigen in Dkk3 deficient mice. In order to analyze 
the response to LPS, total IgM and LPS-specific IgM levels were determined after 
LPS injection, as LPS has the ability to activate B cells polyclonally by TLR 
stimulation and specifically by binding to LPS-specific BCRs. The polyclonal 
stimulation by LPS activates all B cells polyclonally independent of BCR and subset 
[154, 240], whereas LPS-specific BCRs are mainly found in the B1 subset [241]. 
Strikingly, in this experiment the LPS-specific IgM response was significantly 
increased in Dkk3-/- mice while the polyclonal response was not affected by Dkk3 
deficiency (Figure 3.13). This confirms the finding that B1 specific antibody 
responses are stronger in the absence of Dkk3.  
 
Barrantes et al. described that total IgM levels of Dkk3 deficient mice are increased 
in the steady state [189]. This observation was confirmed in our studies (Figure 3.13, 
A, Day0). As B1 cells are responsible for the steady state level of natural IgM [133], 
the increased IgM levels of Dkk3-/- mice is explainable by the increased B1 cell 
numbers in Dkk3-/- mice. This is further supported by the findings that IgM levels of 
transferred B cells into immunodeficient hosts correlate perfectly with B1 cell 
numbers (Figure 3.24).  
 
The response to TNP-Ficoll, an antigen which has been demonstrated to activate MZ 
B cells [157], was not altered in Dkk3-/- mice (Figure 3.12). This is not surprising, as 
we found no differences in MZ B cell numbers between Dkk3 sufficient and deficient 
mice (Figure 3.20).  
 
TNP-BSA is regarded as a thymus dependent (TD) B cell antigen activating FO B 
cells [300, 301]. We observed increased TNP-BSA specific IgM levels in Dkk3 
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deficient mice already in the steady state (Figure 3.11, A, Day0). How can we 
explain this phenomenon, since FO B cell numbers were decreased? When looking at 
the antigen TNP-BSA more in detail, it can be recognized that the TD response will 
be due to the BSA part, which is able to be processed and presented by MHCII 
molecules to T cells. However, the TNP part might activate B1 B cells leading to 
TNP-specific antibodies, which could not be distinguished from BSA-specific 
antibodies in our analysis. This argument is supported by early studies showing that 
TNP-specific B cells arise early in ontogeny [302, 303], a hallmark of B1 cells [133], 
and that anti-TNP antibodies display characteristic features of naturally occurring 
autoantibodies [304], whose secretion is another hallmark of B1 cells [132, 133]. 
Hence, it is likely that higher numbers of TNP-BSA specific IgM levels in the steady 
state are due to the same reason why total IgM levels were increased (as described 
above). As the IgM response to this antigen was weak, IgM levels did not change 
drastically on day 7 post immunization and the difference was still observed between 
wt and Dkk3-/- mice. On day 14 no significant difference between Dkk3 sufficient and 
deficient mice was observed.  
Furthermore, TNP-BSA specific IgG1 and IgG3 levels were significantly increased in 
Dkk3 deficient animals upon immunization, whereas the TNP-BSA specific IgG2a 
and IgG2b response was not affected by Dkk3 (Figure 3.11). IgG3 is an antibody 
typically produced by B1 cells after class switch recombination (CSR) [132]. 
Therefore, this finding is most likely due to the increased B1 cell numbers. Also IgG1 
antibodies have been reported to be expressed by B1 cells, and in the same study B1 
cells were implicated to be enhanced by T cell help [156]. This could also account for 
B1 cell secreted IgG1. However, we can not rule out that FO B cells lead to 
increased TNP-BSA specific antibody levels in Dkk3 deficient mice, as TNP-BSA 
activates not preferentially B1 cells. Nevertheless, we can conclude that despite the 
decreased numbers of FO cells present in Dkk3-/- mice the response to TD antigens is 
not impaired. Thus, the reduction of FO B cell numbers in Dkk3-/- mice does not 
seem to have a dramatic consequence for immune responses. On the contrary, the 
approximately double number of B1 cells present in Dkk3-/- mice influences B1 
related immune responses.  
 
The next B cell function we explored to be dependent on Dkk3 was cytokine 
secretion. We started this analysis with performing a small screen, in which we found 
that MCP-1 (CCL2) and IL-10 are increased in supernatants of stimulated 
splenocytes from Dkk3-/- mice compared to wt mice (Figure 3.15). MCP-1 turned out 
not to be secreted by B cells in our assay system, as later experiments conducted 
with purified B cells showed no detection of MCP-1 in supernatants. Nevertheless, it 
is interesting that this chemokine is increased in supernatants of Dkk3-/- splenocytes, 
since it has been shown to promote Th2 differentiation [305], which we in fact 
observed to be increased in Dkk3-/- mice detected by T cell differentiation analysis 
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(as described above). Also the cytokine IL-10 is known to drive Th2 differentiation 
[306, 307], which might as well contribute to the increased Th2 phenotype in Dkk3 
deficient mice.  
 
The increased IL-10 level in supernatants of Dkk3-/- splenocytes was confirmed to be 
B cell derived (Figure 3.16). When comparing IL-10 levels in supernatants of purified 
B cells from spleen with peritoneal cavity (PerC), we found that PerC B cells 
secreted enormously higher amounts of IL-10 (Figure 3.16/Figure 3.17). In the 
literature B1 cells have been shown to secrete large amounts of IL-10 [174], and as 
the PerC is besides the pleural cavity the compartment with the largest numbers of 
B1 cells [133], it is not surprising, that we detected such high levels of IL-10 in 
supernatants of PerC B cells. The difference observed between wt and Dkk3-/- B cell 
derived IL-10 levels was more pronounced when using PerC B cells as when using 
splenic B cells in the assay (Figure 3.16/Figure 3.17). This fits with the finding that 
also the increased number of B1 cells in Dkk3-/- mice was more pronounced within 
the PerC compartment compared to the spleen (Figure 3.18). That the secreted IL-
10 was in deed B1 cell derived in our system was demonstrated by analyzing its 
expression on a single cell level (Figure 3.17). Only B1 cells expressed the cytokine 
IL-10. Additionally, this analysis showed that that the increased IL-10 levels detected 
in B cell supernatants of Dkk3-/- mice are not only due to higher numbers of B1 cells 
present in Dkk3-/- mice, but also due to higher numbers of IL-10 secreting cells within 
the B1 cell subset in Dkk3-/- mice. Therefore, this analysis indicated that not only the 
number of B1 cells is regulated by Dkk3 but also their threshold of activation.  
 
Concluding, Dkk3 deficiency leads to decreased numbers of FO B cells and higher 
numbers of B1 cells. So far no defects of B cell function were found due to the 
decreased number of FO B cells in Dkk3-/- mice. Presumably, the remaining 
approximately 75% of FO B cells are enough to compensate the reduction. However, 
the approximately double number of B1 cells in Dkk3 deficient mice leads to an 
increased B1 cell function demonstrated by the increased antibody response to B1 
cell specific antigens and the increased production of B1 derived IL-10.  
 
4.5 Dkk3 regulates B cell development and maintenance 
In order to answer the question why numbers of B cells were altered in Dkk3-/- mice 
in comparison to wt mice, B cell development and maintenance was investigated. FO 
B cells are generated during the whole lifetime from the BM, sustaining the pool of 
peripheral B cells, whereas B1 cell development occurs early in ontogeny and does 
poorly take place in the adult BM [141, 142]. In adult mice B1 cells are maintained 
by continuous self-renewal taking place in the periphery [133].  
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The investigation of B cell development was started by analyzing neonatal spleen, as 
there the final steps of B1 cell development are still visible [139]. Interestingly, we 
found decreased numbers of immature cells (in the periphery called transitional) in 
the spleen as well as in the PerC of Dkk3-/- mice (Figure 3.22). Although the PerC 
was supposed to mainly contain mature cells [247], this was not confirmed in our 
experiment, as large B cell numbers expressed the molecule CD93, a surface marker 
commonly expressed by B cell progenitors [4]. Mature cells were found as a minor 
population in spleen and PerC. There, the B1 cell population was already increased 
in Dkk3-/- mice, whereas the FO B cell population was not yet decreased at this time 
in ontogeny in Dkk3-/- mice (Figure 3.22). This indicates that B cell development 
might be impaired due to Dkk3 deficiency before or at the step to immature B cell 
generation and not at a later step, as FO B cell numbers would then be decreased 
directly, which was not the case. As already higher numbers of B1 cells were found in 
neonatal Dkk3-/- spleens, B1 cell development does not seem to be impaired. It 
indicates that the impairment of B cell development lies within the FO B cell subset.  
 
To further investigate the impairment of B cell development due to a deficiency of 
Dkk3, BM of adult mice was analyzed. The investigation of adult BM has the 
advantage that the all developmental stages of B cells can be found in this site, 
whereas in the neonatal spleen only immature until mature stages can be found.  
Similar to the neonatal spleen reduced numbers of immature B cells were found in 
Dkk3-/- BM and numbers of mature FO B cell were not altered in comparison to wt 
BM (Figure 3.23). Also, the number of B1 cells was found to be increased in the BM 
of Dkk3 deficient mice. Interestingly, numbers of pre-B cells were equal in Dkk3 
sufficient and deficient mice, demonstrating that the impairment of B cell 
development observed in Dkk3-/- mice occurs after this developmental stage. In 
addition, we even found higher numbers of prepro- and pro-B cells is Dkk3-/- mice, 
which could be caused by the failure of pre- B cells to further continue their 
maturation program, leading to an accumulation of prepro- and pro-B cells is Dkk3-/- 
mice. These data indicate that B cell development is impaired at the maturation step 
from pre- to immature B cells.  
The finding that numbers of mature FO B cells were not different between wt and 
Dkk3-/- mice in sites of development (neonatal spleen/adult BM) demonstrates that 
the maturation step from immature to mature B cells is not impaired. However, it 
raises the question why numbers of mature FO B cells are then decreased in the 
periphery in adult Dkk3-/- mice. One possible explanation could be that the BM 
yields mechanisms to release B cells to the periphery only after a certain number of 
mature B cells is reached. As B cell development is impaired in Dkk3-/- mice, this 
process would be delayed and less mature FO B cells would be released to the 
periphery.  
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BM B cell development in adult mice mainly mirrors B2 development. Therefore, the 
analysis of adult BM indicated that in the absence of Dkk3 FO B cell generation is 
impaired without dampening B1 cell development. However, it was still unclear, 
which mechanism is responsible for the increased B1 cell numbers in Dkk3 deficient 
mice. Is Dkk3 actively regulating B1 cell numbers?  
This question can not easily be investigated, since the mechanisms of B1 cell 
development are not yet fully understood. As presented in the introduction two main 
hypotheses have evolved: the selection model and the lineage model, which 
nevertheless do not need to be mutually exclusive as proposed by Baumgarth [133]. 
B1 cells arise early in ontogeny and are then maintained by self-renewal [139]. Hence, 
in Dkk3-/- mice B1 cells either possess a selection advantage during the development 
or they receive increased survival/proliferation signals and as a result have an 
increased self-renewal capacity, or both. As B1 and B2 transitional cells can 
currently not be distinguished, the question whether Dkk3 affects B1 cell 
development could not be fully answered by the analysis of neonatal spleens. 
Therefore, we decided to investigate in another experiment whether self-renewal of 
B1 cells is influenced by Dkk3. Purified B cells from wt or Dkk3-/- mice were 
transferred into immunodeficient (Rag2-/-) mice sufficient or deficient for Dkk3. We 
used cells from wt and Dkk3-/- mice to additionally answer the question whether 
potential intrinsic Dkk3 or only environmental Dkk3 plays a role in self-renewal of B 
cells.  
As the spleen does not contain progenitor cells in adult mice, the resulting B cell 
numbers after a period of incubation in the host mice represent the self-renewal 
capacity of the B cells, which in turn depends on survival and proliferation. Clearly, 
numbers of B1 cells were increased in mice with a deficiency in environmental Dkk3, 
but also in mice where Dkk3 was present in the environment but absent in the donor 
B cells, which was associated with higher levels of serum IgM and IL-10 secretion 
(Figure 3.24). This demonstrated that the self-renewal capacity of B1 cells is 
increased in Dkk3-/- mice and that this mechanism is contributing (or even 
responsible) for the increased B1 cell numbers in Dkk3 deficient animals.  
 
The surprising finding in this experiment was that not only environmental Dkk3 
deficiency but also intrinsic Dkk3 deficiency of donor cells increased B1 cell numbers. 
There are several options of how this could be explained. One explanation could be 
that the higher proportion of B1 cells in purified B cell samples of Dkk3-/- spleens 
compared to wt spleens was sustained throughout the time from transfer until 
analysis. A second explanation could be that B1 cells are irreversibly “primed” in 
Dkk3-/- mice. Another explanation is, as B cell purification never leads to 100% of 
purity, that contaminating other splenocytes created a Dkk3 deficient environment. 
A last explanation, which should not be forgotten, although thought to be unlikely, 
is that Dkk3 expressed by the B cells themselves and by the environment act 
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together to regulate B1 cell numbers. Then deficiency in either the environmental or 
the intrinsic Dkk3 production leads to higher levels of B1 cells.  
To address the last assumption, Dkk3 expression in purified B cells from the spleen 
and the PerC was analyzed. However, neither in splenic B cells nor in PerC B cells 
yielding high numbers of B1 cells, mRNA transcripts for Dkk3 could be detected 
(Figure 3.25). Therefore, it is unlikely that B cells themselves express Dkk3, 
contributing to the regulation of the self-renewal capacity of B1 cells. However, this 
can not be completely ruled out, as the analysis could possibly not be sensitive 
enough.  
Although we can not yet answer which of the hypotheses is right and how Dkk3 
exactly regulates B1 cell numbers, we can conclude that an increased self-renewal 
capacity of B1 cells in Dkk3-/- mice contributes to higher numbers of these cells.  
 
The number of FO B cells was also analyzed in this experiment. No difference was 
found between the different groups in FO B cell numbers (Figure 3.24 A). This 
demonstrates that neither environmental nor intrinsic Dkk3 influences the self-
renewal capacity of FO B cells. As they continuously develop from the BM in 
contrast to B1 cells self-renewal is anyway not an important feature of FO B cells. 
Nevertheless, the finding confirms our hypothesis that the decreased FO B cell 
numbers in Dkk3-/- mice are due to a developmental defect (as described above).  
 
In summary, two different mechanisms have been demonstrated to contribute to the 
observation that the absence of Dkk3 shifted the B1/B2 balance towards the B1 
direction: The impaired development of FO B cells and the increased self-renewal 
capacity of B1 cells. However, there are still remaining questions. As the 
development of FO cells is impaired at the important step of B cell development 
where negative selection occurs, we may hypothesize whether Dkk3 presence is 
necessary for the positive selection of non-self-reactive B cells (FO B cells), and for 
negative selection of self-reactive cells (B1 cells). This would mean that Dkk3 is an 
important molecule in deciding whether a cell is harmful and needs to be deleted. 
Findings supporting this hypothesis are that in the neonatal spleen and in the adult 
BM of Dkk3-/- mice increased numbers of mature B1 cells were found. This indicates 
that B1 cell development could be favored while B2 development is impaired in 
Dkk3-/- mice. Furthermore, MZ numbers were besides B1 cell numbers increased in 
the neonatal spleen of Dkk3-/- mice (Figure 3.22). As MZ B cells have been described 
to exhibit a similar selection process to B1 cells [125, 308, 309], this additionally 
strengthens the hypothesis. It is also possible that similar mechanisms are used by 
Dkk3 to act on self-renewal, which we demonstrated to be increased in the absence of 
Dkk3, and on survival of B1 cells during development. Furthermore, it remains to be 
determined whether the observed modulation of B cell development and maintenance 
is a direct effect of Dkk3 or whether other cells and molecules are important 
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intermediates. A model of Dkk3 action on B cell development and maintenance is 
depicted in Figure 4.2.  
 
 
 
 
Figure 4.2  | Model of Dkk3 action on B cell development and maintenance. The figure illustrates 
the FO B cell development, which takes place during the whole life-span of a mouse, and the B1 cell 
development taking place mainly in the fetal until neonatal stage. In adult mice B1 cells are maintained 
by self-renewal. Dkk3 was shown in this thesis to support FO B cell development at the step to 
immature FO B cells, whereas B1 cell development could be inhibited at the same step. In adult mice 
Dkk3 was demonstrated to inhibit the self-renewal of B1 cells. Here, B1 and FO B cell development is 
illustrated as two separate lineages, this is however still controversial. Dkk3 might influence the process 
of positive/negative selection of B cells in general taking place at the immature step, where the mature 
B cell receptor is expressed for the first time, thereby supporting FO B cell development and decreasing 
B1 development.  
 
 
4.6 Dkk3 regulates B cell mediated autoimmunity 
The investigation of the B cell compartment in Dkk3-/- mice revealed that Dkk3 
deficiency leads to increased B1 cell numbers associated with increased B1 related 
antibody responses and IL-10 secretion. As B1 cells are the B cell subset mostly 
considered to be responsible for auto-reactivity [132, 133, 167] and also B1 derived, 
IL-10 has been shown to exacerbate autoimmune disease [175-178[175-178], it is 
intriguing to explore whether Dkk3 deficiency leads to increased B cell mediated 
autoimmunity.  
 
We used the LPR/MRL mouse strain, which is a model of human systemic lupus 
erythematosus (SLE) [182], and treated the mice with a neutralizing anti-Dkk3 
antibody in order to eliminate Dkk3 function. It has been demonstrated by our group 
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that the anti-Dkk3 antibody abolishes Dkk3 function [214]. Control mice were 
treated with an isotype control antibody.  
 
After 6 weeks of treatment (as described in Figure 3.26), LN and kidneys of anti-
Dkk3 antibody treated mice possessed an increased weight compared to isotype 
control treated mice (Figure 3.27), suggesting an increased number of accumulated 
leukocytes and inflammation within the organs. The analysis of T and B cell 
populations demonstrated that B1 cells were selectively expanded in anti-Dkk3 
antibody treated mice in the spleen and the PerC (Figure 3.28). The selective 
expansion of B1 cells in the absence of Dkk3 in these mice confirms the results 
obtained in C57BL/6 mice deficient for Dkk3 in a different mouse strain, in which 
Dkk3 function was abrogated by another method than genetic manipulation. The 
increased weight of the analyzed LN (inguinal, axillary and MLN) in anti-Dkk3 
antibody treated mice together with the population analysis showed that in contrast 
to the spleen and the PerC in these sites of the body numbers of all cells were 
increased in anti-Dkk3 antibody treated mice. The relative proportion between the 
cell subsets did not change in these areas by abrogation of Dkk3 function.  
Furthermore, levels of autoantibodies were determined in serum of MRL/LPR mice 
treated with anti-Dkk3 antibody or isotype control antibody. Higher levels of anti-
MOG IgM and IgG, anti-ss-DNA IgG and anti-ds-DNA IgG were detected in anti-
Dkk3 antibody treated mice (Figure 3.30/Figure 3.31/Figure 3.32). The histological 
examination analysis of organs revealed that anti-Dkk3 antibody treated mice 
suffered from more severe tissue damage (Figure 3.33). This was presumably due to 
the increased amounts of autoantibodies as well as the increased number of 
infiltrated leukocytes in pancreas, lung and kidney found in anti-Dkk3 antibody 
treated mice (Figure 3.33).  
 
Taken together, the treatment of MRL/LPR mice with an antibody abrogating Dkk3 
function, lead to increased pathology of the disease. This was associated with 
increased numbers of B1 cells.  
 
In summary, Dkk3 seems to be an important molecule to control the development 
and maintenance of different B cell subsets. In the absence of Dkk3, higher numbers 
of auto-reactive B1 cells arise, which can lead to autoimmunity under specific 
genetical and environmental conditions (as here shown by using the MRL/LPR 
mouse strain). It would be interesting to explore, whether human patients of SLE 
show defects in Dkk3 expression or related pathways.  
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4.7 Identification of Soggy as a novel immune modulator 
Soggy shares the unique sgy domain with Dkk3. To investigate whether the sgy 
domain might be responsible for conferring the immune-modulatory function to 
Dkk3, Soggy-/- mice were analyzed.  
 
One hallmark feature of Dkk3 is the expression in immune privileged sites. 
Interestingly, Soggy was also found to be expressed in immune privileged sites 
although its expression was restricted to fewer tissues. In the literature it has already 
been described to be expressed in the testis, the placenta, the trophoblast, fetal eye 
and fetal neural tissue, as well as various tumors in mice and humans [188, 215, 216, 
218]. We detected RNA and protein expression of Soggy in the testis, confirming the 
reports in the literature but interestingly also in the adult brain and the skin (Figure 
3.36). Both the brain and the hair follicles of the skin belong to the immune 
privileged sites. In future studies, a histological analysis could clarify in which regions 
and by which cell types Soggy is produced in these areas.  
We could not detect Soggy in lymphoid tissues. This is important if we assume 
Soggy to be an immuno-suppressive molecule, since in these sites immune responses 
need to take place. In contrast to Dkk3, it was not found in the serum. A genetic 
complementation by Soggy in Dkk3-/- mice could not be revealed by our analysis as 
Dkk3 deficient mice did not show increased expression of Soggy (Figure 3.36).  
In conclusion, the expression analysis was the first hint that Soggy might be an 
immune-modulatory molecule similar to Dkk3 contributing to the protection of 
immune-privileged sites.  
 
Dkk3 has been shown not to influence T cell populations in the thymus and the 
periphery [212, 214]. However, mice deficient for Soggy exhibited altered numbers of 
T cell populations in the spleen and the MLN (Figure 3.39/Figure 3.40). There, the 
ratio of CD4:CD8 T cells was shifted towards CD4 T cells. Furthermore, CD44 
expressing cells were decreased. This could be due to an impaired upregulation of 
CD44 or due to decreased development or survival of memory T cells in Soggy-/- 
mice. As CD44 is generally used as a marker to identify memory T cells, we analyzed 
whether the reduction would be due to a reduction of central or effector memory 
cells. In both analyzed sites the reduction of CD4 memory T cell was due to a 
reduction of both, central and effector memory T cells, whereas the reduction of CD8 
memory T cells was due to a reduction of central memory T cells alone. 
The most striking observation in Soggy-/- mice was the reduced number of Tregs 
(Figure 3.39/Figure 3.40). In order to clarify whether thymic or induced Tregs are 
affected by the absence of Soggy, Tregs were analyzed for the expression of Helios. 
FoxP3 cells exhibiting low expression of Helios were claimed to be Tregs induced in 
the periphery [58]. Also in our analysis, Tregs within the thymus were mainly Helios 
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positive (Figure 3.38). However, conflicting results were obtained in the two analyzed 
lymphoid sites. Splenic Tregs displayed increased numbers of Helioslow cells, whereas 
Tregs in the MLN showed slightly decreased Helioslow cells in Soggy-/- mice. The 
finding in the spleen could indicate that higher numbers of Tregs are induced in the 
periphery in order to compensate the reduced number of Tregs in Sogyy-/- mice. But 
as the MLN belongs to the system of the GALT, where high numbers of Tregs are 
commonly induced within the body [310], and Soggy-/- mice do not show increased 
Helios+ cells at this site, the argument is invalidated. Therefore, the analysis of Tregs 
for Helios expression could not give a conclusive explanation, which kind of Tregs are 
decreased in Soggy deficient mice.  
 
The analysis of T cell development in the thymus showed some minor changes within 
the immature T cell population. The number of double negative (DN) cells was 
decreased, whereas the number of double positive (DP) cells was increased in Soggy-/- 
mice compared to wt mice (Figure 3.37). Within the DN population CD44+ 
expressing cells were decreased as observed in the periphery. This was due to 
CD44highCD25- cells. As Soggy deficiency seems to affect CD44 expression in all 
lymphoid tissues including the thymus, where CD44 cells present immature cells, not 
memory cells, the suggestion is raised that Soggy regulates the expression level of 
this surface marker rather than the survival of memory T cells. This would be 
interesting to clarify in future studies.  
Furthermore, the same number of mature single positive CD4, CD8 and Tregs were 
present in the thymus of wt and Soggy-/- mice (Figure 3.37/Figure 3.38). These are 
the cells eventually released to the periphery to build the pool of peripheral T cells. 
Therefore, an altered T cell development in Soggy deficient mice can not be 
responsible for altered frequencies of T cells in the periphery of Soggy-/- mice. 
Changes in the number of CD4, CD8 and Tregs must be due to a regulation in the 
periphery.  
 
To analyze whether T cell reactivity is affected in Soggy-/- mice, we investigated two 
important features of T cells; the ability to proliferate and the ability to secrete IL-2. 
Whereas Dkk3-/- T cells have been demonstrated to exhibit a higher proliferation rate 
under suboptimal stimulation concentration compared to wt T cells in vitro ([214] 
and Figure 3.41), Soggy-/- CD4 T cells exhibited even an increased proliferation rate 
also at optimal stimulation concentrations (Figure 3.41). The higher proliferation of 
CD4 T cell of Soggy-/- mice could explain why we observed increased numbers of 
CD4 T cells in Soggy-/- mice, at least it might contribute to this phenomenon. The 
proliferation of CD8 T cells, however, was not affected by Soggy deficiency (Figure 
3.42).  
The secretion of IL-2 was strongly increased in T cells cultures of Soggy-/- mice 
(Figure 3.43). After depletion of CD25+ T cells, CD4 T cells of Soggy-/- mice did not 
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secrete higher levels of IL-2 in comparison to wt T cells (Figure 3.45). CD25+ 
depletion eliminates both, recently activated CD25+ effector T cells and Tregs.  
As anti-CD3/anti-CD28 stimulation leads to the activation of T cells, CD25 is 
upregulated and new effector T cells expressing CD25 and secreting IL-2 will be 
generated. Therefore, the depletion of these cells would presumably not influence   
IL-2 secretion drastically. Nevertheless, we can not exclude, that the effect was due 
to these cells. This needs to be clarified by future studies.  
Tregs have been demonstrated to decrease IL-2 secretion of T cells by consumption 
of IL-2 and suppression of T cells via different other molecules (as described in the 
introduction) [17, 18]. We found decreased numbers of Tregs in Soggy-/- mice in 
comparison to wt and Dkk3-/- mice (Figure 3.39/Figure 3.40). When this difference 
was eliminated by using CD4 T cells devoid of CD25+ Tregs, the effect of higher IL-2 
secretion of Soggy-/- T cells was abrogated. Therefore, Soggy-/- T cells might secrete 
increased levels of IL-2 due to lower numbers of Tregs present in the T cell cultures. 
This would imply that the increased secretion of IL-2 of Soggy-/- T cells is not a 
feature of the T cells per se to secrete higher levels of IL-2 or to possess a stronger 
activation status, but an indirect feature due to less suppression of Tregs.  
 
To finally investigate whether the observed immunological changes in Soggy deficient 
mice affect autoimmunity, the course of EAE was analyzed in Soggy-/- mice and 
compared to wt and Dkk3-/- mice. Very strikingly, the absence of Soggy led to an 
earlier onset of EAE and increased severity of symptoms (Figure 3.46). This might 
be due to a decreased level of regulatory T cells in Soggy-/- mice, presumably also 
present at lower numbers within the CNS, as they have been shown to be able to 
regulate the pathogenesis of EAE [225]. Future studies should analyze whether 
indeed lower numbers of Tregs can be found in the brain of Soggy-/- mice affected by 
EAE. Furthermore, it needs to be clarified whether Soggy produced locally within 
the brain is important for the regulation of EAE, as this is assumed for Dkk3. Cell 
infiltrates of the brain could be compared to those of Dkk3-/- mice, giving initial 
hints. Moreover, transfer experiments could help clarifying this issue, since there are 
no tissue specific knockout mice for the Soggy gene available.  
 
Given the high abundance of Soggy in the testis, we analyzed whether Soggy 
expression in the testis affects T cell populations in the periphery, T cell 
proliferation, IL-2 secretion or EAE. Therefore, T cells of male and female Soggy-/- 
mice were compared in the relevant assays. However, the expression of Soggy in the 
testis did not affect any analyzed parameters. Therefore, male and female mice were 
pooled for experimental presentation in the figures.  
It is unclear where the molecule Soggy might meet the immune system to lead to the 
observed immunological phenotype of Soggy-/- mice. In addition, we do not know the 
molecular mechanisms how Soggy acts on immune cells. It could act directly or 
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indirectly via other cell types or molecules. These questions will be addressed in 
future studies.  
 
In conclusion, we identified Soggy as a novel immune-mediator. Soggy exhibits 
several similarities to Dkk3 but also differences as listed briefly in Table 4.1. Like 
Dkk3, Soggy is expressed in immune-privileged tissues, although its expression was 
restricted to fewer tissues compared to Dkk3. Furthermore, similar to T cells from 
Dkk3-/- mice, Soggy-/- CD4 T cells exhibited an increased proliferation and IL-2 
secretion. EAE was found to be even stronger regulated by Soggy than by Dkk3. 
These findings suggest that the shared sgy-domain is contributing to the immune-
suppressive capacity of Dkk3 and Soggy. The sgy-domain of Dkk3 and Soggy exhibit 
41% homology, and the entire Dkk3 and Soggy protein only 22% homology (Figure 
3.35). Therefore, it is not surprising that also differences in Soggy and Dkk3 action 
on the immune system were found, such as the decreased number of Tregs and 
CD44+ cells in the absence of Soggy but not in the absence of Dkk3. Future studies 
may clarify whether the sgy-domain is indeed responsible for the immune-suppressive 
capacity of both molecules and which part of the sgy domain or the rest of the 
protein contributes to the specific function distinguishing Dkk3 and Soggy. 
 
 
Table 4.1 | Similarities and differences of Dkk3 and Soggy function in the immune system 
 
 
Similarities Differences 
 Expression in immune-privileged sites  Broader expression of Dkk3 than 
Soggy 
 Regulation of CD4 T cell proliferation  Dkk3 regulates CD8 T cell 
proliferation in addition 
 Regulation of IL-2 secretion   Soggy regulates numbers of Tregs, 
and this mechanism might be used 
to regulate IL-2 secretion. Dkk3 
does not affect Treg numbers and 
might use a different mechanism to 
act on IL-2 secretion 
 Regulation of EAE  
  Soggy regulates numbers of CD44+ 
T cells 
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4.8 Conclusion and outlook 
Dkk3 and Soggy, both proteins belonging to the Dkk family and sharing the unique 
sgy domain, have been demonstrated in this thesis to act as modulators of the 
adaptive immune system. Dkk3 affects both, T and B cell function, whereas for 
Soggy a regulation of T cell responses was so far revealed. The functional regulation 
of T and B cells included the dampening of autoimmune responses mediated by both 
kinds of lymphocytes.  
 
Many interesting questions remain about the molecular function of Dkk3 and Soggy. 
One of the most important questions which needs to be addressed is the to date 
unknown receptor for both molecules. It could be a classical membrane receptor but 
as Dkk3 and Soggy are secreted molecules, they could also be internalized by cells 
and interact with intracellular signalling partners. We presently favor the second 
possibility because Dkk3 has been suggested to interact with βTrCP in the 
cytoplasm, thereby modulating β-catenin signalling [195, 311]. The identification of 
the receptor(s) or intracellular signalling partners would help characterizing the 
molecular pathway triggered by Dkk3 and Soggy leading to the observed effects. It 
would furthermore tell us whether the effects on T and B cells are directly or 
indirectly caused by Dkk3 and Soggy. In case they are caused indirectly, it has to be 
analyzed which cell types or intermediate molecules would be involved. As Dkk3 has 
been shown to be posttranslationally processed in a similar way to proinsulin [193], it 
would also be of interest to investigate whether these posttranslational changes alter 
the activity of Dkk3. The processing of Dkk3 could possibly be used by the immune 
system to control Dkk3 activity.  
 
Dkk3 and Soggy are both molecules which we just recently identified to act on the 
immune system. The effects appear to be broad and to influence several different cell 
types and pathways. Therefore, the interesting journey to explore the mechanistic 
action of these molecules is just starting and might lead us to therapeutic 
applications in the field of autoimmune diseases and transplantation.  
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